US20210395344A1

US20210395344A1 - Variant nucleic acid libraries for coronavirus

Info

Publication number: US20210395344A1
Application number: US17/242,179
Authority: US
Inventors: Aaron Sato; Qiang Liu; Tom YUAN
Original assignee: Twist Bioscience Corp
Current assignee: Twist Bioscience Corp
Priority date: 2020-04-27
Filing date: 2021-04-27
Publication date: 2021-12-23
Also published as: KR20230016184A; CA3177029A1; EP4142739A2; WO2021222316A3; CA3177030A1; US12304965B2; WO2021222316A2; EP4142784A2; KR20230017781A; JP2023523336A; WO2021222315A3; IL297701A; MX2022013499A; EP4142784A4; JP2023523335A; AU2021263755A1; MX2022013513A; BR112022021780A2; CN116209463A; US20240400710A1

Abstract

Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding SARS-CoV-2 or ACE2 antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Description

CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Patent Application No. 63/115,568 filed on Nov. 18, 2020, U.S. Provisional Patent Application No. 63/104,465 filed on Oct. 22, 2020, U.S. Provisional Patent Application No. 63/073,362 filed on Sep. 1, 2020, U.S. Provisional Patent Application No. 63/069,665 filed on Aug. 24, 2020, U.S. Provisional Patent Application No. 63/034,896 filed on Jun. 4, 2020, U.S. Provisional Patent Application No. 63/016,254 filed on Apr. 27, 2020, each of which is incorporated by reference in its entirety.

BACKGROUND

Coronaviruses like severe acute respiratory coronavirus 2 (SARS-CoV-2) can cause severe respiratory problems. Therapies are needed for treating and preventing viral infection caused by coronaviruses like SARS-CoV-2. Antibodies possess the capability to bind with high specificity and affinity to biological targets. However, the design of therapeutic antibodies is challenging due to balancing of immunological effects with efficacy. Thus, there is a need to develop compositions and methods for the optimization of antibody properties in order to develop effective therapies for treating coronavirus infections.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

Provided herein are nucleic acid libraries comprising: a plurality of sequences that when translated encode for antibodies or antibody fragments that bind to SARS-CoV-2 or ACE2 protein, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody, and wherein the library comprises at least 50,000 variant sequences. Further provided herein are nucleic acid libraries, wherein the antibodies or antibody fragments bind to a spike glycoprotein, a membrane protein, an envelope protein, a nucleocapsid protein, or combinations thereof of the SARS-CoV-2. Further provided herein are nucleic acid libraries, wherein the antibodies or antibody fragments bind to a spike glycoprotein. Further provided herein are nucleic acid libraries, wherein the antibodies or antibody fragment bind to a receptor binding domain of the spike glycoprotein. Further provided herein are nucleic acid libraries, wherein the library comprises at least 100,000 variant sequences. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody light chain. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody heavy chain. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least two variants in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least two individuals. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least three individuals. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 50× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a heavy chain. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a light chain. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having at least 70× higher binding affinity than the input sequence. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 50 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 25 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 10 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 5 nM. Further provided herein are nucleic acid libraries, wherein the library encodes a CDR sequence of any one of SEQ ID NOs: 1-591.
Provided herein are nucleic acid libraries comprising: a plurality of sequences that when translated encode for antibodies or antibody fragments that bind to a coronavirus or a receptor of the coronavirus, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody, and wherein the library comprises at least 50,000 variant sequences. Further provided herein are nucleic acid libraries, wherein the coronavirus is SARS-CoV, MERS-CoV, CoV-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKU1. Further provided herein are nucleic acid libraries, wherein the receptor of the coronavirus is ACE2 or dipeptidyl peptidase 4 (DPP4). Further provided herein are nucleic acid libraries, wherein the library comprises at least 100,000 variant sequences. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody light chain. Further provided herein are nucleic acid libraries, wherein at least some of the sequences encode for an antibody heavy chain. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least two variants in the CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least two individuals. Further provided herein are nucleic acid libraries, wherein at least one of the variants is present in at least three individuals. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 50× higher binding affinity than a binding affinity of the input sequence. Further provided herein are nucleic acid libraries, wherein each sequence of the plurality of sequences comprises at least one variant in the CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a heavy chain. Further provided herein are nucleic acid libraries, wherein the CDR is a CDR1, CDR2, and CDR3 on a light chain. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having at least 70× higher binding affinity than the input sequence. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 50 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 25 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 10 nM. Further provided herein are nucleic acid libraries, wherein the at least one sequence that when translated encodes for an antibody or antibody fragment having a K_Dof less than 5 nM.
Provided herein are antibodies, wherein the antibody comprises a sequence comprising at least 90% sequence identity to any one of SEQ ID NOs: 1-716.
Provided herein are antibodies, wherein the antibody comprises a sequence comprising at least 90% sequence identity to SEQ ID NOs: 1-716; and wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.
Provided herein are methods of treating a SARS-CoV-2 infection, comprising administering the antibody as described herein. Further provided herein are methods, wherein the antibody is administered prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 1 week prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 1 month prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 5 months prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 24 hours after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 week after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 month after exposure to SARS-CoV-2.
Provided herein are methods of treating an individual with a SARS-CoV-2 infection with the antibody as described herein comprising: (a) obtaining or having obtained a sample from the individual; (b) performing or having performed an expression level assay on the sample to determine expression levels of SARS-CoV-2 antibodies; and (c) if the sample has an expression level of the SARS-CoV-2 antibodies then administering to the individual the antibody as described herein, thereby treating the SARS-CoV-2 infection.
Provided herein are methods for optimizing an antibody comprising: (a) providing a plurality of polynucleotide sequences encoding for an antibody or antibody fragment, wherein the antibody or antibody fragment is derived from a subject having SARS-CoV-2; (b) generating a nucleic acid library comprising the plurality of sequences that when translated encode for antibodies or antibody fragments that bind SARS-CoV-2 or ACE2 protein, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody; wherein the library comprises at least 50,000 variant sequences; and (c) synthesizing the at least 50,000 variant sequences. Further provided herein are methods, wherein the antibody library comprises at least 100,000 sequences. Further provided herein are methods, wherein the method further comprises enriching a subset of the variant sequences. Further provided herein are methods, wherein the method further comprises expressing the antibody or antibody fragments corresponding to the variant sequences. Further provided herein are methods, wherein the polynucleotide sequence is a murine, human, or chimeric antibody sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least one variant in each CDR of a heavy chain or light chain, relative to the input sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least two variants in each CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 50× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein each sequence comprises at least one variant in each CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10¹⁰sequences. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10¹²sequences.
Provided herein are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 145-180 or 415-473; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 181-216 or 533-591. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 30; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 66; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 102; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 138; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 174; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 210. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 35; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 71; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 107; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 143; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 179; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 215. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 12; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 48; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 84; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 120; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 156; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 192. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 31; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 67; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 103; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 139; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 175; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 211. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 240; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 306; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 372; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 244; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 310; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 376; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555. Further provided herein are antibodies or antibody fragments, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 270; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 336; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 402; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 461; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 520; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 579. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_Dof less than 50 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_Dof less than 25 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_Dof less than 10 nM. Further provided herein are antibodies or antibody fragments, wherein the antibody or antibody fragment comprises a K_Dof less than 5 nM.
Provided herein are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 594, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 660. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 595, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 661. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 598, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 664. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 603, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 669. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 615, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 680. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 631, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 691. Further provided herein are antibodies or antibody fragments, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 645, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 704. Further provided herein are antibodies, wherein the antibody comprises a sequence comprising at least 90% sequence identity to any one of SEQ ID NOs: 1-716; and wherein the antibody is a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv), a single chain antibody, a Fab fragment, a F(ab′)2 fragment, a Fd fragment, a Fv fragment, a single-domain antibody, an isolated complementarity determining region (CDR), a diabody, a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof.
Provided herein are nucleic acid compositions comprising: a) a first nucleic acid encoding a variable domain, heavy chain region (VH) comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657; b) a second nucleic acid encoding a variable domain, light chain region (VL) comprising at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716; and an excipient.
Provided herein are methods of treating a SARS-CoV-2 infection, comprising administering the antibody or antibody fragment described herein. Further provided herein are methods, wherein the antibody is administered prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 1 week prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 1 month prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at least about 5 months prior to exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 24 hours after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 week after exposure to SARS-CoV-2. Further provided herein are methods, wherein the antibody is administered at most about 1 month after exposure to SARS-CoV-2.
Provided herein are methods of treating an individual with a SARS-CoV-2 infection with the antibody or antibody fragment described herein comprising: a) obtaining or having obtained a sample from the individual; b) performing or having performed an expression level assay on the sample to determine expression levels of SARS-CoV-2 antibodies; and if the sample has an expression level of the SARS-CoV-2 antibodies then administering to the individual the antibody or antibody fragment described herein, thereby treating the SARS-CoV-2 infection.
Provided herein are methods for optimizing an antibody comprising: a) providing a plurality of polynucleotide sequences encoding for an antibody or antibody fragment, wherein the antibody or antibody fragment is derived from a subject having SARS-CoV-2; b) generating a nucleic acid library comprising the plurality of sequences that when translated encode for antibodies or antibody fragments that bind SARS-CoV-2 or ACE2 protein, wherein each of the sequences comprises a predetermined number of variants within a CDR relative to an input sequence that encodes an antibody; wherein the library comprises at least 50,000 variant sequences; and c) synthesizing the at least 50,000 variant sequences. Further provided herein are methods, wherein the antibody library comprises at least 100,000 sequences. Further provided herein are methods, wherein the method further comprises enriching a subset of the variant sequences. Further provided herein are methods, wherein the method further comprises expressing the antibody or antibody fragments corresponding to the variant sequences. Further provided herein are methods, wherein the polynucleotide sequence is a murine, human, or chimeric antibody sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least one variant in each CDR of a heavy chain or light chain, relative to the input sequence. Further provided herein are methods, wherein each sequence of the plurality of variant sequences comprises at least two variants in each CDR of a heavy chain or light chain relative to the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 5× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 25× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein at least one sequence when translated encodes for an antibody or antibody fragment having at least 50× higher binding affinity than a binding affinity of the input sequence. Further provided herein are methods, wherein each sequence comprises at least one variant in each CDR of a heavy chain or light chain relative to a germline sequence of the input sequence. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10¹⁰sequences. Further provided herein are methods, wherein the nucleic acid library has a theoretical diversity of at least 10¹²sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a workflow for antibody optimization.

FIG. 2 presents a diagram of steps demonstrating an exemplary process workflow for gene synthesis as disclosed herein.

FIG. 3 illustrates an example of a computer system.

FIG. 4 is a block diagram illustrating an architecture of a computer system.

FIG. 5 is a diagram demonstrating a network configured to incorporate a plurality of computer systems, a plurality of cell phones and personal data assistants, and Network Attached Storage (NAS).

FIG. 6 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.

FIG. 7 is a schema of a panning workflow.

FIGS. 8A-8B are graphs of panning data from round 4 for antibody 1.

FIGS. 8C-8D are graphs of panning data from round 4 for antibody 2.

FIGS. 9A-9B are graphs of panning data from round 4 for antibody 3.

FIGS. 9C-9D are graphs of panning data from round 4 for antibody 4.

FIG. 10 shows graphs of ACE2 binding to SARS-CoV-2 variant antibodies.

FIGS. 11A-11B are graphs of affinity data for SARS-CoV-2 variant antibodies.

FIG. 12 is a graph of binding of SARS-CoV-2 variant antibodies to 51 protein.

FIG. 13A is a graph of SARS-CoV-2 and ACE2 competition ELISAs from a first set.

FIG. 13B is a graph of SARS-CoV-2 and ACE2 competition ELISAs from a first set showing SARS-CoV-2 variant antibodies.

FIGS. 14A-14B are graphs from a first set (FIG. 14A) and second set (FIG. 14B) showing ACE2 variant antibodies.

FIGS. 14C-14D are graphs of SARS-CoV-2 variant antibodies in neutralization assays.

FIG. 15 is a graph of SARS-CoV-2 and ACE2 inhibition.

FIGS. 16A-16B are graphs of SARS-CoV-2 variant antibodies on VERO E6 inhibition measured by FACS.

FIG. 17A is a graph of SARS-CoV-2 variant antibodies on VERO E6 inhibition measured by FACS as compared to CR3022.

FIGS. 17B-17C are graphs of affinity of SARS-CoV-2 variant antibodies determined by coating ELISA plates with SARS-CoV-2 Spike Glycoprotein 51 (FIG. 17B) or S protein trimer (FIG. 17C).

FIG. 17D is a graph of mean fluorescent intensity (MFI) plotted for each SARS-CoV-2 variant antibody dilution.

FIGS. 18A-18C are graphs of mean fluorescent intensity (MFI) plotted for each SARS-CoV-2 variant antibody dilution.

FIGS. 19A-19B are graphs of antibody kinetics for variants 2-5, 2-2, and 2-6 (FIG. 19A) and variants 1-12, 1-42, 1-20, and 1-19 (FIG. 19B).

FIG. 19C is a graph of percent neutralization for variants 1-12, 1-42 and 1-20.

FIG. 19D is a graph of percent neutralization for variants 1-12, 1-42 and 1-20 using live virus.

FIGS. 20A-20D are graphs of variant antibodies neutralizing live virus.

FIG. 20E is a graph of variant antibodies neutralizing live virus FRNT.

FIG. 20E-20I show data of variant antibodies neutralizing live virus PRNT.

FIG. 21A shows a graph of percent weight change (y-axis) versus day post injection (PI, x-axis) for positive control convalescent plasma and negative control Mab c7d11.

FIG. 21B shows a graph of percent weight change (y-axis) versus day post injection (PI, x-axis) for variant antibody 6-63.

FIG. 21C shows a graph of percent weight change (y-axis) versus day post injection (PI, x-axis) for variant antibody 6-3.

FIG. 21D shows a graph of percent weight change (y-axis) versus day post injection (PI, x-axis) for variant antibody 6-36.

FIG. 21E shows graphs of percent weight change (y-axis) versus day post injection (PI, x-axis) based on dose.

FIG. 21F shows graphs of percent weight change (y-axis) versus day post injection (PI, x-axis) based on dose for variant antibodies 2-3, 2-63, and 1-20.

FIG. 21G shows a graph of data from a plaque assay to detect infectious virus in Day 9 lungs. The indicated antibodies were administered Day −1. Lungs were collected on Day 9, the right lobe was homogenized, clarified and supernatants were quantified by plaque titration. Individual hamster values are shown as symbols. White symbols indicate no infectious virus detected. The geometric mean PFU/gram is shown as bars. Limit of assay shown as dotted line.

FIG. 21H shows a graph of data from in situ hybridization (ISH) to detect infected cells in Day 9 lungs. The indicated antibodies were administered Day −1. Three animals per group were analyzed. Individual hamster values are shown as symbols. Median ISH scores are shown as bars.

FIG. 21I shows a graph of data from cumulative inflammation and edema scores for Day 9 lungs. The indicated antibodies were administered Day −1. Three animals per group were analyzed. Individual hamster cumulative pathology scores are shown as symbols. Median scores are shown as bars.

FIG. 22A shows a graph of the positive control pAb in a neutralization assay.

FIG. 22B shows a graph of neutralization of antibodies 6-63, 6-3, and 1-12 in VSV-SARS B.135 strain.

FIG. 23A shows a graph of the positive control in a neutralization assay.

FIGS. 23B-23C show graphs of neutralization by antibodies described herein.

FIG. 24A shows graphs weight change. Animals were immunosuppressed and then exposed to SARS-CoV-2 virus, WA1 strain, on Day 0. Top graph indicates data from the control group that received the cocktail on Day −1 (D−1, Group A). A group was immunosuppressed but not exposed to virus (CYP Control, Group I). Negative control is an IgG monoclonal (Group H). The cocktail was administered on the indicated day post-exposure (Groups B-G; middle and bottom graphs). Arrows indicate day of antibody administration. Symbols are mean±SEM. Statistical differences in the area under the curve (AOC) are shown to the right of each line. * indicates p value <0.05, ns=not significant.

FIG. 24B shows a graph of data from FIG. 24A plotted on one graph.

FIG. 24C shows a graph of infectious virus in lungs on Day 14. Plaque assays were run on Day 14 lung homogenates. Plaque forming units (PFU) per gram of tissue were calculated and plotted. The limit of the assay is shown as a dotted line. Bars are the geometric means for each group. Group ID are in parentheses. White symbols indicated no infectious virus was detected. CYP=cyclophosphamide; Neg=Negative; Cont=control.

FIG. 24D shows a graph infectious virus in lungs of untreated control hamsters. CYP-treated animals were exposed to 1,000 pfu of virus by intranasal route on Day 0. Groups of four animals were euthanized and lungs were collected on the indicated days. Lung homogenates were assayed for infectious virus by plaque assay. Plaque forming units (PFU) per gram lung tissue are plotted. Geometric mean titers and SD are shown.

DETAILED DESCRIPTION

The present disclosure employs, unless otherwise indicated, conventional molecular biology techniques, which are within the skill of the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art.

Definitions

Throughout this disclosure, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of any embodiments. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range to the tenth of the unit of the lower limit unless the context clearly dictates otherwise. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual values within that range, for example, 1.1, 2, 2.3, 5, and 5.9. This applies regardless of the breadth of the range. The upper and lower limits of these intervening ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, unless the context clearly dictates otherwise.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of any embodiment. As used herein, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
Unless specifically stated or obvious from context, as used herein, the term “about” in reference to a number or range of numbers is understood to mean the stated number and numbers +/−10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range.
Unless specifically stated, as used herein, the term “nucleic acid” encompasses double- or triple-stranded nucleic acids, as well as single-stranded molecules. In double- or triple-stranded nucleic acids, the nucleic acid strands need not be coextensive (i.e., a double-stranded nucleic acid need not be double-stranded along the entire length of both strands). Nucleic acid sequences, when provided, are listed in the 5′ to 3′ direction, unless stated otherwise. Methods described herein provide for the generation of isolated nucleic acids. Methods described herein additionally provide for the generation of isolated and purified nucleic acids. A “nucleic acid” as referred to herein can comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, or more bases in length. Moreover, provided herein are methods for the synthesis of any number of polypeptide-segments encoding nucleotide sequences, including sequences encoding non-ribosomal peptides (NRPs), sequences encoding non-ribosomal peptide-synthetase (NRPS) modules and synthetic variants, polypeptide segments of other modular proteins, such as antibodies, polypeptide segments from other protein families, including non-coding DNA or RNA, such as regulatory sequences e.g. promoters, transcription factors, enhancers, siRNA, shRNA, RNAi, miRNA, small nucleolar RNA derived from microRNA, or any functional or structural DNA or RNA unit of interest. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, intergenic DNA, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), small nucleolar RNA, ribozymes, complementary DNA (cDNA), which is a DNA representation of mRNA, usually obtained by reverse transcription of messenger RNA (mRNA) or by amplification; DNA molecules produced synthetically or by amplification, genomic DNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. cDNA encoding for a gene or gene fragment referred herein may comprise at least one region encoding for exon sequences without an intervening intron sequence in the genomic equivalent sequence. cDNA described herein may be generated by de novo synthesis.
Antibody Optimization Library for Coronavirus
Provided herein are methods, compositions, and systems for the optimization of antibodies for coronavirus. In some embodiments, the antibodies are optimized for SARS-CoV, MERS-CoV, CoV-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKU1. In some embodiments, the antibodies are optimized for SARS-CoV-2. In some embodiments, the antibodies are optimized for a receptor that binds to the coronavirus. In some embodiments, the receptor of the coronavirus is ACE2 or dipeptidyl peptidase 4 (DPP4). In some embodiments, the antibodies are optimized based on interactions between the coronavirus and the receptor that binds the coronavirus. In some embodiments, the antibodies are optimized for angiotensin-converting enzyme 2 (ACE2). In some embodiments, the antibodies are optimized based on interactions between SARS-CoV-2 and ACE2.
Antibodies are in some instances optimized by the design of in-silico libraries comprising variant sequences of an input antibody sequence (FIG. 1). Input sequences 100 are in some instances modified in-silico 102 with one or more mutations or variants to generate libraries of optimized sequences 103. In some instances, such libraries are synthesized, cloned into expression vectors, and translation products (antibodies) evaluated for activity. In some instances, fragments of sequences are synthesized and subsequently assembled. In some instances, expression vectors are used to display and enrich desired antibodies, such as phage display. Selection pressures used during enrichment in some instances includes, but is not limited to, binding affinity, toxicity, immunological tolerance, stability, receptor-ligand competition, or developability. Such expression vectors allow antibodies with specific properties to be selected (“panning”), and subsequent propagation or amplification of such sequences enriches the library with these sequences Panning rounds can be repeated any number of times, such as 1, 2, 3, 4, 5, 6, 7, or more than 7 rounds. Sequencing at one or more rounds is in some instances used to identify which sequences 105 have been enriched in the library.
Described herein are methods and systems of in-silico library design. For example, an antibody or antibody fragment sequence is used as input. In some instances, the antibody sequence used as input is an antibody or antibody fragment sequence that binds SARS-CoV-2. In some instances, the input is an antibody or antibody fragment sequence that binds a protein of SARS-CoV-2. In some instances, the protein is a spike glycoprotein, a membrane protein, an envelope protein, a nucleocapsid protein, or combinations thereof. In some instances, the protein is a spike glycoprotein of SARS-CoV-2. In some instances, the protein is a receptor binding domain of SARS-CoV-2. In some instances, the input sequence is an antibody or antibody fragment sequence that binds angiotensin-converting enzyme 2 (ACE2). In some instances, the input sequence is an antibody or antibody fragment sequence that binds an extracellular domain of the angiotensin-converting enzyme 2 (ACE2).
A database 102 comprising known mutations or variants of one or more viruses is queried 101, and a library 103 of sequences comprising combinations of these mutations or variants are generated. In some instances, the database comprises known mutations or variants of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof. In some instances, the database comprises known mutations or variants of the spike protein of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof. In some instances, the database comprises known mutations or variants of the receptor binding domain of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof. In some instances, the database comprises mutations or variants of a protein of SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof that binds to ACE2.
In some instances, the input sequence is a heavy chain sequence of an antibody or antibody fragment that binds SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof. In some instances, the input sequence is a light chain sequence of an antibody or antibody fragment that binds SARS-CoV-like coronaviruses, SARS-CoV-2, SARS-CoV, or combinations thereof. In some instances, the heavy chain sequence comprises varied CDR regions. In some instances, the light chain sequence comprises varied CDR regions. In some instances, known mutations or variants from CDRs are used to build the sequence library. Filters 104, or exclusion criteria, are in some instances used to select specific types of variants for members of the sequence library. For example, sequences having a mutation or variant are added if a minimum number of organisms in the database have the mutation or variant. In some instances, additional CDRs are specified for inclusion in the database. In some instances, specific mutations or variants or combinations of mutations or variants are excluded from the library (e.g., known immunogenic sites, structure sites, etc.). In some instances, specific sites in the input sequence are systematically replaced with histidine, aspartic acid, glutamic acid, or combinations thereof. In some instances, the maximum or minimum number of mutations or variants allowed for each region of an antibody are specified. Mutations or variants in some instances are described relative to the input sequence or the input sequence's corresponding germline sequence. For example, sequences generated by the optimization comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the input sequence. In some instances, sequences generated by the optimization comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the input sequence. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the input sequence. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a second CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a second CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a first CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a second CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the input sequence in a third CDR region of a light chain. In some instances, a first CDR region is CDR1. In some instances, a second CDR region is CDR2. In some instances, a third CDR region is CDR3. In-silico antibodies libraries are in some instances synthesized, assembled, and enriched for desired sequences.
The germline sequences corresponding to an input sequence may also be modified to generate sequences in a library. For example, sequences generated by the optimization methods described herein comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the germline sequence. In some instances, sequences generated by the optimization comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the germline sequence. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the germline sequence.
Provided herein are methods, systems, and compositions for antibody optimization, wherein the input sequence comprises mutations or variants in an antibody region. Exemplary regions of the antibody include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain. In some instances, the CDR is CDR1, CDR2, or CDR3. In some instances, the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3. In some instances, the CDR is a light domain including, but not limited to, CDRL1, CDRL2, and CDRL3. In some instances, the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH). In some instances, the VL domain comprises kappa or lambda chains. In some instances, the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH). In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a second CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a second CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region of a heavy chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a first CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a second CDR region of a light chain. In some instances, sequences generated by the optimization comprise about 1, 2, 3, 4, 5, 6, or 7 mutations or variants from the germline sequence in a third CDR region of a light chain. In some instances, a first CDR region is CDR1. In some instances, a second CDR region is CDR2. In some instances, a third CDR region is CDR3.
VHH Libraries
Provided herein are methods, compositions, and systems for generation of antibodies or antibody fragments. In some instances, the antibodies or antibody fragments are single domain antibodies. Methods, compositions, and systems described herein for the optimization of antibodies comprise a ratio-variant approach that mirror the natural diversity of antibody sequences. In some instances, libraries of optimized antibodies comprise variant antibody sequences. In some instances, the variant antibody sequences are designed comprising variant CDR regions. In some instances, the variant antibody sequences comprising variant CDR regions are generated by shuffling the natural CDR sequences in a llama, humanized, or chimeric framework. In some instances, such libraries are synthesized, cloned into expression vectors, and translation products (antibodies) evaluated for activity. In some instances, fragments of sequences are synthesized and subsequently assembled. In some instances, expression vectors are used to display and enrich desired antibodies, such as phage display. In some instances, the phage vector is a Fab phagemid vector. Selection pressures used during enrichment in some instances includes, but is not limited to, binding affinity, toxicity, immunological tolerance, stability, receptor-ligand competition, or developability. Such expression vectors allow antibodies with specific properties to be selected (“panning”), and subsequent propagation or amplification of such sequences enriches the library with these sequences. Panning rounds can be repeated any number of times, such as 1, 2, 3, 4, 5, 6, 7, or more than 7 rounds. In some instances, each round of panning involves a number of washes. In some instances, each round of panning involves at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 washes.
Described herein are methods and systems of in-silico library design. Libraries as described herein, in some instances, are designed based on a database comprising a variety of antibody sequences. In some instances, the database comprises a plurality of variant antibody sequences against various targets. In some instances, the database comprises at least 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 antibody sequences. An exemplary database is an iCAN database. In some instances, the database comprises naïve and memory B-cell receptor sequences. In some instances, the naïve and memory B-cell receptor sequences are human, mouse, or primate sequences. In some instances, the naïve and memory B-cell receptor sequences are human sequences. In some instances, the database is analyzed for position specific variation. In some instances, antibodies described herein comprise position specific variations in CDR regions. In some instances, the CDR regions comprise multiple sites for variation.
Described herein are libraries comprising variation in a CDR region. In some instances, the CDR is CDR1, CDR2, or CDR3 of a variable heavy chain. In some instances, the CDR is CDR1, CDR2, or CDR3 of a variable light chain. In some instances, the libraries comprise multiple variants encoding for CDR1, CDR2, or CDR3. In some instances, the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR1 sequences. In some instances, the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR2 sequences. In some instances, the libraries as described herein encode for at least 50, 100, 200, 300, 400, 500, 1000, 1200, 1500, 1700, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more than 5000 CDR3 sequences. In-silico antibodies libraries are in some instances synthesized, assembled, and enriched for desired sequences.
Following synthesis of CDR1 variants, CDR2 variants, and CDR3 variants, in some instances, the CDR1 variants, the CDR2 variants, and the CDR3 variants are shuffled to generate a diverse library. In some instances, the diversity of the libraries generated by methods described herein have a theoretical diversity of at least or about 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, or more than 10¹⁸sequences. In some instances, the library has a final library diversity of at least or about 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, 10¹⁵, 10¹⁶, 10¹⁷, 10¹⁸, or more than 10¹⁸sequences.
The germline sequences corresponding to a variant sequence may also be modified to generate sequences in a library. For example, sequences generated by methods described herein comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more than 16 mutations or variants from the germline sequence. In some instances, sequences generated comprise no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or no more than 18 mutations or variants from the germline sequence. In some instances, sequences generated comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or about 18 mutations or variants relative to the germline sequence.
Coronavirus Antibody Libraries
Provided herein are libraries generated from antibody optimization methods described herein. Antibodies described herein result in improved functional activity, structural stability, expression, specificity, or a combination thereof.
Provided herein are methods and compositions relating to SARS-CoV-2 binding libraries comprising nucleic acids encoding for a SARS-CoV-2 antibody. Further provided herein are methods and compositions relating to ACE2 binding libraries comprising nucleic acids encoding for an ACE2 antibody. Such methods and compositions in some instances are generated by the antibody optimization methods and systems described herein. Libraries as described herein may be further variegated to provide for variant libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries that may be generated when the nucleic acid libraries are translated. In some instances, nucleic acid libraries as described herein are transferred into cells to generate a cell library. Also provided herein are downstream applications for the libraries synthesized using methods described herein. Downstream applications include identification of variant nucleic acids or protein sequences with enhanced biologically relevant functions, e.g., improved stability, affinity, binding, functional activity, and for the treatment or prevention of an infection caused by a coronavirus such as SARS-CoV-2.
In some instances, an antibody or antibody fragment described herein comprises a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a sequence of any one of SEQ ID NOs: 1-716. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a sequence of any one of SEQ ID NOs: 1-716.
In some instances, an antibody or antibody fragment described herein comprises a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH1 sequence of any one of SEQ ID NOs: 1-36 or 217-282. In some instances, an antibody or antibody fragment described herein comprises a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH2 sequence of any one of SEQ ID NOs: 37-72 or 283-348. In some instances, an antibody or antibody fragment described herein comprises a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRH3 sequence of any one of SEQ ID NOs: 73-108 or 349-414.
In some instances, an antibody or antibody fragment described herein comprises a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL1 sequence of any one of SEQ ID NOs: 109-144 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL2 sequence of any one of SEQ ID NOs: 145-180 or 415-473. In some instances, an antibody or antibody fragment described herein comprises a CDRL3 sequence of any one of SEQ ID NOs: 181-216, 442-456, or 532-546. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 80% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 85% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 90% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591. In some instances, an antibody or antibody fragment described herein comprises a sequence that is at least 95% identical to a CDRL3 sequence of any one of SEQ ID NOs: 181-216 or 533-591.
In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 145-180 or 415-473; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 181-216 or 533-591. In some embodiments, the antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 145-180 or 415-473; and (f) an amino acid sequence of CDRL3 is at least or about 80%, 85%, 90%, or 95% identical to any one of SEQ ID NOs: 181-216 or 533-591.
Described herein, in some embodiments, are antibodies or antibody fragments comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716. In some instances, the antibodies or antibody fragments comprise VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 592-657, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 658-716.
The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
The term “homology” or “similarity” between two proteins is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one protein sequence to the second protein sequence. Similarity may be determined by procedures which are well-known in the art, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information).
Provided herein are libraries comprising nucleic acids encoding for SARS-CoV-2 antibodies. Antibodies described herein allow for improved stability for a range of SARS-CoV-2 or ACE2 binding domain encoding sequences. In some instances, the binding domain encoding sequences are determined by interactions between SARS-CoV-2 and ACE2.
Sequences of binding domains based on surface interactions between SARS-CoV-2 and ACE2 are analyzed using various methods. For example, multispecies computational analysis is performed. In some instances, a structure analysis is performed. In some instances, a sequence analysis is performed. Sequence analysis can be performed using a database known in the art. Non-limiting examples of databases include, but are not limited to, NCBI BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), UCSC Genome Browser (genome.ucsc.edu/), UniProt (www.uniprot.org/), and IUPHAR/BPS Guide to PHARMACOLOGY (guidetopharmacology.org/).
Described herein are SARS-CoV-2 or ACE2 binding domains designed based on sequence analysis among various organisms. For example, sequence analysis is performed to identify homologous sequences in different organisms. Exemplary organisms include, but are not limited to, mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, fish, fly, and human. In some instances, homologous sequences are identified in the same organism, across individuals.
Following identification of SARS-CoV-2 or ACE2 binding domains, libraries comprising nucleic acids encoding for the SARS-CoV-2 or ACE2 binding domains may be generated. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains comprise sequences of SARS-CoV-2 or ACE2 binding domains designed based on conformational ligand interactions, peptide ligand interactions, small molecule ligand interactions, extracellular domains of SARS-CoV-2 or ACE2, or antibodies that target SARS-CoV-2 or ACE2. Libraries of SARS-CoV-2 or ACE2 binding domains may be translated to generate protein libraries. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate peptide libraries, immunoglobulin libraries, derivatives thereof, or combinations thereof. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate protein libraries that are further modified to generate peptidomimetic libraries. In some instances, libraries of SARS-CoV-2 or ACE2 binding domains are translated to generate protein libraries that are used to generate small molecules.
Methods described herein provide for synthesis of libraries of SARS-CoV-2 or ACE2 binding domains comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the libraries of SARS-CoV-2 or ACE2 binding domains comprise varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a SARS-CoV-2 or ACE2 binding domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a SARS-CoV-2 or ACE2 binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
Methods described herein provide for synthesis of libraries comprising nucleic acids encoding for the SARS-CoV-2 or ACE2 binding domains, wherein the libraries comprise sequences encoding for variation of length of the SARS-CoV-2 or ACE2 binding domains. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
Following identification of SARS-CoV-2 or ACE2 binding domains, antibodies may be designed and synthesized to comprise the SARS-CoV-2 or ACE2 binding domains. Antibodies comprising SARS-CoV-2 or ACE2 binding domains may be designed based on binding, specificity, stability, expression, folding, or downstream activity. In some instances, the antibodies comprising SARS-CoV-2 or ACE2 binding domains enable contact with the SARS-CoV-2 or ACE2. In some instances, the antibodies comprising SARS-CoV-2 or ACE2 binding domains enables high affinity binding with the SARS-CoV-2 or ACE2. Exemplary amino acid sequences of SARS-CoV-2 or ACE2 binding domains comprise any one of SEQ ID NOs: 1-716.
In some instances, the SARS-CoV-2 antibody comprises a binding affinity (e.g., K_D) to SARS-CoV-2 of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 1 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 1.2 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 2 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 5 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 10 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 13.5 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 15 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 20 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 25 nM. In some instances, the SARS-CoV-2 antibody comprises a K_Dof less than 30 nM.
In some instances, the ACE2 antibody comprises a binding affinity (e.g., K_D) to ACE2 of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 11 nm, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 1 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 1.2 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 2 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 5 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 10 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 13.5 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 15 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 20 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 25 nM. In some instances, the ACE2 antibody comprises a K_Dof less than 30 nM.
In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is an agonist. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is an antagonist. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is an allosteric modulator. In some instances, the allosteric modulator is a negative allosteric modulator. In some instances, the allosteric modulator is a positive allosteric modulator. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin results in agonistic, antagonistic, or allosteric effects at a concentration of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 160 nM, 180 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1000 nM, or more than 1000 nM. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator at a concentration of at least or about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, or more than 100 nM. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin is a negative allosteric modulator at a concentration in a range of about 0.001 to about 100, 0.01 to about 90, about 0.1 to about 80, 1 to about 50, about 10 to about 40 nM, or about 1 to about 10 nM. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin comprises an EC50 or IC50 of at least or about 0.001, 0.0025, 0.005, 0.01, 0.025, 0.05, 0.06, 0.07, 0.08, 0.9, 0.1, 0.5, 1, 2, 3, 4, 5, 6, or more than 6 nM. In some instances, the SARS-CoV-2 or ACE2 immunoglobulin comprises an EC50 or IC50 of at least or about 1 nM, 2 nM, 4 nM, 6 nM, 8 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, or more than 100 nM.
In some instances, the affinity of the SARS-CoV-2 or ACE2 antibody generated by methods as described herein is at least or about 1.5×, 2.0×, 5×, 10×, 20×, 30×, 40×, 50×, 60×, 70×, 80×, 90×, 100×, 200×, or more than 200× improved binding affinity as compared to a comparator antibody. In some instances, the SARS-CoV-2 or ACE2 antibody generated by methods as described herein is at least or about 1.5×, 2.0×, 5×, 10×, 20×, 30×, 40×, 50×, 60×, 70×, 80×, 90×, 100×, 200×, or more than 200× improved function as compared to a comparator antibody. In some instances, the comparator antibody is an antibody with similar structure, sequence, or antigen target.
Provided herein are SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise variation in domain type, domain length, or residue variation. In some instances, the domain is a region in the antibody comprising the SARS-CoV-2 or ACE2 binding domains. For example, the region is the VH, CDRH3, or VL domain. In some instances, the domain is the SARS-CoV-2 or ACE2 binding domain.
Methods described herein provide for synthesis of a SARS-CoV-2 or ACE21 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the SARS-CoV-2 or ACE2 binding library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a VH or VL domain. In some instances, the variant library comprises sequences encoding for variation of at least a single codon in a SARS-CoV-2 or ACE2 binding domain. For example, at least one single codon of a SARS-CoV-2 or ACE2 binding domain is varied. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a VH or VL domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons in a SARS-CoV-2 or ACE2 binding domain. An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
Methods described herein provide for synthesis of a SARS-CoV-2 or ACE2 binding library of nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence, wherein the SARS-CoV-2 or ACE2 binding library comprises sequences encoding for variation of length of a domain. In some instances, the domain is VH or VL domain. In some instances, the domain is the SARS-CoV-2 or ACE2binding domain. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons less as compared to a predetermined reference sequence. In some instances, the library comprises sequences encoding for variation of length of at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, or more than 300 codons more as compared to a predetermined reference sequence.
Provided herein are SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains, wherein the SARS-CoV-2 or ACE2 binding libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the VH or VL domain. In some instances, the SARS-CoV-2 or ACE2 binding libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.
SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 to about 75 amino acids.
SARS-CoV-2 or ACE2 binding libraries comprising de novo synthesized variant sequences encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise a number of variant sequences. In some instances, a number of variant sequences is de novo synthesized for a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or a combination thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, a number of variant sequences are de novo synthesized for a SARS-CoV-2 or ACE2 binding domain. The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is about 10 to 300, 25 to 275, 50 to 250, 75 to 225, 100 to 200, or 125 to 150 sequences.
SARS-CoV-2 or ACE2 binding libraries comprising de novo synthesized variant sequences encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains comprise improved diversity. In some instances, variants include affinity maturation variants. Alternatively or in combination, variants include variants in other regions of the antibody including, but not limited to, CDRH1, CDRH2, CDRL1, CDRL2, and CDRL3. In some instances, the number of variants of the SARS-CoV-2 or ACE2 binding libraries is least or about 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴or more than 10¹⁴non-identical sequences.
Following synthesis of SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding antibodies comprising SARS-CoV-2 or ACE2 binding domains, libraries may be used for screening and analysis. For example, libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. For example, SARS-CoV-2 or ACE2 binding libraries comprise nucleic acids encoding antibodies comprising SARS-CoV-2 or ACE2 binding domains with multiple tags such as GFP, FLAG, and Lucy as well as a DNA barcode. In some instances, libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis.
As used herein, the term antibody will be understood to include proteins having the characteristic two-armed, Y-shape of a typical antibody molecule as well as one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Exemplary antibodies include, but are not limited to, a monoclonal antibody, a polyclonal antibody, a bi-specific antibody, a multispecific antibody, a grafted antibody, a human antibody, a humanized antibody, a synthetic antibody, a chimeric antibody, a camelized antibody, a single-chain Fvs (scFv) (including fragments in which the VL and VH are joined using recombinant methods by a synthetic or natural linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules, including single chain Fab and scFab), a single chain antibody, a Fab fragment (including monovalent fragments comprising the VL, VH, CL, and CH1 domains), a F(ab′)2 fragment (including bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region), a Fd fragment (including fragments comprising the VH and CH1 fragment), a Fv fragment (including fragments comprising the VL and VH domains of a single arm of an antibody), a single-domain antibody (dAb or sdAb) (including fragments comprising a VH domain), an isolated complementarity determining region (CDR), a diabody (including fragments comprising bivalent dimers such as two VL and VH domains bound to each other and recognizing two different antigens), a fragment comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), an intrabody, an anti-idiotypic (anti-Id) antibody, or ab antigen-binding fragments thereof. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an antibody, wherein the antibody is a Fv antibody, including Fv antibodies comprised of the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. In some embodiments, the Fv antibody consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association, and the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. In some embodiments, the six hypervariable regions confer antigen-binding specificity to the antibody. In some embodiments, a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen, including single domain antibodies isolated from camelid animals comprising one heavy chain variable domain such as VHH antibodies or nanobodies) has the ability to recognize and bind antigen. In some instances, the libraries disclosed herein comprise nucleic acids encoding for an antibody, wherein the antibody is a single-chain Fv or scFv, including antibody fragments comprising a VH, a VL, or both a VH and VL domain, wherein both domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains allowing the scFv to form the desired structure for antigen binding. In some instances, a scFv is linked to the Fc fragment or a VHH is linked to the Fc fragment (including minibodies). In some instances, the antibody comprises immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, e.g., molecules that contain an antigen binding site. Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG 2, IgG 3, IgG 4, IgA 1 and IgA 2) or subclass.
In some embodiments, the antibody is a multivalent antibody. In some embodiments, the antibody is a monovalent, bivalent, or multivalent antibody. In some instances, the antibody is monospecific, bispecific, or multispecific. In some embodiments, the antibody is monovalent monospecific, monovalent bispecific, monovalent multispecific, bivalent monospecific, bivalent bispecific, bivalent multispecific, multivalent monospecific, multivalent bispecific, multivalent multispecific. In some instances, the antibody is homodimeric, heterodimeric, or heterotrimeric.
In some embodiments, libraries comprise immunoglobulins that are adapted to the species of an intended therapeutic target. Generally, these methods include “mammalization” and comprises methods for transferring donor antigen-binding information to a less immunogenic mammal antibody acceptor to generate useful therapeutic treatments. In some instances, the mammal is mouse, rat, equine, sheep, cow, primate (e.g., chimpanzee, baboon, gorilla, orangutan, monkey), dog, cat, pig, donkey, rabbit, and human. In some instances, provided herein are libraries and methods for felinization and caninization of antibodies.
“Humanized” forms of non-human antibodies can be chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. In some instances, these modifications are made to further refine antibody performance.
“Caninization” can comprise a method for transferring non-canine antigen-binding information from a donor antibody to a less immunogenic canine antibody acceptor to generate treatments useful as therapeutics in dogs. In some instances, caninized forms of non-canine antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-canine antibodies. In some instances, caninized antibodies are canine antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-canine species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the canine antibody are replaced by corresponding non-canine FR residues. In some instances, caninized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The caninized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a canine antibody.
“Felinization” can comprise a method for transferring non-feline antigen-binding information from a donor antibody to a less immunogenic feline antibody acceptor to generate treatments useful as therapeutics in cats. In some instances, felinized forms of non-feline antibodies provided herein are chimeric antibodies that contain minimal sequence derived from non-feline antibodies. In some instances, felinized antibodies are feline antibody sequences (“acceptor” or “recipient” antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-feline species (“donor” antibody) such as mouse, rat, rabbit, cat, dogs, goat, chicken, bovine, horse, llama, camel, dromedaries, sharks, non-human primates, human, humanized, recombinant sequence, or an engineered sequence having the desired properties. In some instances, framework region (FR) residues of the feline antibody are replaced by corresponding non-feline FR residues. In some instances, felinized antibodies include residues that are not found in the recipient antibody or in the donor antibody. In some instances, these modifications are made to further refine antibody performance. The felinized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc) of a felinize antibody.
Methods as described herein may be used for optimization of libraries encoding a non-immunoglobulin. In some instances, the libraries comprise antibody mimetics. Exemplary antibody mimetics include, but are not limited to, anticalins, affilins, affibody molecules, affimers, affitins, alphabodies, avimers, atrimers, DARPins, fynomers, Kunitz domain-based proteins, monobodies, anticalins, knottins, armadillo repeat protein-based proteins, and bicyclic peptides.
Libraries described herein comprising nucleic acids encoding for an antibody comprise variations in at least one region of the antibody. Exemplary regions of the antibody for variation include, but are not limited to, a complementarity-determining region (CDR), a variable domain, or a constant domain. In some instances, the CDR is CDR1, CDR2, or CDR3. In some instances, the CDR is a heavy domain including, but not limited to, CDRH1, CDRH2, and CDRH3. In some instances, the CDR is a light domain including, but not limited to, CDRL1, CDRL2, and CDRL3. In some instances, the variable domain is variable domain, light chain (VL) or variable domain, heavy chain (VH). In some instances, the VL domain comprises kappa or lambda chains. In some instances, the constant domain is constant domain, light chain (CL) or constant domain, heavy chain (CH).
Methods described herein provide for synthesis of libraries comprising nucleic acids encoding an antibody, wherein each nucleic acid encodes for a predetermined variant of at least one predetermined reference nucleic acid sequence. In some cases, the predetermined reference sequence is a nucleic acid sequence encoding for a protein, and the variant library comprises sequences encoding for variation of at least a single codon such that a plurality of different variants of a single residue in the subsequent protein encoded by the synthesized nucleic acid are generated by standard translation processes. In some instances, the antibody library comprises varied nucleic acids collectively encoding variations at multiple positions. In some instances, the variant library comprises sequences encoding for variation of at least a single codon of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of a CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the variant library comprises sequences encoding for variation of multiple codons of framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). An exemplary number of codons for variation include, but are not limited to, at least or about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 225, 250, 275, 300, or more than 300 codons.
In some instances, the at least one region of the antibody for variation is from heavy chain V-gene family, heavy chain D-gene family, heavy chain J-gene family, light chain V-gene family, or light chain J-gene family. In some instances, the light chain V-gene family comprises immunoglobulin kappa (IGK) gene or immunoglobulin lambda (IGL). Exemplary regions of the antibody for variation include, but are not limited to, IGHV1-18, IGHV1-69, IGHV1-8, IGHV3-21, IGHV3-23, IGHV3-30/33rn, IGHV3-28, IGHV1-69, IGHV3-74, IGHV4-39, IGHV4-59/61, IGKV1-39, IGKV1-9, IGKV2-28, IGKV3-11, IGKV3-15, IGKV3-20, IGKV4-1, IGLV1-51, IGLV2-14, IGLV1-40, and IGLV3-1. In some instances, the gene is IGHV1-69, IGHV3-30, IGHV3-23, IGHV3, IGHV1-46, IGHV3-7, IGHV1, or IGHV1-8. In some instances, the gene is IGHV1-69 and IGHV3-30. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, IGHJ4, IGHJ5, IGHJ2, or IGH1. In some instances, the region of the antibody for variation is IGHJ3, IGHJ6, IGHJ, or IGHJ4. In some instances, the at least one region of the antibody for variation is IGHV1-69, IGHV3-23, IGKV3-20, IGKV1-39, or combinations thereof. In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV3-20, In some instances, the at least one region of the antibody for variation is IGHV1-69 and IGKV1-39. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV3-20. In some instances, the at least one region of the antibody for variation is IGHV3-23 and IGKV1-39.
Provided herein are libraries comprising nucleic acids encoding for antibodies, wherein the libraries are synthesized with various numbers of fragments. In some instances, the fragments comprise the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, or VH domain. In some instances, the fragments comprise framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the antibody libraries are synthesized with at least or about 2 fragments, 3 fragments, 4 fragments, 5 fragments, or more than 5 fragments. The length of each of the nucleic acid fragments or average length of the nucleic acids synthesized may be at least or about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more than 600 base pairs. In some instances, the length is about 50 to 600, 75 to 575, 100 to 550, 125 to 525, 150 to 500, 175 to 475, 200 to 450, 225 to 425, 250 to 400, 275 to 375, or 300 to 350 base pairs.
Libraries comprising nucleic acids encoding for antibodies as described herein comprise various lengths of amino acids when translated. In some instances, the length of each of the amino acid fragments or average length of the amino acid synthesized may be at least or about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, or more than 150 amino acids. In some instances, the length of the amino acid is about 15 to 150, 20 to 145, 25 to 140, 30 to 135, 35 to 130, 40 to 125, 45 to 120, 50 to 115, 55 to 110, 60 to 110, 65 to 105, 70 to 100, or 75 to 95 amino acids. In some instances, the length of the amino acid is about 22 amino acids to about 75 amino acids. In some instances, the antibodies comprise at least or about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, or more than 5000 amino acids.
A number of variant sequences for the at least one region of the antibody for variation are de novo synthesized using methods as described herein. In some instances, a number of variant sequences is de novo synthesized for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, a number of variant sequences is de novo synthesized for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). The number of variant sequences may be at least or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or more than 500 sequences. In some instances, the number of variant sequences is at least or about 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, or more than 8000 sequences. In some instances, the number of variant sequences is about 10 to 500, 25 to 475, 50 to 450, 75 to 425, 100 to 400, 125 to 375, 150 to 350, 175 to 325, 200 to 300, 225 to 375, 250 to 350, or 275 to 325 sequences.
Variant sequences for the at least one region of the antibody, in some instances, vary in length or sequence. In some instances, the at least one region that is de novo synthesized is for CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, VL, VH, or combinations thereof. In some instances, the at least one region that is de novo synthesized is for framework element 1 (FW1), framework element 2 (FW2), framework element 3 (FW3), or framework element 4 (FW4). In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50 variant nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 additional nucleotides or amino acids as compared to wild-type. In some instances, the variant sequence comprises at least or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 less nucleotides or amino acids as compared to wild-type. In some instances, the libraries comprise at least or about 10¹, 10², 10³, 10⁴, 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, or more than 10¹⁰variants.
Following synthesis of antibody libraries, antibody libraries may be used for screening and analysis. For example, antibody libraries are assayed for library displayability and panning. In some instances, displayability is assayed using a selectable tag. Exemplary tags include, but are not limited to, a radioactive label, a fluorescent label, an enzyme, a chemiluminescent tag, a colorimetric tag, an affinity tag or other labels or tags that are known in the art. In some instances, the tag is histidine, polyhistidine, myc, hemagglutinin (HA), or FLAG. In some instances, antibody libraries are assayed by sequencing using various methods including, but not limited to, single-molecule real-time (SMRT) sequencing, Polony sequencing, sequencing by ligation, reversible terminator sequencing, proton detection sequencing, ion semiconductor sequencing, nanopore sequencing, electronic sequencing, pyrosequencing, Maxam-Gilbert sequencing, chain termination (e.g., Sanger) sequencing, +S sequencing, or sequencing by synthesis. In some instances, antibody libraries are displayed on the surface of a cell or phage. In some instances, antibody libraries are enriched for sequences with a desired activity using phage display.
In some instances, the antibody libraries are assayed for functional activity, structural stability (e.g., thermal stable or pH stable), expression, specificity, or a combination thereof. In some instances, the antibody libraries are assayed for antibody capable of folding. In some instances, a region of the antibody is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof. For example, a VH region or VL region is assayed for functional activity, structural stability, expression, specificity, folding, or a combination thereof.
In some instances, the affinity of antibodies or IgGs generated by methods as described herein is at least or about 1.5×, 2.0×, 5×, 10×, 20×, 30×, 40×, 50×, 60×, 70×, 80×, 90×, 100×, 200×, or more than 200× improved binding affinity as compared to a comparator antibody. In some instances, the affinity of antibodies or IgGs generated by methods as described herein is at least or about 1.5×, 2.0×, 5×, 10×, 20×, 30×, 40×, 50×, 60×, 70×, 80×, 90×, 100×, 200×, or more than 200× improved function as compared to a comparator antibody. In some instances, the comparator antibody is an antibody with similar structure, sequence, or antigen target.
Expression Systems
Provided herein are libraries comprising nucleic acids encoding for antibody comprising binding domains, wherein the libraries have improved specificity, stability, expression, folding, or downstream activity. In some instances, libraries described herein are used for screening and analysis.
Provided herein are libraries comprising nucleic acids encoding for antibody comprising binding domains, wherein the nucleic acid libraries are used for screening and analysis. In some instances, screening and analysis comprises in vitro, in vivo, or ex vivo assays. Cells for screening include primary cells taken from living subjects or cell lines. Cells may be from prokaryotes (e.g., bacteria and fungi) or eukaryotes (e.g., animals and plants). Exemplary animal cells include, without limitation, those from a mouse, rabbit, primate, and insect. In some instances, cells for screening include a cell line including, but not limited to, Chinese Hamster Ovary (CHO) cell line, human embryonic kidney (HEK) cell line, or baby hamster kidney (BHK) cell line. In some instances, nucleic acid libraries described herein may also be delivered to a multicellular organism. Exemplary multicellular organisms include, without limitation, a plant, a mouse, rabbit, primate, and insect.
Nucleic acid libraries described herein may be screened for various pharmacological or pharmacokinetic properties. In some instances, the libraries are screened using in vitro assays, in vivo assays, or ex vivo assays. For example, in vitro pharmacological or pharmacokinetic properties that are screened include, but are not limited to, binding affinity, binding specificity, and binding avidity. Exemplary in vivo pharmacological or pharmacokinetic properties of libraries described herein that are screened include, but are not limited to, therapeutic efficacy, activity, preclinical toxicity properties, clinical efficacy properties, clinical toxicity properties, immunogenicity, potency, and clinical safety properties.
Provided herein are nucleic acid libraries, wherein the nucleic acid libraries may be expressed in a vector. Expression vectors for inserting nucleic acid libraries disclosed herein may comprise eukaryotic or prokaryotic expression vectors. Exemplary expression vectors include, without limitation, mammalian expression vectors: pSF-CMV-NEO-NH2-PPT-3XFLAG, pSF-CMV-NEO-COOH-3XFLAG, pSF-CMV-PURO-NH2-GST-TEV, pSF-OXB20-COOH-TEV-FLAG(R)-6His, pCEP4 pDEST27, pSF-CMV-Ub-KrYFP, pSF-CMV-FMDV-daGFP, pEF1a-mCherry-N1 Vector, pEF1a-tdTomato Vector, pSF-CMV-FMDV-Hygro, pSF-CMV-PGK-Puro, pMCP-tag(m), and pSF-CMV-PURO-NH2-CMYC; bacterial expression vectors: pSF-OXB20-BetaGal,pSF-OXB20-Fluc, pSF-OXB20, and pSF-Tac; plant expression vectors: pRI 101-AN DNA and pCambia2301; and yeast expression vectors: pTYB21 and pKLAC2, and insect vectors: pAc5.1/V5-His A and pDEST8. In some instances, the vector is pcDNA3 or pcDNA3.1.
Described herein are nucleic acid libraries that are expressed in a vector to generate a construct comprising an antibody. In some instances, a size of the construct varies. In some instances, the construct comprises at least or about 500, 600, 700, 800, 900, 1000, 1100, 1300, 1400, 1500, 1600, 1700, 1800, 2000, 2400, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600, 4800, 5000, 6000, 7000, 8000, 9000, 10000, or more than 10000 bases. In some instances, a the construct comprises a range of about 300 to 1,000, 300 to 2,000, 300 to 3,000, 300 to 4,000, 300 to 5,000, 300 to 6,000, 300 to 7,000, 300 to 8,000, 300 to 9,000, 300 to 10,000, 1,000 to 2,000, 1,000 to 3,000, 1,000 to 4,000, 1,000 to 5,000, 1,000 to 6,000, 1,000 to 7,000, 1,000 to 8,000, 1,000 to 9,000, 1,000 to 10,000, 2,000 to 3,000, 2,000 to 4,000, 2,000 to 5,000, 2,000 to 6,000, 2,000 to 7,000, 2,000 to 8,000, 2,000 to 9,000, 2,000 to 10,000, 3,000 to 4,000, 3,000 to 5,000, 3,000 to 6,000, 3,000 to 7,000, 3,000 to 8,000, 3,000 to 9,000, 3,000 to 10,000, 4,000 to 5,000, 4,000 to 6,000, 4,000 to 7,000, 4,000 to 8,000, 4,000 to 9,000, 4,000 to 10,000, 5,000 to 6,000, 5,000 to 7,000, 5,000 to 8,000, 5,000 to 9,000, 5,000 to 10,000, 6,000 to 7,000, 6,000 to 8,000, 6,000 to 9,000, 6,000 to 10,000, 7,000 to 8,000, 7,000 to 9,000, 7,000 to 10,000, 8,000 to 9,000, 8,000 to 10,000, or 9,000 to 10,000 bases.
Provided herein are libraries comprising nucleic acids encoding for antibodies, wherein the nucleic acid libraries are expressed in a cell. In some instances, the libraries are synthesized to express a reporter gene. Exemplary reporter genes include, but are not limited to, acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), cerulean fluorescent protein, citrine fluorescent protein, orange fluorescent protein, cherry fluorescent protein, turquoise fluorescent protein, blue fluorescent protein, horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), luciferase, and derivatives thereof. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), and antibiotic resistance determination.
Diseases and Disorders
Provided herein are SARS-CoV-2 or ACE2 binding libraries comprising nucleic acids encoding for antibodies comprising SARS-CoV-2 or ACE2 binding domains may have therapeutic effects. In some instances, the SARS-CoV-2 or ACE2 binding libraries result in protein when translated that is used to treat a disease or disorder. In some instances, the protein is an immunoglobulin. In some instances, the protein is a peptidomimetic. In some instances, the disease or disorder is a viral infection caused by SARS-CoV-2. In some instances, the disease or disorder is a respiratory disease or disorder caused by SARS-CoV-2.
SARS-CoV-2 or ACE2 variant antibody libraries as described herein may be used to treat SARS-CoV-2. In some embodiments, the SARS-CoV-2 or ACE2 variant antibody libraries are used to treat or prevent symptoms of SARS-CoV-2. These symptoms include, but are not limited to, fever, chills, cough, fatigue, headaches, loss of taste, loss of smell, nausea, vomiting, muscle weakness, sleep difficulties, anxiety, and depression. In some embodiments, the SARS-CoV-2 or ACE2 variant antibody libraries are used to treat a subject who has symptoms for an extended period of time. In some embodiments, the subject has symptoms for an extended period of time after testing negative for SARS-CoV-2. In some embodiments, the subject has symptoms for an extended period of time including at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, or more than 1 year.
In some instances, the subject is a mammal. In some instances, the subject is a mouse, rabbit, dog, or human. Subjects treated by methods described herein may be infants, adults, or children. Pharmaceutical compositions comprising antibodies or antibody fragments as described herein may be administered intravenously or subcutaneously. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH1 sequence of any one of SEQ ID NOs: 217-266, 1495-1635, or 2059-2238. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH2 sequence of any one of SEQ ID NOs: 267-316, 1636-1776, or 2239-2418 In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a CDRH3 sequence of any one of SEQ ID NOs: 317-366, 1777-1917, or 2419-2598. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 145-180 or 415-473; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 181-216 or 533-591. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a VH comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 592-657, and VL comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 658-716. In some instances, a pharmaceutical composition comprises an antibody or antibody fragment described herein comprising a heavy chain variable domain comprising at least or about 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of SEQ ID NOs: 1918-2058, 2599-2778, and 3095-3173.
SARS-CoV-2 or ACE2 antibodies as described herein may confer immunity after exposure to SARS-CoV-2 or ACE2 antibodies. In some embodiments, the SARS-CoV-2 or ACE2 antibodies described herein are used for passive immunization of a subject. In some instances, the subject is actively immunized after exposure to SARS-CoV-2 or ACE2 antibodies followed by exposure to SARS-CoV-2. In some embodiments, SARS-CoV-2 or ACE2 antibodies are derived from a subject who has recovered from SARS-CoV-2.
In some embodiments, the immunity occurs at least about 30 minutes, 1 hour, 5 hours, 10 hours, 16 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, or more than 2 weeks after exposure to SARS-CoV-2 or ACE2 antibodies. In some instances, the immunity lasts for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years after exposure to SARS-CoV-2 or ACE2 antibodies.
In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies prior to exposure to SARS-CoV-2. In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies at least about 30 minutes, 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years prior to exposure to SARS-CoV-2. In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies after exposure to SARS-CoV-2. In some embodiments, the subject receives the SARS-CoV-2 or ACE2 antibodies at least about 30 minutes, 1 hour, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more than 5 years after exposure to SARS-CoV-2.
SARS-CoV-2 or ACE2 antibodies described herein may be administered through various routes. The administration may, depending on the composition being administered, for example, be oral, pulmonary, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal.
Described herein are compositions or pharmaceutical compositions comprising SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof that comprise various dosages of the antibodies or antibody fragment. In some instances, the dosage is ranging from about 1 to 25 mg/kg, from about 1 to 50 mg/kg, from about 1 to 80 mg/kg, from about 1 to about 100 mg/kg, from about 5 to about 100 mg/kg, from about 5 to about 80 mg/kg, from about 5 to about 60 mg/kg, from about 5 to about 50 mg/kg or from about 5 to about 500 mg/kg which can be administered in single or multiple doses. In some instances, the dosage is administered in an amount of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 105 mg/kg, about 110 mg/kg, about 115 mg/kg, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 240, about 250, about 260, about 270, about 275, about 280, about 290, about 300, about 310, about 320, about 330, about 340, about 350, about 360 mg/kg, about 370 mg/kg, about 380 mg/kg, about 390 mg/kg, about 400 mg/kg, 410 mg/kg, about 420 mg/kg, about 430 mg/kg, about 440 mg/kg, about 450 mg/kg, about 460 mg/kg, about 470 mg/kg, about 480 mg/kg, about 490 mg/kg, or about 500 mg/kg.
SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof described herein, in some embodiments, improve disease severity. In some embodiments, the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof improve disease severity at a dose level of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, or about 20 mg/kg. In some embodiments, the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof improve disease severity at a dose level of about 1 mg/kg, about 5 mg/kg, or about 10 mg/kg. In some embodiments, disease severity is determined by percent weight loss. In some embodiments, the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof protects against weight loss at a dose level of about 0.01 mg/kg, about 0.05 mg/kg, about 0.10 mg/kg, about 0.25 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, or about 20 mg/kg. In some embodiments, the SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof protects against weight loss at a dose level of about 1 mg/kg, about 5 mg/kg, or about 10 mg/kg. In some embodiments, SARS-CoV-2 or ACE2 antibodies or antibody fragment thereof
Variant Libraries
Codon Variation
Variant nucleic acid libraries described herein may comprise a plurality of nucleic acids, wherein each nucleic acid encodes for a variant codon sequence compared to a reference nucleic acid sequence. In some instances, each nucleic acid of a first nucleic acid population contains a variant at a single variant site. In some instances, the first nucleic acid population contains a plurality of variants at a single variant site such that the first nucleic acid population contains more than one variant at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding multiple codon variants at the same variant site. The first nucleic acid population may comprise nucleic acids collectively encoding up to 19 or more codons at the same position. The first nucleic acid population may comprise nucleic acids collectively encoding up to 60 variant triplets at the same position, or the first nucleic acid population may comprise nucleic acids collectively encoding up to 61 different triplets of codons at the same position. Each variant may encode for a codon that results in a different amino acid during translation. Table 1 provides a listing of each codon possible (and the representative amino acid) for a variant site.

TABLE 1

List of codons and amino acids

	One	Three
	letter	letter
Amino Acids	code	code	Codons

Alanine

A

Ala

GCA

GCC

GCG

GCT

Cysteine	C	Cys	TGC	TGT
Aspartic	D	Asp	GAC	GAT
acid
Glutamic	E	Glu	GAA	GAG
acid
Phenylalanine	F	Phe	TTC	TTT

Glycine

G

Gly

GGA

GGC

GGG

GGT

Histidine

H

His

CAC

CAT

Isoleucine

I

Iso

ATA

ATC

ATT

Lysine

K

Lys

AAA

AAG

Leucine

L

Leu

TTA

TTG

CTA

CTC

CTG

CTT

Methionine

M

Met

ATG

Asparagine

N

Asn

AAC

AAT

Proline

P

Pro

CCA

CCC

CCG

CCT

Glutamine

Q

Gln

CAA

CAG

Arginine	R	Arg	AGA	AGG	CGA	CGC	CGG	CGT
Serine	S	Ser	AGC	AGT	TCA	TCC	TCG	TCT

Threonine	T	Thr	ACA	ACC	ACG	ACT
Valine	V	Val	GTA	GTC	GTG	GTT

Tryptophan

W

Trp

TGG

Tyrosine	Y	Tyr	TAC	TAT

A nucleic acid population may comprise varied nucleic acids collectively encoding up to 20 codon variations at multiple positions. In such cases, each nucleic acid in the population comprises variation for codons at more than one position in the same nucleic acid. In some instances, each nucleic acid in the population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more codons in a single nucleic acid. In some instances, each variant long nucleic acid comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single long nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more codons in a single nucleic acid. In some instances, the variant nucleic acid population comprises variation for codons in at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more codons in a single long nucleic acid.
Highly Parallel Nucleic Acid Synthesis
Provided herein is a platform approach utilizing miniaturization, parallelization, and vertical integration of the end-to-end process from polynucleotide synthesis to gene assembly within nanowells on silicon to create a revolutionary synthesis platform. Devices described herein provide, with the same footprint as a 96-well plate, a silicon synthesis platform is capable of increasing throughput by a factor of up to 1,000 or more compared to traditional synthesis methods, with production of up to approximately 1,000,000 or more polynucleotides, or 10,000 or more genes in a single highly-parallelized run.
With the advent of next-generation sequencing, high resolution genomic data has become an important factor for studies that delve into the biological roles of various genes in both normal biology and disease pathogenesis. At the core of this research is the central dogma of molecular biology and the concept of “residue-by-residue transfer of sequential information.” Genomic information encoded in the DNA is transcribed into a message that is then translated into the protein that is the active product within a given biological pathway.
Another exciting area of study is on the discovery, development and manufacturing of therapeutic molecules focused on a highly-specific cellular target. High diversity DNA sequence libraries are at the core of development pipelines for targeted therapeutics. Gene variants are used to express proteins in a design, build, and test protein engineering cycle that ideally culminates in an optimized gene for high expression of a protein with high affinity for its therapeutic target. As an example, consider the binding pocket of a receptor. The ability to test all sequence permutations of all residues within the binding pocket simultaneously will allow for a thorough exploration, increasing chances of success. Saturation mutagenesis, in which a researcher attempts to generate all possible mutations or variants at a specific site within the receptor, represents one approach to this development challenge. Though costly and time and labor-intensive, it enables each variant to be introduced into each position. In contrast, combinatorial mutagenesis, where a few selected positions or short stretch of DNA may be modified extensively, generates an incomplete repertoire of variants with biased representation.
To accelerate the drug development pipeline, a library with the desired variants available at the intended frequency in the right position available for testing—in other words, a precision library, enables reduced costs as well as turnaround time for screening. Provided herein are methods for synthesizing nucleic acid synthetic variant libraries which provide for precise introduction of each intended variant at the desired frequency. To the end user, this translates to the ability to not only thoroughly sample sequence space but also be able to query these hypotheses in an efficient manner, reducing cost and screening time. Genome-wide editing can elucidate important pathways, libraries where each variant and sequence permutation can be tested for optimal functionality, and thousands of genes can be used to reconstruct entire pathways and genomes to re-engineer biological systems for drug discovery.
In a first example, a drug itself can be optimized using methods described herein. For example, to improve a specified function of an antibody, a variant polynucleotide library encoding for a portion of the antibody is designed and synthesized. A variant nucleic acid library for the antibody can then be generated by processes described herein (e.g., PCR mutagenesis followed by insertion into a vector). The antibody is then expressed in a production cell line and screened for enhanced activity. Example screens include examining modulation in binding affinity to an antigen, stability, or effector function (e.g., ADCC, complement, or apoptosis). Exemplary regions to optimize the antibody include, without limitation, the Fc region, Fab region, variable region of the Fab region, constant region of the Fab region, variable domain of the heavy chain or light chain (V_Hor V_L), and specific complementarity-determining regions (CDRs) of V_Hor V_L.
Nucleic acid libraries synthesized by methods described herein may be expressed in various cells associated with a disease state. Cells associated with a disease state include cell lines, tissue samples, primary cells from a subject, cultured cells expanded from a subject, or cells in a model system. Exemplary model systems include, without limitation, plant and animal models of a disease state.
To identify a variant molecule associated with prevention, reduction or treatment of a disease state, a variant nucleic acid library described herein is expressed in a cell associated with a disease state, or one in which a cell a disease state can be induced. In some instances, an agent is used to induce a disease state in cells. Exemplary tools for disease state induction include, without limitation, a Cre/Lox recombination system, LPS inflammation induction, and streptozotocin to induce hypoglycemia. The cells associated with a disease state may be cells from a model system or cultured cells, as well as cells from a subject having a particular disease condition. Exemplary disease conditions include a bacterial, fungal, viral, autoimmune, or proliferative disorder (e.g., cancer). In some instances, the variant nucleic acid library is expressed in the model system, cell line, or primary cells derived from a subject, and screened for changes in at least one cellular activity. Exemplary cellular activities include, without limitation, proliferation, cycle progression, cell death, adhesion, migration, reproduction, cell signaling, energy production, oxygen utilization, metabolic activity, and aging, response to free radical damage, or any combination thereof
Substrates
Devices used as a surface for polynucleotide synthesis may be in the form of substrates which include, without limitation, homogenous array surfaces, patterned array surfaces, channels, beads, gels, and the like. Provided herein are substrates comprising a plurality of clusters, wherein each cluster comprises a plurality of loci that support the attachment and synthesis of polynucleotides. In some instances, substrates comprise a homogenous array surface. For example, the homogenous array surface is a homogenous plate. The term “locus” as used herein refers to a discrete region on a structure which provides support for polynucleotides encoding for a single predetermined sequence to extend from the surface. In some instances, a locus is on a two dimensional surface, e.g., a substantially planar surface. In some instances, a locus is on a three-dimensional surface, e.g., a well, microwell, channel, or post. In some instances, a surface of a locus comprises a material that is actively functionalized to attach to at least one nucleotide for polynucleotide synthesis, or preferably, a population of identical nucleotides for synthesis of a population of polynucleotides. In some instances, polynucleotide refers to a population of polynucleotides encoding for the same nucleic acid sequence. In some cases, a surface of a substrate is inclusive of one or a plurality of surfaces of a substrate. The average error rates for polynucleotides synthesized within a library described here using the systems and methods provided are often less than 1 in 1000, less than about 1 in 2000, less than about 1 in 3000 or less often without error correction.
Provided herein are surfaces that support the parallel synthesis of a plurality of polynucleotides having different predetermined sequences at addressable locations on a common support. In some instances, a substrate provides support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more non-identical polynucleotides. In some cases, the surfaces provide support for the synthesis of more than 50, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2,000; 5,000; 10,000; 20,000; 50,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; 10,000,000 or more polynucleotides encoding for distinct sequences. In some instances, at least a portion of the polynucleotides have an identical sequence or are configured to be synthesized with an identical sequence. In some instances, the substrate provides a surface environment for the growth of polynucleotides having at least 80, 90, 100, 120, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 bases or more.
Provided herein are methods for polynucleotide synthesis on distinct loci of a substrate, wherein each locus supports the synthesis of a population of polynucleotides. In some cases, each locus supports the synthesis of a population of polynucleotides having a different sequence than a population of polynucleotides grown on another locus. In some instances, each polynucleotide sequence is synthesized with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more redundancy across different loci within the same cluster of loci on a surface for polynucleotide synthesis. In some instances, the loci of a substrate are located within a plurality of clusters. In some instances, a substrate comprises at least 10, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 20000, 30000, 40000, 50000 or more clusters. In some instances, a substrate comprises more than 2,000; 5,000; 10,000; 100,000; 200,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,100,000; 1,200,000; 1,300,000; 1,400,000; 1,500,000; 1,600,000; 1,700,000; 1,800,000; 1,900,000; 2,000,000; 300,000; 400,000; 500,000; 600,000; 700,000; 800,000; 900,000; 1,000,000; 1,200,000; 1,400,000; 1,600,000; 1,800,000; 2,000,000; 2,500,000; 3,000,000; 3,500,000; 4,000,000; 4,500,000; 5,000,000; or 10,000,000 or more distinct loci. In some instances, a substrate comprises about 10,000 distinct loci. The amount of loci within a single cluster is varied in different instances. In some cases, each cluster includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 150, 200, 300, 400, 500 or more loci. In some instances, each cluster includes about 50-500 loci. In some instances, each cluster includes about 100-200 loci. In some instances, each cluster includes about 100-150 loci. In some instances, each cluster includes about 109, 121, 130 or 137 loci. In some instances, each cluster includes about 19, 20, 61, 64 or more loci. Alternatively or in combination, polynucleotide synthesis occurs on a homogenous array surface.
In some instances, the number of distinct polynucleotides synthesized on a substrate is dependent on the number of distinct loci available in the substrate. In some instances, the density of loci within a cluster or surface of a substrate is at least or about 1, 10, 25, 50, 65, 75, 100, 130, 150, 175, 200, 300, 400, 500, 1,000 or more loci per mm². In some cases, a substrate comprises 10-500, 25-400, 50-500, 100-500, 150-500, 10-250, 50-250, 10-200, or 50-200 mm². In some instances, the distance between the centers of two adjacent loci within a cluster or surface is from about 10-500, from about 10-200, or from about 10-100 um. In some instances, the distance between two centers of adjacent loci is greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some instances, the distance between the centers of two adjacent loci is less than about 200, 150, 100, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, each locus has a width of about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 um. In some cases, each locus has a width of about 0.5-100, 0.5-50, 10-75, or 0.5-50 um.
In some instances, the density of clusters within a substrate is at least or about 1 cluster per 100 mm², 1 cluster per 10 mm², 1 cluster per 5 mm², 1 cluster per 4 mm², 1 cluster per 3 mm², 1 cluster per 2 mm², 1 cluster per 1 mm², 2 clusters per 1 mm², 3 clusters per 1 mm², 4 clusters per 1 mm², 5 clusters per 1 mm², 10 clusters per 1 mm², 50 clusters per 1 mm²or more. In some instances, a substrate comprises from about 1 cluster per 10 mm²to about 10 clusters per 1 mm². In some instances, the distance between the centers of two adjacent clusters is at least or about 50, 100, 200, 500, 1000, 2000, or 5000 um. In some cases, the distance between the centers of two adjacent clusters is between about 50-100, 50-200, 50-300, 50-500, and 100-2000 um. In some cases, the distance between the centers of two adjacent clusters is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some cases, each cluster has a cross section of about 0.5 to about 2, about 0.5 to about 1, or about 1 to about 2 mm. In some cases, each cluster has a cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm. In some cases, each cluster has an interior cross section of about 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.15, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 mm.
In some instances, a substrate is about the size of a standard 96 well plate, for example between about 100 and about 200 mm by between about 50 and about 150 mm. In some instances, a substrate has a diameter less than or equal to about 1000, 500, 450, 400, 300, 250, 200, 150, 100 or 50 mm. In some instances, the diameter of a substrate is between about 25-1000, 25-800, 25-600, 25-500, 25-400, 25-300, or 25-200 mm. In some instances, a substrate has a planar surface area of at least about 100; 200; 500; 1,000; 2,000; 5,000; 10,000; 12,000; 15,000; 20,000; 30,000; 40,000; 50,000 mm²or more. In some instances, the thickness of a substrate is between about 50-2000, 50-1000, 100-1000, 200-1000, or 250-1000 mm.
Surface Materials
Substrates, devices, and reactors provided herein are fabricated from any variety of materials suitable for the methods, compositions, and systems described herein. In certain instances, substrate materials are fabricated to exhibit a low level of nucleotide binding. In some instances, substrate materials are modified to generate distinct surfaces that exhibit a high level of nucleotide binding. In some instances, substrate materials are transparent to visible and/or UV light. In some instances, substrate materials are sufficiently conductive, e.g., are able to form uniform electric fields across all or a portion of a substrate. In some instances, conductive materials are connected to an electric ground. In some instances, the substrate is heat conductive or insulated. In some instances, the materials are chemical resistant and heat resistant to support chemical or biochemical reactions, for example polynucleotide synthesis reaction processes. In some instances, a substrate comprises flexible materials. For flexible materials, materials can include, without limitation: nylon, both modified and unmodified, nitrocellulose, polypropylene, and the like. In some instances, a substrate comprises rigid materials. For rigid materials, materials can include, without limitation: glass; fuse silica; silicon, plastics (for example polytetrafluoroethylene, polypropylene, polystyrene, polycarbonate, and blends thereof, and the like); metals (for example, gold, platinum, and the like). The substrate, solid support or reactors can be fabricated from a material selected from the group consisting of silicon, polystyrene, agarose, dextran, cellulosic polymers, polyacrylamides, polydimethylsiloxane (PDMS), and glass. The substrates/solid supports or the microstructures, reactors therein may be manufactured with a combination of materials listed herein or any other suitable material known in the art.
Surface Architecture
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates have a surface architecture suitable for the methods, compositions, and systems described herein. In some instances, a substrate comprises raised and/or lowered features. One benefit of having such features is an increase in surface area to support polynucleotide synthesis. In some instances, a substrate having raised and/or lowered features is referred to as a three-dimensional substrate. In some cases, a three-dimensional substrate comprises one or more channels. In some cases, one or more loci comprise a channel. In some cases, the channels are accessible to reagent deposition via a deposition device such as a material deposition device. In some cases, reagents and/or fluids collect in a larger well in fluid communication one or more channels. For example, a substrate comprises a plurality of channels corresponding to a plurality of loci with a cluster, and the plurality of channels are in fluid communication with one well of the cluster. In some methods, a library of polynucleotides is synthesized in a plurality of loci of a cluster.
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates are configured for polynucleotide synthesis. In some instances, the structure is configured to allow for controlled flow and mass transfer paths for polynucleotide synthesis on a surface. In some instances, the configuration of a substrate allows for the controlled and even distribution of mass transfer paths, chemical exposure times, and/or wash efficacy during polynucleotide synthesis. In some instances, the configuration of a substrate allows for increased sweep efficiency, for example by providing sufficient volume for a growing polynucleotide such that the excluded volume by the growing polynucleotide does not take up more than 50, 45, 40, 35, 30, 25, 20, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less of the initially available volume that is available or suitable for growing the polynucleotide. In some instances, a three-dimensional structure allows for managed flow of fluid to allow for the rapid exchange of chemical exposure.
Provided herein are substrates for the methods, compositions, and systems described herein, wherein the substrates comprise structures suitable for the methods, compositions, and systems described herein. In some instances, segregation is achieved by physical structure. In some instances, segregation is achieved by differential functionalization of the surface generating active and passive regions for polynucleotide synthesis. In some instances, differential functionalization is achieved by alternating the hydrophobicity across the substrate surface, thereby creating water contact angle effects that cause beading or wetting of the deposited reagents. Employing larger structures can decrease splashing and cross-contamination of distinct polynucleotide synthesis locations with reagents of the neighboring spots. In some cases, a device, such as a material deposition device, is used to deposit reagents to distinct polynucleotide synthesis locations. Substrates having three-dimensional features are configured in a manner that allows for the synthesis of a large number of polynucleotides (e.g., more than about 10,000) with a low error rate (e.g., less than about 1:500, 1:1000, 1:1500, 1:2,000, 1:3,000, 1:5,000, or 1:10,000). In some cases, a substrate comprises features with a density of about or greater than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400 or 500 features per mm².
A well of a substrate may have the same or different width, height, and/or volume as another well of the substrate. A channel of a substrate may have the same or different width, height, and/or volume as another channel of the substrate. In some instances, the diameter of a cluster or the diameter of a well comprising a cluster, or both, is between about 0.05-50, 0.05-10, 0.05-5, 0.05-4, 0.05-3, 0.05-2, 0.05-1, 0.05-0.5, 0.05-0.1, 0.1-10, 0.2-10, 0.3-10, 0.4-10, 0.5-10, 0.5-5, or 0.5-2 mm. In some instances, the diameter of a cluster or well or both is less than or about 5, 4, 3, 2, 1, 0.5, 0.1, 0.09, 0.08, 0.07, 0.06, or 0.05 mm. In some instances, the diameter of a cluster or well or both is between about 1.0 and 1.3 mm. In some instances, the diameter of a cluster or well, or both is about 1.150 mm. In some instances, the diameter of a cluster or well, or both is about 0.08 mm. The diameter of a cluster refers to clusters within a two-dimensional or three-dimensional substrate.
In some instances, the height of a well is from about 20-1000, 50-1000, 100-1000, 200-1000, 300-1000, 400-1000, or 500-1000 um. In some cases, the height of a well is less than about 1000, 900, 800, 700, or 600 um.
In some instances, a substrate comprises a plurality of channels corresponding to a plurality of loci within a cluster, wherein the height or depth of a channel is 5-500, 5-400, 5-300, 5-200, 5-100, 5-50, or 10-50 um. In some cases, the height of a channel is less than 100, 80, 60, 40, or 20 um.
In some instances, the diameter of a channel, locus (e.g., in a substantially planar substrate) or both channel and locus (e.g., in a three-dimensional substrate wherein a locus corresponds to a channel) is from about 1-1000, 1-500, 1-200, 1-100, 5-100, or 10-100 um, for example, about 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the diameter of a channel, locus, or both channel and locus is less than about 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 um. In some instances, the distance between the center of two adjacent channels, loci, or channels and loci is from about 1-500, 1-200, 1-100, 5-200, 5-100, 5-50, or 5-30, for example, about 20 um.
Surface Modifications
Provided herein are methods for polynucleotide synthesis on a surface, wherein the surface comprises various surface modifications. In some instances, the surface modifications are employed for the chemical and/or physical alteration of a surface by an additive or subtractive process to change one or more chemical and/or physical properties of a substrate surface or a selected site or region of a substrate surface. For example, surface modifications include, without limitation, (1) changing the wetting properties of a surface, (2) functionalizing a surface, i.e., providing, modifying or substituting surface functional groups, (3) defunctionalizing a surface, i.e., removing surface functional groups, (4) otherwise altering the chemical composition of a surface, e.g., through etching, (5) increasing or decreasing surface roughness, (6) providing a coating on a surface, e.g., a coating that exhibits wetting properties that are different from the wetting properties of the surface, and/or (7) depositing particulates on a surface.
In some cases, the addition of a chemical layer on top of a surface (referred to as adhesion promoter) facilitates structured patterning of loci on a surface of a substrate. Exemplary surfaces for application of adhesion promotion include, without limitation, glass, silicon, silicon dioxide and silicon nitride. In some cases, the adhesion promoter is a chemical with a high surface energy. In some instances, a second chemical layer is deposited on a surface of a substrate. In some cases, the second chemical layer has a low surface energy. In some cases, surface energy of a chemical layer coated on a surface supports localization of droplets on the surface. Depending on the patterning arrangement selected, the proximity of loci and/or area of fluid contact at the loci are alterable.
In some instances, a substrate surface, or resolved loci, onto which nucleic acids or other moieties are deposited, e.g., for polynucleotide synthesis, are smooth or substantially planar (e.g., two-dimensional) or have irregularities, such as raised or lowered features (e.g., three-dimensional features). In some instances, a substrate surface is modified with one or more different layers of compounds. Such modification layers of interest include, without limitation, inorganic and organic layers such as metals, metal oxides, polymers, small organic molecules and the like.
In some instances, resolved loci of a substrate are functionalized with one or more moieties that increase and/or decrease surface energy. In some cases, a moiety is chemically inert. In some cases, a moiety is configured to support a desired chemical reaction, for example, one or more processes in a polynucleotide synthesis reaction. The surface energy, or hydrophobicity, of a surface is a factor for determining the affinity of a nucleotide to attach onto the surface. In some instances, a method for substrate functionalization comprises: (a) providing a substrate having a surface that comprises silicon dioxide; and (b) silanizing the surface using, a suitable silanizing agent described herein or otherwise known in the art, for example, an organofunctional alkoxysilane molecule. Methods and functionalizing agents are described in U.S. Pat. No. 5,474,796, which is herein incorporated by reference in its entirety.
In some instances, a substrate surface is functionalized by contact with a derivatizing composition that contains a mixture of silanes, under reaction conditions effective to couple the silanes to the substrate surface, typically via reactive hydrophilic moieties present on the substrate surface. Silanization generally covers a surface through self-assembly with organofunctional alkoxysilane molecules. A variety of siloxane functionalizing reagents can further be used as currently known in the art, e.g., for lowering or increasing surface energy. The organofunctional alkoxysilanes are classified according to their organic functions.
Polynucleotide Synthesis
Methods of the current disclosure for polynucleotide synthesis may include processes involving phosphoramidite chemistry. In some instances, polynucleotide synthesis comprises coupling a base with phosphoramidite. Polynucleotide synthesis may comprise coupling a base by deposition of phosphoramidite under coupling conditions, wherein the same base is optionally deposited with phosphoramidite more than once, i.e., double coupling. Polynucleotide synthesis may comprise capping of unreacted sites. In some instances, capping is optional. Polynucleotide synthesis may also comprise oxidation or an oxidation step or oxidation steps. Polynucleotide synthesis may comprise deblocking, detritylation, and sulfurization. In some instances, polynucleotide synthesis comprises either oxidation or sulfurization. In some instances, between one or each step during a polynucleotide synthesis reaction, the device is washed, for example, using tetrazole or acetonitrile. Time frames for any one step in a phosphoramidite synthesis method may be less than about 2 min, 1 min, 50 sec, 40 sec, 30 sec, 20 sec and 10 sec.
Polynucleotide synthesis using a phosphoramidite method may comprise a subsequent addition of a phosphoramidite building block (e.g., nucleoside phosphoramidite) to a growing polynucleotide chain for the formation of a phosphite triester linkage. Phosphoramidite polynucleotide synthesis proceeds in the 3′ to 5′ direction. Phosphoramidite polynucleotide synthesis allows for the controlled addition of one nucleotide to a growing nucleic acid chain per synthesis cycle. In some instances, each synthesis cycle comprises a coupling step. Phosphoramidite coupling involves the formation of a phosphite triester linkage between an activated nucleoside phosphoramidite and a nucleoside bound to the substrate, for example, via a linker. In some instances, the nucleoside phosphoramidite is provided to the device activated. In some instances, the nucleoside phosphoramidite is provided to the device with an activator. In some instances, nucleoside phosphoramidites are provided to the device in a 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100-fold excess or more over the substrate-bound nucleosides. In some instances, the addition of nucleoside phosphoramidite is performed in an anhydrous environment, for example, in anhydrous acetonitrile. Following addition of a nucleoside phosphoramidite, the device is optionally washed. In some instances, the coupling step is repeated one or more additional times, optionally with a wash step between nucleoside phosphoramidite additions to the substrate. In some instances, a polynucleotide synthesis method used herein comprises 1, 2, 3 or more sequential coupling steps. Prior to coupling, in many cases, the nucleoside bound to the device is de-protected by removal of a protecting group, where the protecting group functions to prevent polymerization. A common protecting group is 4,4′-dimethoxytrityl (DMT).
Following coupling, phosphoramidite polynucleotide synthesis methods optionally comprise a capping step. In a capping step, the growing polynucleotide is treated with a capping agent. A capping step is useful to block unreacted substrate-bound 5′-OH groups after coupling from further chain elongation, preventing the formation of polynucleotides with internal base deletions. Further, phosphoramidites activated with 1H-tetrazole may react, to a small extent, with the O6 position of guanosine. Without being bound by theory, upon oxidation with I₂/water, this side product, possibly via O6-N7 migration, may undergo depurination. The apurinic sites may end up being cleaved in the course of the final deprotection of the polynucleotide thus reducing the yield of the full-length product. The O6 modifications may be removed by treatment with the capping reagent prior to oxidation with I₂/water. In some instances, inclusion of a capping step during polynucleotide synthesis decreases the error rate as compared to synthesis without capping. As an example, the capping step comprises treating the substrate-bound polynucleotide with a mixture of acetic anhydride and 1-methylimidazole. Following a capping step, the device is optionally washed.
In some instances, following addition of a nucleoside phosphoramidite, and optionally after capping and one or more wash steps, the device bound growing nucleic acid is oxidized. The oxidation step comprises the phosphite triester is oxidized into a tetracoordinated phosphate triester, a protected precursor of the naturally occurring phosphate diester internucleoside linkage. In some instances, oxidation of the growing polynucleotide is achieved by treatment with iodine and water, optionally in the presence of a weak base (e.g., pyridine, lutidine, collidine). Oxidation may be carried out under anhydrous conditions using, e.g. tert-Butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO). In some methods, a capping step is performed following oxidation. A second capping step allows for device drying, as residual water from oxidation that may persist can inhibit subsequent coupling. Following oxidation, the device and growing polynucleotide is optionally washed. In some instances, the step of oxidation is substituted with a sulfurization step to obtain polynucleotide phosphorothioates, wherein any capping steps can be performed after the sulfurization. Many reagents are capable of the efficient sulfur transfer, including but not limited to 3-(Dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione, DDTT, 3H-1,2-benzodithiol-3-one 1,1-dioxide, also known as Beaucage reagent, and N,N,N′N′-Tetraethylthiuram disulfide (TETD).
In order for a subsequent cycle of nucleoside incorporation to occur through coupling, the protected 5′ end of the device bound growing polynucleotide is removed so that the primary hydroxyl group is reactive with a next nucleoside phosphoramidite. In some instances, the protecting group is DMT and deblocking occurs with trichloroacetic acid in dichloromethane. Conducting detritylation for an extended time or with stronger than recommended solutions of acids may lead to increased depurination of solid support-bound polynucleotide and thus reduces the yield of the desired full-length product. Methods and compositions of the disclosure described herein provide for controlled deblocking conditions limiting undesired depurination reactions. In some instances, the device bound polynucleotide is washed after deblocking. In some instances, efficient washing after deblocking contributes to synthesized polynucleotides having a low error rate.
Methods for the synthesis of polynucleotides typically involve an iterating sequence of the following steps: application of a protected monomer to an actively functionalized surface (e.g., locus) to link with either the activated surface, a linker or with a previously deprotected monomer; deprotection of the applied monomer so that it is reactive with a subsequently applied protected monomer; and application of another protected monomer for linking. One or more intermediate steps include oxidation or sulfurization. In some instances, one or more wash steps precede or follow one or all of the steps.
Methods for phosphoramidite-based polynucleotide synthesis comprise a series of chemical steps. In some instances, one or more steps of a synthesis method involve reagent cycling, where one or more steps of the method comprise application to the device of a reagent useful for the step. For example, reagents are cycled by a series of liquid deposition and vacuum drying steps. For substrates comprising three-dimensional features such as wells, microwells, channels and the like, reagents are optionally passed through one or more regions of the device via the wells and/or channels.
Methods and systems described herein relate to polynucleotide synthesis devices for the synthesis of polynucleotides. The synthesis may be in parallel. For example, at least or about at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 10000, 50000, 75000, 100000 or more polynucleotides can be synthesized in parallel. The total number polynucleotides that may be synthesized in parallel may be from 2-100000, 3-50000, 4-10000, 5-1000, 6-900, 7-850, 8-800, 9-750, 10-700, 11-650, 12-600, 13-550, 14-500, 15-450, 16-400, 17-350, 18-300, 19-250, 20-200, 21-150, 22-100, 23-50, 24-45, 25-40, 30-35. Those of skill in the art appreciate that the total number of polynucleotides synthesized in parallel may fall within any range bound by any of these values, for example 25-100. The total number of polynucleotides synthesized in parallel may fall within any range defined by any of the values serving as endpoints of the range. Total molar mass of polynucleotides synthesized within the device or the molar mass of each of the polynucleotides may be at least or at least about 10, 20, 30, 40, 50, 100, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 25000, 50000, 75000, 100000 picomoles, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at least or about at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 300, 400, 500 nucleotides, or more. The length of each of the polynucleotides or average length of the polynucleotides within the device may be at most or about at most 500, 400, 300, 200, 150, 100, 50, 45, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 nucleotides, or less. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall from 10-500, 9-400, 11-300, 12-200, 13-150, 14-100, 15-50, 16-45, 17-40, 18-35, 19-25. Those of skill in the art appreciate that the length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range bound by any of these values, for example 100-300. The length of each of the polynucleotides or average length of the polynucleotides within the device may fall within any range defined by any of the values serving as endpoints of the range.
Methods for polynucleotide synthesis on a surface provided herein allow for synthesis at a fast rate. As an example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 nucleotides per hour, or more are synthesized. Nucleotides include adenine, guanine, thymine, cytosine, uridine building blocks, or analogs/modified versions thereof. In some instances, libraries of polynucleotides are synthesized in parallel on substrate. For example, a device comprising about or at least about 100; 1,000; 10,000; 30,000; 75,000; 100,000; 1,000,000; 2,000,000; 3,000,000; 4,000,000; or 5,000,000 resolved loci is able to support the synthesis of at least the same number of distinct polynucleotides, wherein polynucleotide encoding a distinct sequence is synthesized on a resolved locus. In some instances, a library of polynucleotides is synthesized on a device with low error rates described herein in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less. In some instances, larger nucleic acids assembled from a polynucleotide library synthesized with low error rate using the substrates and methods described herein are prepared in less than about three months, two months, one month, three weeks, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 days, 24 hours or less.
In some instances, methods described herein provide for generation of a library of nucleic acids comprising variant nucleic acids differing at a plurality of codon sites. In some instances, a nucleic acid may have 1 site, 2 sites, 3 sites, 4 sites, 5 sites, 6 sites, 7 sites, 8 sites, 9 sites, 10 sites, 11 sites, 12 sites, 13 sites, 14 sites, 15 sites, 16 sites, 17 sites 18 sites, 19 sites, 20 sites, 30 sites, 40 sites, 50 sites, or more of variant codon sites.
In some instances, the one or more sites of variant codon sites may be adjacent. In some instances, the one or more sites of variant codon sites may not be adjacent and separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more codons.
In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein all the variant codon sites are adjacent to one another, forming a stretch of variant codon sites. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein none the variant codon sites are adjacent to one another. In some instances, a nucleic acid may comprise multiple sites of variant codon sites, wherein some the variant codon sites are adjacent to one another, forming a stretch of variant codon sites, and some of the variant codon sites are not adjacent to one another.
Referring to the Figures, FIG. 2 illustrates an exemplary process workflow for synthesis of nucleic acids (e.g., genes) from shorter nucleic acids. The workflow is divided generally into phases: (1) de novo synthesis of a single stranded nucleic acid library, (2) joining nucleic acids to form larger fragments, (3) error correction, (4) quality control, and (5) shipment. Prior to de novo synthesis, an intended nucleic acid sequence or group of nucleic acid sequences is preselected. For example, a group of genes is preselected for generation.
Once large nucleic acids for generation are selected, a predetermined library of nucleic acids is designed for de novo synthesis. Various suitable methods are known for generating high density polynucleotide arrays. In the workflow example, a device surface layer is provided. In the example, chemistry of the surface is altered in order to improve the polynucleotide synthesis process. Areas of low surface energy are generated to repel liquid while areas of high surface energy are generated to attract liquids. The surface itself may be in the form of a planar surface or contain variations in shape, such as protrusions or microwells which increase surface area. In the workflow example, high surface energy molecules selected serve a dual function of supporting DNA chemistry, as disclosed in International Patent Application Publication WO/2015/021080, which is herein incorporated by reference in its entirety.
In situ preparation of polynucleotide arrays is generated on a solid support and utilizes single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device 201, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 202. In some instances, polynucleotides are cleaved from the surface at this stage. Cleavage includes gas cleavage, e.g., with ammonia or methylamine.
The generated polynucleotide libraries are placed in a reaction chamber. In this exemplary workflow, the reaction chamber (also referred to as “nanoreactor”) is a silicon coated well, containing PCR reagents and lowered onto the polynucleotide library 203. Prior to or after the sealing 204 of the polynucleotides, a reagent is added to release the polynucleotides from the substrate. In the exemplary workflow, the polynucleotides are released subsequent to sealing of the nanoreactor 205. Once released, fragments of single stranded polynucleotides hybridize in order to span an entire long range sequence of DNA. Partial hybridization 205 is possible because each synthesized polynucleotide is designed to have a small portion overlapping with at least one other polynucleotide in the pool.
After hybridization, a PCA reaction is commenced. During the polymerase cycles, the polynucleotides anneal to complementary fragments and gaps are filled in by a polymerase. Each cycle increases the length of various fragments randomly depending on which polynucleotides find each other. Complementarity amongst the fragments allows for forming a complete large span of double stranded DNA 206.
After PCA is complete, the nanoreactor is separated from the device 207 and positioned for interaction with a device having primers for PCR 208. After sealing, the nanoreactor is subject to PCR 209 and the larger nucleic acids are amplified. After PCR 210, the nanochamber is opened 211, error correction reagents are added 212, the chamber is sealed 213 and an error correction reaction occurs to remove mismatched base pairs and/or strands with poor complementarity from the double stranded PCR amplification products 214. The nanoreactor is opened and separated 215. Error corrected product is next subject to additional processing steps, such as PCR and molecular bar coding, and then packaged 222 for shipment 223.
In some instances, quality control measures are taken. After error correction, quality control steps include for example interaction with a wafer having sequencing primers for amplification of the error corrected product 216, sealing the wafer to a chamber containing error corrected amplification product 217, and performing an additional round of amplification 218. The nanoreactor is opened 219 and the products are pooled 220 and sequenced 221. After an acceptable quality control determination is made, the packaged product 222 is approved for shipment 223.
In some instances, a nucleic acid generate by a workflow such as that in FIG. 2 is subject to mutagenesis using overlapping primers disclosed herein. In some instances, a library of primers are generated by in situ preparation on a solid support and utilize single nucleotide extension process to extend multiple oligomers in parallel. A deposition device, such as a material deposition device, is designed to release reagents in a step wise fashion such that multiple polynucleotides extend, in parallel, one residue at a time to generate oligomers with a predetermined nucleic acid sequence 202.
Computer Systems
Any of the systems described herein, may be operably linked to a computer and may be automated through a computer either locally or remotely. In various instances, the methods and systems of the disclosure may further comprise software programs on computer systems and use thereof. Accordingly, computerized control for the synchronization of the dispense/vacuum/refill functions such as orchestrating and synchronizing the material deposition device movement, dispense action and vacuum actuation are within the bounds of the disclosure. The computer systems may be programmed to interface between the user specified base sequence and the position of a material deposition device to deliver the correct reagents to specified regions of the substrate.
The computer system 300 illustrated in FIG. 3 may be understood as a logical apparatus that can read instructions from media 311 and/or a network port 305, which can optionally be connected to server 309 having fixed media 312. The system, such as shown in FIG. 3 can include a CPU 301, disk drives 303, optional input devices such as keyboard 315 and/or mouse 316 and optional monitor 307. Data communication can be achieved through the indicated communication medium to a server at a local or a remote location. The communication medium can include any means of transmitting and/or receiving data. For example, the communication medium can be a network connection, a wireless connection or an internet connection. Such a connection can provide for communication over the World Wide Web. It is envisioned that data relating to the present disclosure can be transmitted over such networks or connections for reception and/or review by a party 322 as illustrated in FIG. 3.
FIG. 4 is a block diagram illustrating a first example architecture of a computer system 400 that can be used in connection with example instances of the present disclosure. As depicted in FIG. 4, the example computer system can include a processor 402 for processing instructions. Non-limiting examples of processors include: Intel Xeon™ processor, AMD Opteron™ processor, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0™ processor, ARM Cortex-A8 Samsung S5PC100™ processor, ARM Cortex-A8 Apple A4™ processor, Marvell PXA 930™ processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing. In some instances, multiple processors or processors with multiple cores can also be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, and/or personal data assistant devices.
As illustrated in FIG. 4, a high speed cache 404 can be connected to, or incorporated in, the processor 402 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by processor 402. The processor 402 is connected to a north bridge 406 by a processor bus 408. The north bridge 406 is connected to random access memory (RAM) 410 by a memory bus 412 and manages access to the RAM 410 by the processor 402. The north bridge 406 is also connected to a south bridge 414 by a chipset bus 416. The south bridge 414 is, in turn, connected to a peripheral bus 418. The peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus. The north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 418. In some alternative architectures, the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip. In some instances, system 400 can include an accelerator card 422 attached to the peripheral bus 418. The accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing. For example, an accelerator can be used for adaptive data restructuring or to evaluate algebraic expressions used in extended set processing.
Software and data are stored in external storage 424 and can be loaded into RAM 410 and/or cache 404 for use by the processor. The system 400 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, Windows™, MACOS™, BlackBerry OS™, iOS™, and other functionally-equivalent operating systems, as well as application software running on top of the operating system for managing data storage and optimization in accordance with example instances of the present disclosure. In this example, system 400 also includes network interface cards (NICs) 420 and 421 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.
FIG. 5 is a diagram showing a network 500 with a plurality of computer systems 502 a, and 502 b, a plurality of cell phones and personal data assistants 502 c, and Network Attached Storage (NAS) 504 a, and 504 b. In example instances, systems 502 a, 502 b, and 502 c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 504 a and 504 b. A mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 502 a, and 502 b, and cell phone and personal data assistant systems 502 c. Computer systems 502 a, and 502 b, and cell phone and personal data assistant systems 502 c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 504 a and 504 b. FIG. 5 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various instances of the present disclosure. For example, a blade server can be used to provide parallel processing. Processor blades can be connected through a back plane to provide parallel processing. Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface. In some example instances, processors can maintain separate memory spaces and transmit data through network interfaces, back plane or other connectors for parallel processing by other processors. In other instances, some or all of the processors can use a shared virtual address memory space.
FIG. 6 is a block diagram of a multiprocessor computer system using a shared virtual address memory space in accordance with an example instance. The system includes a plurality of processors 602 a-f that can access a shared memory subsystem 604. The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 606 a-f in the memory subsystem 604. Each MAP 606 a-f can comprise a memory 608 a-f and one or more field programmable gate arrays (FPGAs) 610 a-f. The MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 610 a-f for processing in close coordination with a respective processor. For example, the MAPs can be used to evaluate algebraic expressions regarding the data model and to perform adaptive data restructuring in example instances. In this example, each MAP is globally accessible by all of the processors for these purposes. In one configuration, each MAP can use Direct Memory Access (DMA) to access an associated memory 608 a-f, allowing it to execute tasks independently of, and asynchronously from the respective microprocessor 602 a-f. In this configuration, a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.
The above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example instances, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements. In some instances, all or part of the computer system can be implemented in software or hardware. Any variety of data storage media can be used in connection with example instances, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.
In example instances, the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems. In other instances, the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 4, system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements. For example, the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 422 illustrated in FIG. 4.
The following examples are set forth to illustrate more clearly the principle and practice of embodiments disclosed herein to those skilled in the art and are not to be construed as limiting the scope of any claimed embodiments. Unless otherwise stated, all parts and percentages are on a weight basis.

EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the disclosure and are not meant to limit the present disclosure in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the disclosure. Changes therein and other uses which are encompassed within the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.

Example 1: Functionalization of a Device Surface

A device was functionalized to support the attachment and synthesis of a library of polynucleotides. The device surface was first wet cleaned using a piranha solution comprising 90% H₂SO₄and 10% H₂O₂for 20 minutes. The device was rinsed in several beakers with DI water, held under a DI water gooseneck faucet for 5 min, and dried with N2. The device was subsequently soaked in NH₄OH (1:100; 3 mL:300 mL) for 5 min, rinsed with DI water using a handgun, soaked in three successive beakers with DI water for 1 min each, and then rinsed again with DI water using the handgun. The device was then plasma cleaned by exposing the device surface to O₂. A SAMCO PC-300 instrument was used to plasma etch O₂at 250 watts for 1 min in downstream mode.
The cleaned device surface was actively functionalized with a solution comprising N-(3-triethoxysilylpropyl)-4-hydroxybutyramide using a YES-1224P vapor deposition oven system with the following parameters: 0.5 to 1 torr, 60 min, 70° C., 135° C. vaporizer. The device surface was resist coated using a Brewer Science 200× spin coater. SPR™ 3612 photoresist was spin coated on the device at 2500 rpm for 40 sec. The device was pre-baked for 30 min at 90° C. on a Brewer hot plate. The device was subjected to photolithography using a Karl Suss MA6 mask aligner instrument. The device was exposed for 2.2 sec and developed for 1 min in MSF 26A. Remaining developer was rinsed with the handgun and the device soaked in water for 5 min. The device was baked for 30 min at 100° C. in the oven, followed by visual inspection for lithography defects using a Nikon L200. A descum process was used to remove residual resist using the SAMCO PC-300 instrument to O2 plasma etch at 250 watts for 1 min.
The device surface was passively functionalized with a 100 μL solution of perfluorooctyltrichlorosilane mixed with 10 μL light mineral oil. The device was placed in a chamber, pumped for 10 min, and then the valve was closed to the pump and left to stand for 10 min. The chamber was vented to air. The device was resist stripped by performing two soaks for 5 min in 500 mL NMP at 70° C. with ultrasonication at maximum power (9 on Crest system). The device was then soaked for 5 min in 500 mL isopropanol at room temperature with ultrasonication at maximum power. The device was dipped in 300 mL of 200 proof ethanol and blown dry with N₂. The functionalized surface was activated to serve as a support for polynucleotide synthesis.

Example 2: Synthesis of a 50-Mer Sequence on an Oligonucleotide Synthesis Device

A two dimensional oligonucleotide synthesis device was assembled into a flowcell, which was connected to a flowcell (Applied Biosystems (ABI394 DNA Synthesizer”). The two-dimensional oligonucleotide synthesis device was uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE (Gelest) was used to synthesize an exemplary polynucleotide of 50 bp (“50-mer polynucleotide”) using polynucleotide synthesis methods described herein.
The sequence of the 50-mer was as described.
5′AGACAATCAACCATTTGGGGTGGACAGCCTTGAC

CTCTAGACTTCGGCAT##TTTTTTTTTT3′,

where # denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes), which is a cleavable linker enabling the release of oligos from the surface during deprotection.
The synthesis was done using standard DNA synthesis chemistry (coupling, capping, oxidation, and deblocking) according to the protocol in Table 2 and an ABI synthesizer.

TABLE 2

Synthesis protocols

General DNA Synthesis

Table 2

Process Name	Process Step	Time (sec)

WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	23
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION	Activator Manifold Flush	2
(Phosphoramidite + Activator	Activator to Flowcell	6
Flow)	Activator + Phosphoramidite	6
	to Flowcell
	Activator to Flowcell	0.5
	Activator + Phosphoramidite	5
	to Flowcell
	Activator to Flowcell	0.5
	Activator + Phosphoramidite	5
	to Flowcell
	Activator to Flowcell	0.5
	Activator + Phosphoramidite	5
	to Flowcell
	Incubate for 25 sec	25
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
DNA BASE ADDITION	Activator Manifold Flush	2
(Phosphoramidite + Activator	Activator to Flowcell	5
Flow)	Activator + Phosphoramidite	18
	to Flowcell
	Incubate for 25 sec	25
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
CAPPING (CapA + B, 1:1,	CapA + B to Flowcell	15
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	Acetonitrile to Flowcell	15
	Acetonitrile System Flush	4
OXIDATION (Oxidizer	Oxidizer to Flowcell	18
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	15
	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	23
	N2 System Flush	4
	Acetonitrile System Flush	4
DEBLOCKING (Deblock	Deblock to Flowcell	36
Flow)
WASH (Acetonitrile Wash	Acetonitrile System Flush	4
Flow)	N2 System Flush	4
	Acetonitrile System Flush	4
	Acetonitrile to Flowcell	18
	N2 System Flush	4.13
	Acetonitrile System Flush	4.13
	Acetonitrile to Flowcell	15

The phosphoramidite/activator combination was delivered similar to the delivery of bulk reagents through the flowcell. No drying steps were performed as the environment stays “wet” with reagent the entire time.
The flow restrictor was removed from the ABI 394 synthesizer to enable faster flow. Without flow restrictor, flow rates for amidites (0.1M in ACN), Activator, (0.25M Benzoylthiotetrazole (“BTT”; 30-3070-xx from GlenResearch) in ACN), and Ox (0.02M I2 in 20% pyridine, 10% water, and 70% THF) were roughly ˜100 uL/sec, for acetonitrile (“ACN”) and capping reagents (1:1 mix of CapA and CapB, wherein CapA is acetic anhydride in THF/Pyridine and CapB is 16% 1-methylimidizole in THF), roughly ˜200 uL/sec, and for Deblock (3% dichloroacetic acid in toluene), roughly ˜300 uL/sec (compared to ˜50 uL/sec for all reagents with flow restrictor). The time to completely push out Oxidizer was observed, the timing for chemical flow times was adjusted accordingly and an extra ACN wash was introduced between different chemicals. After polynucleotide synthesis, the chip was deprotected in gaseous ammonia overnight at 75 psi. Five drops of water were applied to the surface to recover polynucleotides. The recovered polynucleotides were then analyzed on a BioAnalyzer small RNA chip.

Example 3: Synthesis of a 100-Mer Sequence on an Oligonucleotide Synthesis Device

The same process as described in Example 2 for the synthesis of the 50-mer sequence was used for the synthesis of a 100-mer polynucleotide (“100-mer polynucleotide”; 5′ CGGGATCCTTATCGTCATCGTCGTACAGATCCCGACCCATTTGCTGTCCACCAGTCATGCTAGC CATACCATGATGATGATGATGATGAGAACCCCGCAT##TTTTTTTTTT3′, where # denotes Thymidine-succinyl hexamide CED phosphoramidite (CLP-2244 from ChemGenes) on two different silicon chips, the first one uniformly functionalized with N-(3-TRIETHOXYSILYLPROPYL)-4-HYDROXYBUTYRAMIDE and the second one functionalized with 5/95 mix of 11-acetoxyundecyltriethoxysilane and n-decyltriethoxysilane, and the polynucleotides extracted from the surface were analyzed on a BioAnalyzer instrument.
All ten samples from the two chips were further PCR amplified using a forward (5′ATGCGGGGTTCTCATCATC3′) and a reverse (5′CGGGATCCTTATCGTCATCG3′) primer in a 50 uL PCR mix (25 uL NEB Q5 mastermix, 2.5 uL 10 uM Forward primer, 2.5 uL 10 uM Reverse primer, 1uL polynucleotide extracted from the surface, and water up to 50 uL) using the following thermalcycling program:
98° C., 30 sec
98° C., 10 sec; 63° C., 10 sec; 72° C., 10 sec; repeat 12 cycles
72° C., 2 min
The PCR products were also run on a BioAnalyzer, demonstrating sharp peaks at the 100-mer position. Next, the PCR amplified samples were cloned, and Sanger sequenced. Table 3 summarizes the results from the Sanger sequencing for samples taken from spots 1-5 from chip 1 and for samples taken from spots 6-10 from chip 2.

TABLE 3

Sequencing results

	Spot		Error rate	Cycle efficiency

1	1/763	bp	99.87%
2	1/824	bp	99.88%
3	1/780	bp	99.87%
4	1/429	bp	99.77%
5	1/1525	bp	99.93%
6	1/1615	bp	99.94%
7	1/531	bp	99.81%
8	1/1769	bp	99.94%
9	1/854	bp	99.88%
10	1/1451	bp	99.93%

Thus, the high quality and uniformity of the synthesized polynucleotides were repeated on two chips with different surface chemistries. Overall, 89% of the 100-mers that were sequenced were perfect sequences with no errors, corresponding to 233 out of 262.
Table 4 summarizes error characteristics for the sequences obtained from the polynucleotides samples from spots 1-10.

TABLE 4

Error characteristics

Spot no.

Sample ID	OSA_0046/1	OSA_0047/2	OSA_0048/3	OSA_0049/4	OSA_0050/5

Total Sequences	32	32	32	32	32
Sequencing Quality	25 of 28	27 of 27	26 of 30	21 of 23	25 of 26
Oligo Quality	23 of 25	25 of 27	22 of 26	18 of 21	24 of 25
ROI Match Count	2500	2698	2561	2122	2499
ROI Mutation	2	2	1	3	1
ROI Multi Base	0	0	0	0	0
Deletion
ROI Small Insertion	1	0	0	0	0
ROI Single Base	0	0	0	0	0
Deletion
Large Deletion	0	0	1	0	0
Count
Mutation: G > A	2	2	1	2	1
Mutation: T > C	0	0	0	1	0
ROI Error Count	3	2	2	3	1
ROI Error Rate	Err: ~1	Err: ~1	Err: ~1	Err: ~1	Err: ~1
	in 834	in 1350	in 1282	in 708	in 2500
ROI Minus Primer	MP Err: ~1	MP Err: ~1	MP Err: ~1	MP Err: ~1	MP Err: ~1
Error Rate	in 763	in 824	in 780	in 429	in 1525

Spot no.

Sample ID	OSA_0051/6	OSA_0052/7	OSA_0053/8	OSA_0054/9	OSA_0055/10

Total Sequences	32	32	32	32	32
Sequencing Quality	29 of 30	27 of 31	29 of 31	28 of 29	25 of 28
Oligo Quality	25 of 29	22 of 27	28 of 29	26 of 28	20 of 25
ROI Match Count	2666	2625	2899	2798	2348
ROI Mutation	0	2	1	2	1
ROI Multi Base	0	0	0	0	0
Deletion
ROI Small Insertion	0	0	0	0	0
ROI Single Base	0	0	0	0	0
Deletion
Large Deletion	1	1	0	0	0
Count
Mutation: G > A	0	2	1	2	1
Mutation: T > C	0	0	0	0	0
ROI Error Count	1	3	1	2	1
ROI Error Rate	Err: ~1	Err: ~1	Err: ~1	Err: ~1	Err: ~1
	in 2667	in 876	in 2900	in 1400	in 2349
ROI Minus Primer	MP Err: ~1	MP Err: ~1	MP Err: ~1	MP Err: ~1	MP Err: ~1
Error Rate	in 1615	in 531	in 1769	in 854	in 1451

Example 4: Panning and Screening for Identification of Antibodies for SARS-CoV-2 and ACE2

This example describes identification of antibodies for SARS-CoV-2 and ACE2.
Phage displayed scFv, VHH, and Fab libraries were panned for binding to biotinylated SARS-CoV-2 S1 and human ACE2. FIG. 7 shows a schema of the panning strategy. Biotinylated antigen was bound to streptavidin coated magnetic beads at a density of 100 pmol antigen per mg of beads (Thermo Fisher #11206D). Phage libraries were blocked with 5% BSA in PBS. Following magnetic bead depletion for 1 hour at room temperature (RT), the beads were removed, and phage supernatant was transferred to 1 mg of antigen-bound beads in 1 ml PBS and incubated at RT with rotation for 1 hour. Non-binding clones were washed away by addition of 1 ml PBST, increasing the number of washes with each panning round. Trypsin was used to elute the phage bound to the antigen-bead complex. Phage were amplified in TG1 E. coli for the next round of selection. This selection strategy was repeated for four rounds, with successively lower amounts of antigen per round. Following all four selection rounds, 400 clones from each of round 2, 3, and 4 were selected for phage expression and phage ELISA screening. Data from the panning is seen in Table 5.

TABLE 5

Panning Data

Antibody	Titer	Round	1	Round 2	Round 3	Round 4	Round 5

1	Input titer	1.5 × 10¹²	1.2 × 10¹³	4.4 × 10¹³	1.8 × 10¹³	—
	Output titer	1.2 × 10⁶	1.5 × 10⁶	2.0 × 10⁶	1.4 × 10⁸	—
2	Input titer	1.4 × 10¹²	2.6 × 10¹³	3.0 × 10¹³	1.0 × 10¹³	—
	Output titer	9.5 × 10⁵	1.2 × 10⁶	2.2 × 10⁶	1.2 × 10⁸	—
3	Input titer	1.7 × 10¹²	2.0 × 10¹³	2.8 × 10¹³	3.2 × 10¹³	—
	Output titer	1.5 × 10⁵	1.7 × 10⁶	1.5 × 10⁶	1.1 × 10⁸	—
4	Input titer	1.2 × 10¹²	1.6 × 10¹³	3.6 × 10¹³	1.5 × 10¹³	—
	Output titer	1.3 × 10⁵	2.2 × 10⁷	2.6 × 10⁷	2.5 × 10⁸	—

To test for binding to SARS-CoV-2 S1 and ACE2, phage were expressed from each picked colony by KO7 superinfection in 384 well microtiter plates. Phage containing supernatant was blocked by 1:1 addition of 4% non-fat milk (NFM). Assay plates were prepared by passive immobilization of 0.4 μg antigen in 384-well Maxisorp plates (Thermo Fisher #464718) and then blocked with 4% NFM. Following 3× wash in PBST, blocked phage supernatant was incubated for 1 hour at RT. After 3× wash in PBST, 0.3 μg/ml anti-M13-HRP (Sino Biological #11973-MM05T-H) was aliquoted for 1 hour incubation at room temperature. Binding of phage-displayed antibody was determined by absorbance at 450 nm with 3,3′,5,5′-tetramethylbenzidine (Thermo Fisher #34029). Phage that bound to antigen with 3× over background of human Fc protein were identified as potential binders for sequencing analysis. DNA was amplified by rolling circle amplification from glycerol stocks of each clone and submitted for Sanger sequencing (Genewiz) to capture the VH and VL domains. FIGS. 8A-8D shows phage ELISA data from round 4 of SARS-CoV-2 S1 (subunit 1) protein panning for antibody 1 (FIGS. 8A-8B) and antibody 2 (FIGS. 8C-8D). FIGS. 9A-9D shows phage ELISA data from round 4 of ACE2 protein panning for antibody 3 (FIGS. 9A-9B) and antibody 4 (FIGS. 9C-9D).
SARS-CoV-2 variants were tested for specificity using a phage ELISA as described above. The antigens used included Acro COVID S1 (S1N-C82E8), COVID S1 RBD Fc fusion (Antigen 1), and COVID S1 RBM Fc fusion (Antigen 2). Data from the phage ELISA is seen in Table 6A. Table 6A shows screening ELISA mean, fold over background (column A), specificity ELISA, fold over background (column B), and specificity ELISA, percent binding relative to binding to Acro S1 (column C). As seen in Table 6A, nearly all receptor binding domain (RBD) specific clones show good binding to full length subunit 1 (S1) and produced S1 RBD Fc. None of the S1 RBD variants were found to bind to S1 RBM Fc.

TABLE 6A

SARS-CoV-2 Phage ELISA

Column A

Column B

Column C

	ELISA		S1-		S1-	S1-		S1-
Variant	(Avg)	Acro S1	RBD-Fc	S1-Fc	RBM-Fc	RBD-Fc	S1-Fc	RBM-Fc

1-21	47.6	19.5	14.8	1.4	1.4	75.7%	7.2%	7.0%
1-22	40.6	32.7	26.5	2.5	1.5	81.2%	7.6%	4.7%
1-30	29.5	16.8	1.7	5.6	1.4	9.8%	33.3%	8.5%
1-35	28.6	21.6	1.8	1.4	1.6	8.2%	6.5%	7.3%
1-17	27.4	25.1	20.1	1.6	1.3	79.8%	6.2%	5.2%
1-27	27.2	1.5	1.9	1.3	1.6	124.5%	84.8%	108.8%
1-37	27.0	11.6	2.0	5.4	1.4	17.7%	46.7%	12.3%
1-12	25.7	1.7	1.7	1.3	1.7	104.0%	79.6%	102.5%
1-2	24.2	1.8	1.9	1.7	1.7	103.3%	95.4%	93.5%
1-3	23.9	1.6	1.8	1.5	1.5	109.3%	91.2%	91.9%
1-23	23.1	5.1	3.6	1.6	1.6	70.9%	31.1%	32.0%
1-7	22.5	6.8	3.3	1.7	1.6	48.7%	24.8%	23.0%
1-31	20.7	30.4	1.3	15.7	1.2	4.3%	51.6%	3.8%
1-4	20.6	1.0	1.4	0.9	1.1	137.5%	90.8%	105.3%
1-38	20.2	1.1	1.5	0.9	1.2	127.9%	82.8%	100.9%
1-8	19.3	12.0	11.2	1.1	1.2	92.9%	8.8%	10.3%
1-9	18.5	10.7	9.8	0.9	1.0	91.1%	8.7%	9.3%
1-32	17.9	11.5	1.5	4.0	1.1	13.1%	35.3%	9.5%
1-33	17.6	7.1	1.5	3.0	1.0	21.1%	42.1%	14.6%
1-24	32.9	12.9	11.0	1.1	1.3	85.4%	8.9%	10.3%
1-39	24.4	18.6	11.6	2.5	1.3	62.5%	13.2%	6.7%
1-40	22.9	18.7	14.3	1.3	1.1	76.7%	7.1%	6.0%
1-5	20.6	1.5	1.6	1.2	1.4	107.8%	82.9%	92.0%
1-41	18.1	4.5	2.7	1.3	1.2	58.8%	28.9%	26.3%
1-28	17.7	1.0	1.1	1.1	1.2	112.9%	109.7%	124.1%
1-10	16.9	17.4	17.4	1.3	1.1	100.5%	7.3%	6.2%
2-1	45.3	39.3	36.8	20.2	1.5	93.7%	51.3%	3.9%
2-10	43.8	38.9	39.9	9.4	1.2	102.7%	24.1%	3.1%
2-5	30.8	38.3	35.9	24.3	1.1	93.7%	63.3%	3.0%
2-2	23.4	39.4	39.6	4.7	1.1	100.4%	12.0%	2.8%
3-10	17.4	1.2	1.2	1.2	1.1	97.2%	99.6%	93.3%
1-26	19.5	1.4	1.1	1.3	1.0	76.8%	98.0%	74.7%
1-42	34.5	22.7	20.8	1.4	1.0	91.4%	6.4%	4.2%
1-13	28.2	4.8	4.3	0.9	1.2	89.3%	18.4%	24.2%
1-43	21.9	6.7	5.8	3.9	1.0	87.3%	58.3%	14.5%
1-44	24.6	10.4	8.2	1.0	0.8	78.6%	9.6%	7.6%
1-14	21.7	16.8	13.5	1.1	0.9	80.6%	6.7%	5.4%
1-6	20.8	1.8	1.3	1.1	0.8	69.6%	60.5%	45.4%
1-45	24.0	12.1	10.3	1.2	1.0	85.3%	9.6%	8.3%
1-46	21.7	4.6	3.1	1.1	0.9	66.6%	24.5%	19.8%
1-20	26.0	5.7	3.9	1.0	0.8	67.3%	17.0%	14.5%
1-47	22.6	8.1	5.5	1.2	0.9	68.9%	14.6%	11.1%
1-29	23.8	1.1	0.9	1.0	0.9	81.4%	94.0%	78.3%
1-1	32.5	4.5	4.0	1.6	1.1	90.7%	35.3%	24.5%
1-19	22.3	24.2	23.9	1.5	1.2	98.7%	6.4%	4.9%
1-16	22.1	3.4	3.1	1.0	0.9	89.7%	29.5%	27.3%
1-34	28.7	7.5	3.1	1.8	1.0	41.3%	24.5%	13.3%
1-48	22.6	2.5	2.1	0.8	0.8	84.7%	31.5%	30.3%
1-49	27.6	1.0	1.0	0.8	0.8	99.3%	85.6%	78.8%
1-18	22.7	9.8	7.0	1.1	0.8	71.0%	11.0%	8.0%
1-11	33.2	4.8	4.8	0.9	1.0	99.5%	18.7%	20.6%
1-50	21.1	13.9	12.4	1.2	0.8	88.9%	8.8%	5.9%
1-25	27.9	3.6	2.7	1.0	0.8	75.4%	28.1%	22.3%
1-36	23.6	10.1	1.2	1.1	0.8	11.5%	10.6%	8.4%
1-15	24.8	2.5	1.4	1.0	0.8	55.4%	41.5%	32.1%
2-4	15.5	37.7	38.8	7.2	1.2	102.7%	19.0%	3.1%
2-6	22.1	11.1	12.8	1.8	1.1	115.8%	16.4%	9.5%
2-11	28.1	1.1	1.0	1.2	0.9	86.3%	103.4%	76.1%
2-12	18.2	39.8	40.3	14.7	1.1	101.3%	37.0%	2.9%
2-13	19.1	27.3	32.1	3.7	0.9	117.5%	13.4%	3.1%
2-14	17.2	31.7	32.9	4.2	0.9	103.9%	13.3%	2.8%
2-7	25.3	37.2	37.3	7.7	0.9	100.3%	20.6%	2.4%
2-8	32.4	35.9	36.5	5.4	1.1	101.8%	15.0%	3.1%
2-15	13.7	31.0	28.1	3.8	0.9	90.6%	12.4%	3.0%
2-9	14.1	24.1	24.3	3.0	0.8	100.7%	12.2%	3.5%

Tables 6B-6C show Carterra SPR kinetics for SARS-CoV-2 variant antibodies ranked by off-rate (Table 6B) and by K_D(Table 6C). FIG. 10 shows that ACE2 binds to S1-RBD-Fc and S1-Fc variants.

TABLE 6B

SARS-CoV-2 Carterra SPR Kinetics Ranked by Off-Rate

		S1-		S1-	ka	K_D
IgG	Acro S1	RBD-Fc	S1-Fc	RBM-Fc	(M−1 s−1)	(s−1)

2-10	38.9	39.9	9.4	1.2	2.08E+05	1.15E−04
2-5	38.3	35.9	24.3	1.1	9.39E+04	2.59E−04
1-31	30.4	1.3	15.7	1.2	2.05E+04	7.62E−04
2-2	39.4	39.6	4.7	1.1	7.74E+04	9.06E−04
1-13	4.8	4.3	0.9	1.2	2.17E+05	1.38E−03
1-30	16.8	1.7	5.6	1.4	4.39E+04	1.64E−03
1-29	1.1	0.9	1.0	0.9	5.35E+02	1.97E−03
1-27	1.5	1.9	1.3	1.6	2.27E+05	2.85E−03
1-35	21.6	1.8	1.4	1.6	5.90E+04	5.43E−03
1-36	10.1	1.2	1.1	0.8	1.14E+05	7.85E−03
1-67	18.6	11.6	2.5	1.3	7.36E+04	8.86E−03
1-2	1.8	1.9	1.7	1.7	1.58E+03	2.72E−02
1-5	1.5	1.6	1.2	1.4	2.15E+03	5.40E−02
1-68	6.7	5.8	3.9	1.0	2.46E+06	8.75E−02
1-69	1.1	1.5	0.9	1.2	3.08E+05	1.23E−01
1-4	1.0	1.4	0.9	1.1	4.20E+04	1.24E−01
1-12	1.7	1.7	1.3	1.7	3.59E+05	1.34E−01
1-11	4.8	4.8	0.9	1.0	5.92E+05	1.43E−01
1-10	17.4	17.4	1.3	1.1	1.04E+06	1.47E−01
1-7	4.5	2.7	1.3	1.2	2.09E+05	1.55E−01
1-15	2.5	1.4	1.0	0.8	4.49E+05	1.56E−01
1-25	3.6	2.7	1.0	0.8	1.98E+06	1.56E−01
1-23	5.1	3.6	1.6	1.6	5.06E+05	1.59E−01
1-7	6.8	3.3	1.7	1.6	1.34E+06	1.70E−01
1-47	8.1	5.5	1.2	0.9	6.32E+03	2.40E−01
1-3	1.6	1.8	1.5	1.5	1.42E+06	3.04E−01
1-32	11.5	1.5	4.0	1.1	5.49E+06	3.17E−01
1-20	5.7	3.9	1.0	0.8	5.17E+02	6.95E−01
1-28	1.0	1.1	1.1	1.2	1.23E+08	9.05E+00
1-48	2.5	2.1	0.8	0.8	5.56E+07	9.11E+00
1-24	12.9	11.0	1.1	1.3	1.94E+08	1.46E+01
1-6	1.8	1.3	1.1	0.8	4.49E+08	2.08E+01
1-17	25.1	20.1	1.6	1.3	3.92E+08	2.63E+01
1-49	1.0	1.0	0.8	0.8	6.00E+08	3.22E+01
1-71	11.6	2.0	5.4	1.4	3.69E+08	4.03E+01
1-42	22.7	20.8	1.4	1.0	9.10E+08	1.03E+02

TABLE 6C

SARS-CoV-2 Carterra SPR Kinetics Ranked by K_D

		S1-		S1-	ka	kd	K_D	Rmax
IgG	Acro S1	RBD-Fc	S1-Fc	RBM-Fc	(M−1 s−1)	(s−1)	(nM)	(RU)

2-10	38.9	39.9	9.4	1.2	2.08E+05	1.15E−04	0.6	20
2-5	38.3	35.9	24.3	1.1	9.39E+04	2.59E−04	2.8	39
1-13	4.8	4.3	0.9	1.2	2.17E+05	1.38E−03	6.4	23
2-2	39.4	39.6	4.7	1.1	7.74E+04	9.06E−04	11.7	131
1-27	1.5	1.9	1.3	1.6	2.27E+05	2.85E−03	12.5	39
1-68	6.7	5.8	3.9	1.0	2.46E+06	8.75E−02	35.6	73
1-30	16.8	1.7	5.6	1.4	4.39E+04	1.64E−03	37.2	98
1-31	30.4	1.3	15.7	1.2	2.05E+04	7.62E−04	37.2	256
1-6	1.8	1.3	1.1	0.8	4.49E+08	2.08E+01	46.3	87
1-49	1.0	1.0	0.8	0.8	6.00E+08	3.22E+01	53.6	72
1-32	11.5	1.5	4.0	1.1	5.49E+06	3.17E−01	57.8	112
1-17	25.1	20.1	1.6	1.3	3.92E+08	2.63E+01	67.1	46
1-36	10.1	1.2	1.1	0.8	1.14E+05	7.85E−03	68.9	150
1-28	1.0	1.1	1.1	1.2	1.23E+08	9.05E+00	73.5	58
1-24	12.9	11.0	1.1	1.3	1.94E+08	1.46E+01	75.5	48
1-25	3.6	2.7	1.0	0.8	1.98E+06	1.56E−01	78.9	46
1-35	21.6	1.8	1.4	1.6	5.90E+04	5.43E−03	91.9	341
1-71	11.6	2.0	5.4	1.4	3.69E+08	4.03E+01	109.3	113
1-42	22.7	20.8	1.4	1.0	9.10E+08	1.03E+02	113.4	68
1-67	18.6	11.6	2.5	1.3	7.36E+04	8.86E−03	120.4	22
1-7	6.8	3.3	1.7	1.6	1.34E+06	1.70E−01	127.1	31
1-10	17.4	17.4	1.3	1.1	1.04E+06	1.47E−01	141.7	27
1-48	2.5	2.1	0.8	0.8	5.56E+07	9.11E+00	163.8	64
1-3	1.6	1.8	1.5	1.5	1.42E+06	3.04E−01	214.6	87
1-11	4.8	4.8	0.9	1.0	5.92E+05	1.43E−01	240.9	53
1-23	5.1	3.6	1.6	1.6	5.06E+05	1.59E−01	314.6	128
1-15	2.5	1.4	1.0	0.8	4.49E+05	1.56E−01	346.9	79
1-12	1.7	1.7	1.3	1.7	3.59E+05	1.34E−01	372.5	112
1-69	1.1	1.5	0.9	1.2	3.08E+05	1.23E−01	398.4	66
1-7	4.5	2.7	1.3	1.2	2.09E+05	1.55E−01	742.5	160
1-4	1.0	1.4	0.9	1.1	4.20E+04	1.24E−01	2946.4	385
1-29	1.1	0.9	1.0	0.9	5.35E+02	1.97E−03	3684.3	1206
1-2	1.8	1.9	1.7	1.7	1.58E+03	2.72E−02	17228.5	1652
1-5	1.5	1.6	1.2	1.4	2.15E+03	5.40E−02	25170.1	4457
1-47	8.1	5.5	1.2	0.9	6.32E+03	2.40E−01	37971.0	5497
1-20	5.7	3.9	1.0	0.8	5.17E+02	6.95E−01	1344113.2	64406

Example 5. SARS-CoV-2 and ACE Variants

SARS-CoV-2 and ACE variant antibodies were tested for specificity and affinity.
Recombinant S1 Protein (Acros Biosystems Cat. No. S1N-S52H5) was passively immobilized on a 384 well ELISA plate and blocked with BSA. The S1 Panel antibodies were diluted from 50 nM to 0.0076 nM and incubated with the blocked plate. Antibody binding was detected using Goat-anti-Human-HRP secondary and developed with HRP substrate (list here). The absorbance signal was plotted as % of maximal binding and fitted to determine the EC50 of each antibody using GraphPad Prism.
Exemplary data for affinity of SARS-CoV-2 variant 2-6 is seen in FIGS. 11A-11B. The binding of SARS-CoV-2 panel of antibodies was measured as seen in FIG. 12 and Tables 7A-7F below.

TABLE 7A

SARS-CoV-2 Variants EC50

	Antibody	EC50 (nM)

	1-31	0.03139
	2-6	0.03364
	ACRO	0.04831
	1-34	0.06522
	2-2	0.07992
	1-27	0.09283
	2-8	0.1029
	1-22	0.1248
	1-32	0.1406
	1-16	0.1435
	1-12	0.1585
	2-5	0.1615
	CR3022	0.1657
	1-53	0.1691
	1-30	0.2084
	1-28	0.2224
	1-71	0.2673
	1-20	0.3236
	1-4	0.4216
	1-35	0.4922
	1-47	0.5893
	1-5	0.774
	2-4	0.8792
	1-3	0.9724
	1-21	1.003
	2-19	1.257
	1-51	1.465
	1-19	1.706
	1-42	1.742
	2-2	1.789
	2-1	1.894
	1-33	3.006
	2-13	5.139
	2-11	6.921
	2-15	8.509
	2-7	10.09
	1-26	11.93
	1-24	12.86
	1-49	13.04
	1-10	18.31
	1-1	21.87
	1-8	25.09
	1-7	26.94
	1-72	29.13
	1-17	33.17
	1-36	34.86
	1-73	43.58
	2-10	46.43
	1-9	46.88
	2-17	51.86
	1-52	57.88
	2-18	74.71
	1-29	83.41
	2-12	95.94
	1-25	107
	2-9	118.3
	1-23	123.9
	1-48	296
	2-14	854.7

TABLE 7B

SARS-CoV-2 Variants Frequency and ELISA Data

	IgG	Freq.	ELISA (Avg)

1-21	1	47.6
1-22	3	40.6
1-30	1	29.5
1-35	3	28.6
1-17	79	27.4
1-27	1	27.2
1-12	2	25.7
1-2	14	24.2
1-3	2	23.9
1-23	1	23.1
1-7	4	22.5
1-31	1	20.7
1-4	1	20.6
1-8	2	19.3
1-9	2	18.5
1-32	1	17.9
1-33	1	17.6
1-24	1	32.9
1-5	1	20.6
1-28	2	17.7
1-10	1	16.9
1-26	1	19.5
1-13	1	28.2
1-14	1	21.7
1-6	1	20.8
1-20	3	26.0
1-29	1	23.8
1-1	1	32.5
1-19	1	22.3
1-16	1	22.1
1-34	1	28.7
1-18	1	22.7
1-11	1	33.2
1-25	1	27.9
1-36	1	23.6
1-15	1	24.8
1-51	1	7.1
1-52	1	3.5
1-53	1	21.7

TABLE 7C

SARS-CoV-2 S1 Variants

			DB/S1	DB/S-T	DC/S1	DC/S-T	Inhibitor	Fc/S1	Fc/S-T
		ELISA	K_D	K_D	K_D	K_D	IC50	K_D	K_D
IgG	Freq	(Avg)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)f

1-21	1	47.6					6.7
1-22	3	40.6					73.2
1-30	1	29.5	37.2		4.7	475861.6	25.3
1-35	3	28.6	91.9	569.8	47.5	16.7	209.2	139.4	0.5
1-17	79	27.4	67.1		6649.2				10.0
1-27	1	27.2	12.5		5519.6			9.6	9.6
1-12	2	25.7	372.5		10.6		33.0	6.1	14.0
1-2	14	24.2	17228.5	304.3
1-3	2	23.9	214.6	423.0	252.8	5306.9	15.7		10.0
1-23	1	23.1	314.6
1-7	4	22.5	127.1
1-31	1	20.7	37.2		14.4		9.2	17.5
1-4	1	20.6	2946.4	6.6	659.2	129.2		25.5	12.3
1-8	2	19.3					97.3
1-9	2	18.5					282.4
1-32	1	17.9	57.8		14.8			2979.8
1-33	1	17.6			8.1	1739312.4
1-24	1	32.9	75.5		2043.7
1-40	2	22.9
1-5	1	20.6	25170.1	1155.7
1-28	2	17.7	73.5	13.4	520.3	96.6		3236.7	8.6
1-10	1	16.9	141.7				17.7
1-26	1	19.5					8.0
1-13	1	28.2	6.4
1-14	1	21.7		8.1
1-6	1	20.8	46.3	684.2
1-20	3	26.0	1344113.2		34.4	145.0		10.3	17.3
1-29	1	23.8	3684.3	36.1					19.3
1-1	1	32.5
1-19	1	22.3			85.4	0.0		14.3	18.6
1-16	1	22.1			2282.0	4487.3	1.7	178.8	2.2
1-34	1	28.7			8.2	623.6		13.4	1.4
1-18	1	22.7
1-11	1	33.2	240.9	30.2
1-25	1	27.9	78.9				3.0		6.1
1-36	1	23.6	68.9	3.9			9.3		33.2
1-15	1	24.8	346.9
1-51	1	7.1
1-52	1	3.5					739.8
1-53	1	21.7					1426.0
2-16	1	7.1					433.4
2-17	1	3.5
2-18	1	43.0
2-19	1	21.7
2-2	1	12.8

TABLE 7D

SARS-CoV-2 S1 Variants Frequency and ELISA Data

	IgG	Freq.	ELISA(Avg)

2-1	1	45.3
2-10	1	43.8
2-5	46	30.8
2-2	2	23.4
2-4	1	15.5
2-6	5	22.1
2-11	3	28.1
2-12	1	18.2
2-13	1	19.1
2-14	1	17.2
2-7	1	25.3
2-8	1	32.4
2-15	1	13.7
2-9	1	14.1
2-16	1	7.1
2-17	1	3.5
2-18	1	43.0
2-19	1	21.7
2-2	1	12.8

TABLE 7E

SARS-CoV-2 S1 Variants

			DB/S1	DB/S-T	DC/S1	DC/S-T	Inhibitor	Fc/S1	Fc/S-T
		ELISA	K_D	K_D	K_D	K_D	IC50	K_D	K_D
IgG	Freq	(Avg)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)

2-10	1	43.8	0.6	125.6
2-5	46	30.8	2.8			17.3	4.2	1.9	90.2
2-2	2	23.4	11.7	1.2		1.4	3.6	58.3	0.8
2-4	1	15.5		4337.7
2-6	5	22.1		3.0	563.8	0.4		32.3	0.01
2-11	3	28.1		3.1				90.0	284.5
2-12	1	18.2		6.4		63.8	1.0		3.2
2-13	1	19.1					45.0
2-14	1	17.2		2.5					34.8
2-7	1	25.3							252.5
2-8	1	32.4		115.1	33.4	47.4	12.2	52.8
2-15	1	13.7		3.5			4.7
2-9	1	14.1					23.2		23582.5

TABLE 7F

Antibody Panel ELISA Binding Titrations (EC50)

	ANTIBODY	EC50 (nM)

	2-8	0.08001
	1-35	0.09604
	1-3	0.133
	2-5	0.1332
	1-27	0.1479
	1-31	0.2035
	2-6	0.283
	1-2	0.523
	1-34	0.5584
	2-2	0.612
	1-67	0.9402
	1-16	1.409
	1-12	2.15
	1-28	2.284
	1-4	2.559
	1-1	4.157
	1-19	4.413
	1-22	6.548
	1-5	7.833
	1-42	7.92
	2-15	7.92
	1-49	8.669
	1-53	10.25
	2-9	12.58
	1-33	17.5
	1-26	48.46
	2-29	63.43
	1-7	95.66
	1-25	95.66
	1-51	98.17
	2-17	100
	2-2	100

Data for competition ELISA for a first set of SARS-CoV-2 S1 RBD and ACE2 variant antibodies is seen in FIGS. 13A-13B and FIG. 14A. SARS-CoV-2 variant antibodies with high potency in order of potency included variant 2-2, Acro mAb (1.5333), variant 2-5, variant 1-12, and variant 2-9. ACE variant antibodies with high potency in order of potency included variant 4-52, variant 4-17, variant 4-39, Acro mAb (1.533), variant 4-54, and variant 3.5. Data for competition ELISA for a second set of ACE2 variant antibodies is seen in FIG. 14B. Variant antibodies with high potency in order of potency included variant 4-101, variant 4-140, variant 4-121, variant 4-118, and Acro mAb (2.76 nM). FIGS. 14C-14D show the SARS-CoV-2 variant antibodies show potent neutralization.
Inhibition assays were also performed as seen in FIG. 15.
SARS-CoV-2 variant antibodies were assayed for Vero inhibition using FACS. Briefly, Vero cells stripped with Cell Stripper (˜20 minutes with 90% viability after removal). Cells were plated at 0.1×10⁶cells per well. Stock solution of the variant antibodies were at 200 nM titrated 1:3. SARS-CoV-2 S protein RBD, SPD-C5259 were made up at 6 ug/mL. Variant antibody titrations were mixed 1:1 with 6 ug/mL S protein (50 uL IgG: 50 uL S protein). 100 uL of the mixture were added to cells and then incubated on ice for 1 hour. The cells were washed 1× followed by addition of 50 uL of goat anti-mouse secondary made up at 1:200. The cells were then incubated on ice for 1 hour in the dark, washed three times, and the plates were then read. Data for SARS-CoV-2 variant antibodies is seen in FIGS. 16A-16D, FIGS. 17A-17D, and Tables 8 and 9. As seen in the data, several variant antibodies blocked labeled S1 RBD from binding to ACE2 on the Vero cells including variants 2-8, 2-5, 2-2, 2-4, and 1-63.

	TABLE 8

	Antibody	IC50 (nM)

	Acro Anti-S1	2.7
	1-30	NC
	1-35	NC
	1-12	NC
	1-31	NC
	1-63	106.6
	2-5	4.4
	2-2	3.0
	2-4	46.3
	2-6	NC
	2-8	19.5

	TABLE 9

	S1 Monomer (nM)	S Trimer (nM)

1-31	0.22	0.80
1-30	0.67	4.02
1-35	0.15	0.76
1-12	2.08	0.61
1-63	1.40	14.39
2-8	1.52	7.08
2-5	0.17	0.59
2-2	0.13	0.64
2-4	1.58	10.18
2-6	0.07	0.43

A summary of epitope binning for SARS-CoV-2 variant antibodies is seen in Table 10 below.

TABLE 10

SARS-CoV-2 Epitope Binning

	Acro		Abcam
ID	mAb	2-2	CR3022	2-5	2-8	2-11	1-32	1-16	2-6	1-35

*Acro	0	0	2	1	1	1	1	1	1	1
mAb
*2-2	0	0	0	0	0	0	2	0	2	1
Abcam	2	0	0	0	0	1	1	2	2	2
CR3022
*2-5	1	0	0	0	0	1	1	1	1	1
*2-8	1	0	0	0	0	1	1	1	1	1
2-11	1	0	0	0	0	0	1	2	1	1
**1-32	2	1	3	1	2	1	0	0	1	1
1-16	1	1	2	2	1	1	1	0	0	0
2-6	2	2	3	2	2	2	1	0	0	0
1-35	1	1	2	2	1	1	1	0	0	0

*Anti-S1 inhibiting IgG in FACS (Vero E6)
**Anti-S1 inhibiting IgG in ELISA (soluble ACE2)

The variant antibodies were also measured in binding against other coronaviruses. Data shows that the variant antibodies do not bind significantly to S1 HCoV-229E (Sino), S1 HCoV-HKU1 (Sino), S1 HCoV-NL63 (Sino), or S1 HCoV-OC43 (Sino) (data not shown).
The data shows that the SARS-CoV-2 and ACE2 variant antibodies have high specificity and affinity to their antigen targets with affinities in the picomolar to nanomolar range.

Example 6. SARS-CoV-2 S1 Variants

VHH-Fc antibodies targeting S1 were titrated 1:3 starting at 200 nM and mixed 1:1 with SARS-COV2-S1 RBD (mouse IgG2Fc tag). The RBD/VHH-Fc complex was added to Vero E6 cells expressing endogenous ACE2 receptor and incubated. Cells were subsequently washed and an anti-mouse secondary was used to measure binding of S1 RBD to ACE2, thus assessing the inhibition of S1. Over 60 clones demonstrated potent inhibition. Data is seen in FIGS. 18A-18C and Tables 11 and 12.

	TABLE 11

	Sample	IC₅₀[nM]

	2-2	0.56
	5-56	0.68
	5-1	0.75
	5-67	0.76
	5-47	0.80
	5-8	0.94
	5-38	0.96
	5-37	1.01
	5-34	1.21
	5-20	1.23
	5-55	1.45
	5-46	1.52
	5-50	1.61
	5-5	1.79
	2-5	2.146
	5-60	2.15
	5-15	2.19
	5-29	2.19
	Acro Anti S1	3.80
	5-49	5.61
	5-44	11.73

	TABLE 12

	Sample	IC₅₀[nM]

	6-85	0.2044
	2-2	0.56
	6-63	0.74
	6-3	0.74
	6-78	0.7427
	6-20	0.76
	6-91	0.89
	6-44	0.97
	6-55	0.97
	6-73	1.01
	6-26	1.07
	6-76	1.11
	6-45	1.16
	6-60	1.31
	6-40	1.36
	6-81	1.383
	6-10	1.44
	6-7	1.53
	6-39	1.53
	6-109	1.60
	6-38	1.94
	2-5	2.146
	6-30	2.94
	6-57	3.13
	Acro Anti S1	3.49
	6-67	3.80
	6-77	4.041
	6-100	5.07
	6-47	5.86
	6-41	6.60
	6-88	7.118
	6-105	7.82
	6-34	8.24
	6-54	8.90
	6-18	12.29
	6-1	15.76
	6-65	37.47

Antibody kinetics were measured for variants 2-5, 2-2, and 2-6 (FIG. 19A) and variants 1-12, 1-42, 1-20, and 1-19 (FIG. 19B). Data is seen in FIGS. 19A-19B. The data shows that the antibodies bind with nanomolar affinities. FIG. 19C shows percent neutralization for variants 1-12, 1-42 and 1-20. FIG. 19D shows percent neutralization for variants 1-12, 1-42 and 1-20 using live virus.

Example 7. Neutralization of Live Virus

VHH-Fc antibodies targeting S1 were titrated 1:3 starting at 200 nM and mixed 1:1 with SARS-COV2-S1 RBD (mouse IgG2Fc tag). The RBD/VHH-Fc complex was added to Vero E6 cells expressing endogenous ACE2 receptor and incubated. Cells were subsequently washed and an anti-mouse secondary was used to measure binding of S1 RBD to ACE2, thus assessing the inhibition of S1. Over 60 clones demonstrated potent inhibition. The data is seen in FIGS. 20A-20B and Table 13.

	TABLE 13

	Antibody	EC50 (ug/mL)

	6-63	0.06
	6-3	0.06
	2165mAb*	0.08
	5-1	0.10
	6-60	0.15
	6-55	0.21
	5-20	0.27
	1-20	0.37
	5-34	0.54
	6-85	0.84
	6-76	1.08
	6-73	1.46
	1-42	2.03
	1-12	2.10
	6-26	2.97
	6-20	5.03
	6-78	8.26
	2-6	11.77
	2-5	18.31
	2-2	67.57
	1-63	106.90

FIG. 20B shows that variant 6-2 showed higher neutralization versus IgG in live virus. Variants 6-63, 6-3, and 5-1 showed comparable neutralization versus 2165 mAb derived from a COVID-19 subject. FIGS. 20C-20E and Table 14 show data from VHH single domain antibodies in VSV-pseudotype SARS-CoV-2 neutralization assays. Variants 5-1, 6-3, and 6-63 showed improved neutralization in pseudovirus testing including in live virus FRNT (FIG. 20E). Variants 6-3, 6-60, 6-63, and 6-76 showed potent neutralization in live virus PRNT as seen in Table 15 and FIG. 20F. Data as seen in Table 16 and FIGS. 20G-20H show that variants 6-3, 6-63, and 1-20 exhibited potent neutralization in live virus PRNT.

	TABLE 14

	Antibody	NC50 (ug/mL)

	6-63	0.06
	6-3	0.06
	5-1	0.10
	6-60	0.15
	6-55	0.21
	5-20	0.27
	1-20	0.37
	5-34	0.54
	6-85	0.84
	6-76	1.08
	6-73	1.46
	1-42	2.03
	1-12	2.10
	6-26	2.97
	6-20	5.03
	6-78	8.26
	2-6	11.77
	2-5	18.31
	2-2	67.57
	1-63	106.90

	TABLE 15

	Antibody	PRNT90 (ng/mL)

	5-1	15.6
	5-20	3.9
	5-34	15.6
	6-26	62.5
	6-60	<0.98
	6-63	3.9
	6-3	<0.98
	6-55	62.5
	6-76	3.9
	6-78	250
	6-20	15.6
	6-73	250
	6-85	62.5

	TABLE 16

	Antibody	EC80 (ug/mL)

	6-63	0.057861
	6-3	0.115234
	1-20	0.171875
	6-60	0.236816
	5-20	0.376
	6-76	0.425781
	6-55	0.445313
	5-34	0.570313
	6-42	0.734375
	5-1	0.810547
	1-12	0.855469
	6-85	1.0625
	5-38	1.5
	5-67	1.566406
	1-42	1.78125
	6-73	2.015625
	6-20	2.3125
	5-47	2.457031
	1-19	2.78125
	6-44	3.15625
	6-26	3.609375
	6-45	4.015625
	5-37	12.4375
	6-78	13.75
	5-63	14.1875
	5-8	15.8125
	6-6	24.375
	6-13	25.6875
	6-24	31.375
	1-63	50.5
	6-32	60.625
	2-6	72.34043
	6-22	103.25
	5-56	104.75
	2-5	106.5
	6-82	107.75
	5-32	180.1418
	6-91	240.5
	2-2	354.6099
	5-51	387.9433

The variants were also tested in pseudovirus neutralization and live virus PRNT studies. Variants 5-20, 6-60, 6-63, and 6-3 showed potent neutralization in live virus PRNT as seen in FIG. 20I.

Example 8. In Vivo Evaluation of Variant Coronavirus Immunoglobulins

This Example assesses the variant coronavirus immunoglobulins in a Syrian hamster model (immunosuppressed) of COVID-19 disease.
8-10 week-old female Syrian hamsters were immunosuppressed using cyclophosphamide (140 mg/kg day 3 days before challenge and then 100 mg/kg every 4 days by i.p. route). Eleven groups of six hamsters per group were injected with antibody on day −1 relative to challenge by the intraperitoneal route (i.p.). On Day 0 all hamster were challenged with 1,000 PFU SARS CoV-2 Washington isolate by the intranasal route and weighed daily. % Weight change relative to starting weight was calculated. Pharyngeal swabs were collected on Days −1, 1, 4, 7, 9. Day 9 lungs were collected and homogenized for viral load. Groups are shown in Table 17.

TABLE 17

Groups

		Diluent/volume
	Group	injected i.p.

	Convalescent plasma	NA/2.5 mL
	Negative control MAb c7d11	PBS/2.5 mL
	6-63	PBS/2.5 mL
	6-3	PBS/2.5 mL
	6-36	PBS/2.5 mL

	NA = not applicable

Animals injected intraperitonealy (i.p.) with the Negative Control antibody lost weight starting losing significant amounts of weight between Days 5 and 6 and continued to decline until the end of the experiment on Day 9. The maximum mean weight loss of the group was −11.7%. In contrast, animals injected with positive control human convalescent plasma maintained weight within −3.2% of their weight on Day 0 indicating this plasma protected against disease manifested by weight loss (FIG. 21A).
Groups of six animals were injected i.p. with 10, 5, or 1 mg/kg of monoclonal antibody 6-63 diluted in PBS. All groups maintained their weight at or above starting weight indicating the antibody protected against disease resulting weight loss (FIG. 21B).
Groups of six animals were injected i.p. with 10, 5, or 1 mg/kg of monoclonal antibody 6-3 diluted in PBS. The 1 and 10 mg/kg groups maintained their weight at or above starting weight at all time points. The 5 mg/kg group weight dipped slightly below the convalescent control on Days 7-9 but clearly was different from the Negative Control antibody. Together, these data indicate the antibody decreased weight loss associated with disease (FIG. 21C).
Groups of six animals were injected i.p. with 10, 5, or 1 mg/kg of monoclonal antibody 6-36 diluted in PBS. The 10 and 5 mg/kg groups maintained their weight at levels similar to the positive control at all time points. The 1 mg/kg group weight dropped significantly similar to the Negative Control. These data indicate antibody 6-36 at 1 mg/kg is insufficient to provide benefit, but a 5-fold or greater dose is adequate to reduce disease as determined by weight loss (FIG. 21D).
FIG. 3421E shows data from the variant antibodies grouped by dose. FIG. 21F shows graphs of percent weight change for antibodies 6-3, 6-63, and 1-20.
In wild type hamsters, virus is typically cleared by Day 7. However, in the cyclophosphamide model, viral levels are not suppressed unless there is intervention (e.g. protective antibodies administered) or the cyclophosphamide is discontinued to allow immune response and clearance. In this experiment the positive control human convalescent serum eliminated virus from the lungs from all except one hamster. In contrast, all but one of the hamsters injected with negative control antibody still had infectious virus in the lungs. Interestingly, hamsters prophylactically treated (24 hour previous to exposure) with any of the three antibodies at the highest dose (10 mg/kg) had infectious virus in the lungs of at least half the animals assessed 9 days later. Paradoxically, 6-63 and 6-3 at the lower doses (5 and 1 mg/kg) had animals with relatively less infectious virus in the lungs. 4 of 6 animals injected with 1-20 at 5 mg/kg dose animals had no detectable virus in the lungs. When the doses of that antibody was reduced to 1 mg/kg, all but one animal had infectious virus. Data is seen in FIGS. 21G-21H.
Lung pathology inflammation and edema scores from three animals were added per group and plotted (FIG. 21I). These were the same lungs used to score ISH. The convalescent sera positive control median score was 2 and the negative control was 4. The only groups with a median score lower than the negative control group were 1 and 5 mg/kg 6-63, 10 and 5 mg/kg 6-3, and 5 mg/kg 1-20. The highest median pathology scores were the 1 and 10 mg/kg 1-20 groups. The lowest median pathology score was the 5 mg/kg 6-63 group.

Example 9. VSV-Pseudotype Neutralization Analysis of Antibodies for SARS-CoV-2 B.135 (South African Strain)

Antibodies described herein were tested in a VSV-pseudotype neutralization assay for SARS-CoV-2 B.135 (South African strain).
Briefly, aerial semi-log dilutions of all test antibodies (TA) and control were prepared and mixed with the VSV-pseudotype virus in a 1:1 ratio for 1 h at RT followed by incubation over Vero cells (ATCC® CCL-81™) seeded at 60,000 cells per well at 37° C. The cells were lysed the following day and luciferase activity was measured to assess the potency of each TA to block viral entry into the Vero cells. All samples will be run in triplicate. Data analysis is conducted using XLFit and Graphpad Prism. The testing concentrations and plate plan are seen in Table 18A.

TABLE 18A

Testing Concentrations and Plate Plan

	Stock	Target	In plate
Samples	(mg/mL)	conc/dilution	concentration

1	6-63	6.39	100 ug/mL	50.00 ug/mL
2	6-3	10.05	100 ug/mL	50.00 ug/mL
3	1-12	2.24	100 ug/mL	50.00 ug/mL
4	mouse	1	1:25	1:50
	pAb

Data is seen in FIGS. 22A-22B. FIG. 22A illustrates positive control pAb has an NT50 of 1: 14, 993 dilution as expected. FIG. 22B illustrates antibodies 6-63 and 6-3 neutralize VSV-SARS B.135 strain with IC50s of ˜3.07 ug/mL and 0.143 ug/mL, respectively. Antibody 1-12 failed to neutralize VSV-SARS B.135 strain.

Example 10. VSV-Pseudotype Neutralization Analysis of Antibodies for SARS-CoV-2 D614G Variant

Antibodies described herein were tested in a VSV-pseudotype neutralization assay for SARS-CoV-2 SARS CoV-2 S D614G variant.
Briefly, serial semi-log dilutions of all test antibodies (TA) and control were prepared and mixed with the VSV-pseudotype virus in a 1:1 ratio for 1 h at RT followed by incubation over Vero cells (ATCC® CCL-81™) seeded at 60,000 cells per well at 37° C. The cells were lysed the following day and luciferase activity was measured to assess the potency of each TA to block viral entry into the Vero cells. All samples will be run in triplicate. Data analysis is conducted using XLFit and Graphpad Prism.
Data is seen in FIGS. 23A-23C. FIG. 23A shows the positive control.

Example 11. Antibody Cocktails for Treating SARS-CoV-2 in Syrian Hamsters

This Example demonstrates pre- and post-exposure efficacy of antibody cocktails in Syrian hamsters.
Methods
In this study the hamsters were transiently immunosuppressed using cyclophosphamide. As a strategy to de-risk selecting viruses with neutralization escape mutations a cocktail of a nanobody (nAb) and a monoclonal antibody (MAb) known to bind different spike protein epitopes were combined and used. The combined dose was 20 mg/Kg in this proof-of-concept experiment. The cocktail consisted of 10 mg/Kg of VHH nanobody 6-63 and 10 mg/Kg of monoclonal antibody 1-20. An equal number of male and female animals were used in each group.
Seventy-eight hamsters were used for this experiment according to Table 18B. On Day 0, animals were exposed via intranasal (IN) instillation to 1,000 pfu of SARS-CoV-2 virus in 50 μL volume. The volume was distributed between both nares. To transiently immunosuppress, all animals were treated with cyclophosphamide starting on Day −3 (140 mg/kg dose) followed by additional doses (100 mg/kg) on Days 1, 5, and 9.
On the indicated day post exposure, MAb/nAb cocktail or c7D11 was administered via the intraperitoneal (IP) route. On Day 0 blood samples were collected from Group I for hematology to confirm immunosuppression. Group I was also the control for any adverse effects of cyclophosphamide treatment on the hamsters. Clinical scores and individual animal weights were recorded daily. Pharyngeal swabs and other key events were determined. Animals in Groups A-I were euthanized on day 14 and lungs were collected for virology and pathology. Group J animals were used for a serial pathology component of this study. Two animals from Group J (2 male and 2 female) were euthanized starting on Day 1 and then each day up to and including Day 6.

TABLE 18B

Experimental design

	Number of	Virus
	Hamsters (Pain	Exposure^a
Group	Category)	(Day 0)	Treatment	Treatment Day

A	6 (3 male, 3	SARS	Cocktail	^b20	−1
	female) (D)	CoV-2	mg/Kg
B	6 (3 male, 3		Cocktail ^b20	+1
	female) (D)		mg/Kg
C	6 (3 male, 3		Cocktail ^b20	+2
	female) (D)		mg/Kg
D	6 (3 male, 3		Cocktail ^b20	+3
	female) (D)		mg/Kg
E	6 (3 male, 3		Cocktail ^b20	+4
	female) (D)		mg/Kg
F	6 (3 male, 3		Cocktail ^b20	+5
	female) (D)		mg/Kg
G	6 (3 male, 3		Cocktail ^b20	+6
	female) (E)		mg/Kg
H	6 (3 male, 3		Neg IgG	+1
	female) (E)		control
I	6 (3 male, 3	No virus	none	Cyclophosphamide
	female)(C)			control
J	24 (12 male, 12	SARS	none	No treatment-
	female) (E)	CoV-2		pathology control^d

78 Syrian hamsters
^achallenge with 1,000 pfu of virus in 50 microliter volume
^bcocktail = 6-63 combined with 1-20 1:1 w/v delivered 2.5 mL per animal by i.p. route
^c negative control 20 mg/kg
^dTwo animals (2 male and 2 female) from Group J were euthanized for pathology/virology on Days 1, 2, 3, 4, 5, 6

Results
Cyclophosphamide treatment in uninfected animals does not result in weight loss. Control animals (CYP Controls, Group I), that were treated with CYP but not challenged gained weight overtime.
Negative control antibody c7D11 at 20 mg/kg, Group H, does not protect against disease associated weight loss. Hamsters in Group H lost weight starting on Day 6 (FIG. 24A). Weight loss continued until Day 10 when it leveled off Animals were still below 10% of their starting weight on the last day of the experiment (Day 14).
The cocktail administered one day prior to exposure protected against weight loss. Hamsters in Group A maintained their weight and stayed within 1% of starting weight (FIG. 24A). This confirmed that treatment with neutralizing antibodies before exposure was sufficient to protect against significant weight loss.
Post-exposure treatment of CYP hamster model of COVID19 produces variable weight loss effects/patterns. A onetime treatment of a cocktail containing 1-20 and 6-63 at final dose of 20 mg/Kg was administered on Days 1 (B), 2 (C), 3 (D), 4 (E), 5 (F), and 6 (G). The percent weight change relative to Day 0 are shown in FIG. 24A. Arrows and dotted vertical lines indicate the day of treatment specific for the treatment regimen being compared. The same data is shown collectively in FIG. 24B. Note that there were two animals in Group B (Day 1) that dropped weight atypically during the experiment and one animal succumbed on Day 12. That animal had a necrotic/hemorrhaging testicle due to an apparent torsion event and was excluded from analysis. No assignable cause was identified for the second animal so that animal was not excluded from analysis. Statistical analysis was performed to compare both the CYP Control (Group I) and the negative control antibody (c7d11, Group H) to all other groups. The significance between groups at individual timepoints and differences in area under the curve (AOC) were determined. Treatment with the cocktail one day after exposure (Group B) results were confounded by the outlier animal There was not a significant differences in AOC between Group B and Group H suggesting no protection; however, there was also no significant difference in the AOC between Group A and Group I indicating Group B weight loss was not significantly different from the CYP control group that was not exposed. Treatment with the cocktail two days after exposure (Group C) clearly protected. There was significant differences in AOC between Group C and Group H; and no significant difference in the AOC between Group C and Group I. Treatment after three days (Day 3 Group D) did not result in a significant difference in AOC between Group D and H. However, treatment on day 4 or 5 after exposure (Groups E and F, respectively) did significant reduce the AOC relative to Group H. Treatment on day 6 (Group G) was similar to treatment on day 3 where no significant difference in AOR between Group G and H. Although there was no significance in the AOC for the Day 6 treatment group, the last three timepoints weight loss was significantly less than the negative control group. Interestingly, groups administered antibody on Days 3, 4, 5, or 6 started to gain weight starting on Day 9 whereas the negative control antibody treated animals did not. This suggests that there was a benefit of all cocktail treatment even at as late as 6 days post-exposure.
Infectious virus in lungs (Day 14/15). In wild type hamsters, virus is typically cleared by Day 7. However, in the cyclophosphamide model virus is not suppressed unless there is intervention (e.g. protective antibodies administered) or the cyclophosphamide is discontinued to allow immune response and clearance. Here, our controls demonstrate that unexposed hamsters were negative for virus (Cyp Cont), whereas all hamsters exposed to virus and treated with an off-target monoclonal antibody (Neg Cont) had more than 10,000 pfu of virus per gram of lung tissue. Most of the hamsters treated with the Cocktail one day prior or one day post virus exposure had detectable levels of virus in lung samples collected on Day 14 (Groups A and B). However, almost all of the hamsters treated with antibody ≥2 day after exposure had undetectable levels of antibody in their lungs. There was only a single animal exception in the Day 2, 3, 4 and 6 treated groups. All of the hamsters treated on Day 5 had lungs that were free of infectious virus. See FIG. 24C.
Sequential Sampling. Hamsters immunosuppressed and exposed to virus on Day 0 were sampled overtime to monitor the infection. Infectious virus was detected in the lungs of 3 of 4 hamsters on Day 1. Levels of infectious virus then increased more than 4 logs by Day 2. Levels of virus then leveled off and stayed between 7-9 log 10 through the last sampling timepoint (Day 6) analyzed to-date. Thus, animals administered the cocktail after Day 1 likely had very high levels of infectious virus present in their lungs before treatment with the antibody. See FIG. 24D.

CONCLUSION

The data demonstrates that when administered at or before Day 2 relative to virus exposure, the combination of antibody and nanobody at 20 mg/kg was sufficient to provide convincing benefit as determined by the disease parameters analyzed. When treated after Day 2, animals still developed weight loss but recovered in approximately 4 days. Two weeks after virus exposure, more infectious virus was detected in the lungs of hamsters receiving antibody early (Day −1 or 1) than day 2 or later. Day 2 (or later) treatment of exposed animals occurred at a time when viral burden in the lungs was already remarkably high. CYP, by itself, does not induce weight loss or clinical signs of disease.

Example 12. Immunity Conferred by SARS-CoV-2 and ACE2 Antibodies

Antibodies described in Examples 4-6 are used to confer immunity in a subject. A subject is passively immunized with a SARS-CoV-2 or ACE2 antibody. The subject is then exposed to SARS-CoV-2 after immunization with the SARS-CoV-2 or ACE2 antibody. Exposure can be within a few days or within a few months. The subject can also receive the SARS-CoV-2 or ACE2 antibody immediately following exposure with SARS-CoV-2. Although the subject is exposed to SARS-CoV-2, the subject has developed an immunity against SARS-CoV-2 and infection is prevented.

Example 13. Sequences

Tables 19-25 show exemplary sequences for CDRH1-H3 and CDRL1-L3 as well as variant heavy chains and variant light chains for the SARS-CoV-2 and ACE2 variants.

TABLE 19

SARS-CoV-2 S1 Variable Heavy Chain CDRs

	SEQ		SEQ		SEQ
Vari-	ID		ID		ID
ant	NO	CDRH1	NO	CDRH2	NO	CDRH3

1-1	1	FTFSSHAMY	37	SAISGSA	73	CAHDTKDFW
				GSTYYA		SGYCIFDPW

1-2	2	FTFSSQAMS	38	SAISGSG	74	CAKDRRFGE
				GGTYYA		FDPW

1-3	3	FTFSSQAMS	39	SAISGSG	75	CAKDRRFGE
				GGTYYA		FDPW

1-4	4	FTFSSQAMS	40	SAISGSG	76	CAKDRRFGE
				GGTYYA		FDPW

1-5	5	FTFSSQAMS	41	SAISGSG	77	CAKDRRFGE
				GGTYYA		FDPW

1-6	6	FTFSSQAMS	42	SAISGSG	78	CAKDRRFGE
				GGTYYA		FDPW

1-7	7	FTFSSYDMS	43	SVISGSG	79	CAKGPLV
				GSTYYA		GWYFDLW

1-8	8	FTFSSYDMS	44	SVISGSG	80	CAKGPLV
				GSTYYA		GWYFDLW

1-9	9	FTFSSYDMS	45	SVISGSG	81	CAKGPLV
				GSTYYA		GWYFDLW

1-10	10	FTFSSYDMS	46	SVISGSG	82	CAKGPLVGW
				GSTYYA		YFDLW

1-11	11	ITFSSYAMS	47	SGISGSG	83	CAKHGSGT
				GSTYYA		IFGVVIAK
						YYFDYC

1-12	12	ITFSSYAMS	48	SGISGSG	84	CAKHGSGTI
				GSTYYA		FGVVIAKYY
						FDYW

1-13	13	VTFSSYAMS	49	SAITGSG	85	CAKHGSGT
				GSTYYA		IFGVVIAK
						YYFDYW

1-14	14	ITFSSYAMS	50	SGISGSG	86	CANHGSGT
				GSTYYA		IFGVVIAK
						YYFDYW

1-15	15	FTFSSHAMY	51	SAISGSA	87	CARDTKD
				GSTYYA		FWSGYSI
						FDPW

1-16	16	FTFSSYAMY	52	SAISGSA	88	CARDT
				GSTYYA		NDFW

1-17	17	FTFSSYAMY	53	SAISGSA	89	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-18	18	FTFSSYAMY	54	SAISGSA	90	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-19	19	FTFTSYAMY	55	SAISGSA	91	CARDTNDF
				GSTYYA		WSGYSIF
						DPW

1-20	20	FTFSSYAMY	56	SAISGSA	92	CARDTND
				GSTYYA		FWSGYSI
						FHPW

1-21	21	FTFSSYTMS	57	SIISGSG	93	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-22	22	FTFSSYAMN	58	SIISGSG	94	CAREGYR
				GSTYYA		DYLWYF
						DLW

1-23	23	FTFSSYAIS	59	SIISGSG	95	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-24	24	FTFSSYAMN	60	SIISGSG	96	CAREGYR
				GSTYYA		DYLWYF
						DLW

1-25	25	FTFSDYAMN	61	SIISGSG	97	CAREGYR
				GSTYYA		DYLWYFDLW

1-26	26	FTFSSYAIS	62	SAISGSG	98	CARGAP
				YSTYYA		DSSGYYFQ
						GEVYFDYW

1-27	27	FTFSSYAMT	63	SAISGSG	99	CASSSSWQ
				GGTYYA		FDYW

1-28	28	FTFSSYGMS	64	SAISGSG	100	CASSSSWQ
				GGTYYA		FDYW

1-29	29	FTFSSYAMT	65	SAISGSG	101	CASSSSWQ
				GGTYYA		FDYW

1-30	30	FTFSSYAMT	66	SAISGSG	102	CTRPPYGDY
				GSTFYA		GDYW

1-31	31	FTFSSYAMN	67	SAISGSG	103	CTRPPYGDY
				GSTFYA		GDYW

1-32	32	FTFSSYAMY	68	SAISGSG	104	CTRPPYGD
				GSTFYA		YGDYW

1-33	33	FTFSSYAMI	69	SAISGSG	105	CTRPPYGD
				GSTFYA		YGDYW

1-34	34	FTFSSYAMY	70	SAISSSG	106	CTRPPYG
				GSTYYA		DYGDYW

1-35	35	FTFSNYAMS	71	SDISGSG	107	CVKGTI
				GSTYYA		PIFGVI
						RSAFDYW

1-36	36	LTFSSYAMS	72	SDISGSG	108	CVKGTIP
				GSTYYA		IFGVIRS
						AFDYW

TABLE 20

SARS-CoV-2 S1 Variable Light Chain CDRs

	SEQ		SEQ		SEQ
	ID		ID		ID
Variant	NO	CDRL1	NO	CDRL2	NO	CDRL3

1-1	109	TGTSSDI	145	EGTKRPS	181	CCSYAGS
		GSYNLVS				RTYVF

1-2	110	TGTSSGV	146	EGIKRPS	182	CCSYAGS
		GSYNLVS				SSFVVF

1-3	111	TGISSDV	147	EGTKRPS	183	CCSYAGS
		GSYNLVS				SSFVVF

1-4	112	TGTSSDV	148	EGSQRPS	184	CCSYAGS
		GTYNLVS				SSF
						VVF

1-5	113	TGTSSGV	149	EASKRPS	185	CCSYAGS
		GSYNLVS				YTF
						AVF

1-6	114	TGTSSGV	150	EGIKRPS	186	CCSYAGS
		GSYNLVS				SSFVVF

1-7	115	TGTSSDF	151	EGNKRPS	187	CCSYAGS
		GSYNLVS				STFVVF

1-8	116	TGTSNDV	152	EGSKRPS	188	CCSYAGS
		GSYNLVS				RYVVF

1-9	117	TGTSSDV	153	EGSNRPS	189	CCSYAGS
		GDYNLVS				SSFVVF

1-10	118	TGTSSNV	154	EGTKRPS	190	CCSYAGS
		GSYNLVS				SSFVVF

1-11	119	TGTSSDV	155	EGTKRPS	191	CCSYAGS
		GHYNLVS				SSFVVF

1-12	120	TGTSSDV	156	EGTKRPS	192	CCSYAGS
		GHYNLVS				SSFVVF

1-13	121	TGTSSDV	157	EGGKRPS	193	CCSYASS
		GRYNLVS				STLVF

1-14	122	TGTSSDV	158	EGTKRPS	194	CCSYAGS
		GHYNLVS				SSFVVF

1-15	123	TGTSSDI	159	EGTNRPS	195	CCSYAGS
		GSYNLVS				RTYVF

1-16	124	TGTSSDI	160	EGTKRPS	196	CCSYAGS
		GSYNLVS				RTYVF

1-17	125	TGTSSDI	161	EGTKRPS	197	CCSYAGS
		GSYNLVS				RTYVF

1-18	126	TGTSSDI	162	EGTKRPS	198	CCSYAGS
		GSYNLVS				RTYVF

1-19	127	TGTSSDI	163	EGTKRPS	199	CCSYAGS
		GSYNLVS				RTYVF

1-20	128	TGTSSDI	164	EGTKRPS	200	CCSYAGS
		GSYNLVS				RTYVF

1-21	129	TGTSSDV	165	EGNKRPS	201	CCSYAGS
		GSNNLVS				VVF

1-22	130	TGTSTDV	166	EGSQRPS	202	CCSYAGS
		GSYNLVS				STVF

1-23	131	TGTSNDV	167	EGNKRPS	203	CCSYAGS
		GSYNLVS				YTVF

1-24	132	TGTSSDV	168	EGNKRPS	204	CCSYAGG
		GYYNLVS				SVVF

1-25	133	SGTSSDV	169	EASKRPS	205	CCSYAGS
		GSYNLVS				STVF

1-26	134	TGTSSDV	170	EGTKRPS	206	CCSFVRS
		GGYNLVS				SAHVVF

1-27	135	TGTSSYV	171	EGSRRPS	207	CCSYAGS
		GHYNLVS				YTHYVF

1-28	136	TGTSSGV	172	EGSQRPS	208	CCSYAGS
		GSYNLVS				STHYVF

1-29	137	TGTSSYV	173	EGSRRPS	209	CCSYAGS
		GHYNLVS				YTHYVF

1-30	138	TGTSRDV	174	EGTKRPS	210	CCSYAGS
		GSYNLVS				RTPVVF

1-31	139	TGTSSDV	175	EGSQRPS	211	CCSYAGS
		GKYNLVS				RTPVVF

1-32	140	TGTSSDV	176	EGNKRPS	212	CCSYAGS
		GGYNLVS				STFPV
						VF

1-33	141	TGTSSDV	177	EASKRPS	213	CCSYAGS
		GSYNLLS				RTPVVF

1-34	142	TGTSSDV	178	EASKRPS	214	CCSYAGS
		GGYNLVS				YIPVVF

1-35	143	TGTSSDV	179	EGTKRPS	215	CCSYAGS
		GSYSLVS				YSYVVF

1-36	144	TGTSSDV	180	EGDKRPS	216	CCSYAGS
		GSYSLVS				YSYVVF

TABLE 21

SARS-CoV-2 S1 Variable Heavy Chain CDRs

	SEQ		SEQ		SEQ
	ID		ID		ID
Name	NO	CDRH1	NO	CDRH2	NO	CDRH3

1-21	217	FTFSSYTMS	283	SIISGSG	349	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-22	218	FTFSSYAMN	284	SIISGSG	350	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-30	219	FTFSSYAMT	285	SAISGSG	351	CTRPPYG
				GSTFYA		DYGDYW

1-35	220	FTFSNYAMS	286	SDISGSG	352	CVKGTIP
				GSTYYA		IFGVIRS
						AFDYW

1-17	221	FTFSSYAMY	287	SAISGSA	353	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-27	222	FTFSSYAMT	288	SAISGSG	354	CASSSSW
				GGTYYA		QFDYW

1-12	223	ITFSSYAMS	289	SGISGSG	355	CAKHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						W

1-2	224	FTFSSQAMS	290	SAISGSG	356	CAKDRRF
				GGTYYA		GEFDPW

1-3	225	FTFSSQAMS	291	SAISGSG	357	CAKDRRF
				GGTYYA		GEFDPW

1-23	226	FTFSSYAIS	292	SIISGSG	358	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-7	227	FTFSSYDMS	293	SVISGSG	359	CAKGPLV
				GSTYYA		GWYFDLW

1-31	228	FTFSSYAMN	294	SAISGSG	360	CTRPPYG
				GSTFYA		DYGDYW

1-4	229	FTFSSQAMS	295	SAISGSG	361	CAKDRRF
				GGTYYA		GEFDPW

1-8	230	FTFSSYDMS	296	SVISGSG	362	CAKGPLV
				GSTYYA		GWYFDLW
1-9	231	FTFSSYDMS	297	SVISGSG	363	CAKGPLV
				GSTYYA		GWYFDLW

1-32	232	FTFSSYAMY	298	SAISGSG	364	CTRPPYG
				GSTFYA		DYGDYW

1-33	233	FTFSSYAMI	299	SAISGSG	365	CTRPPYG
				GSTFYA		DYGDYW

1-24	234	FTFSSYAMN	300	SIISGSG	366	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-40	235	FTFSSYAMY	301	SAISGSA	367	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-5	236	FTFSSQAMS	302	SAISGSG	368	CAKDRRF
				GGTYYA		GEFDPW

1-28	237	FTFSSYGMS	303	SAISGSG	369	CASSSSW
				GGTYYA		QFDYW

1-10	238	FTFSSYDMS	304	SVISGSG	370	CAKGPLV
				GSTYYA		GWYFDLW

1-26	239	FTFSSYAIS	305	SAISGSG	371	CARGAPD
				YSTYYA		SSGYYFQ
						GEVYFDY
						W

1-42	240	VTFSSYAMS	306	SAITGSG	372	CAKHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						W

1-13	241	FTFSSHAMS	307	SAISGSA	373	CARDTKD
				GSTYYA		FWSGYCI
						FDPW

1-14	242	FTFTSYAMS	308	SAISGSG	374	CANDTND
				GSTYYA		FWFGYWI
						FDPW

1-6	243	FTFSSQAMS	309	TAISGSG	375	CAKDTIF
				GGTYYA		GEFYPW

1-20	244	ITFSSYAMS	310	SGISGSG	376	CANHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						W

1-47	245	FTFSSQAMS	311	SAISGSG	377	CAKDRRF
				GGTYYA		GEFDPW

1-29	246	FTFSSYAMY	312	SAISGSA	378	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-1	247	FTFSSHAMY	313	SAISGSA	379	CARDTKD
				GSTYYA		FWSGYSI
						FDPW

1-19	248	ITFSSYAMS	314	SGISGSG	380	CAKHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						C

1-16	249	LTFSSYAMS	315	SDISGSG	381	CVKGTIP
				GSTYYA		IFGVIRS
						AFDYW

1-34	250	FTFSSYAMT	316	SAISGSG	382	CASSSSW
				GGTYYA		QFDYW

1-48	251	FTFSSHAMY	317	SAISGSA	383	CAHDTKD
				GSTYYA		FWSGYCI
						FDPW

1-49	252	FTFSSYAMY	318	SAISGSA	384	CARDTND
				GSTYYA		FW

1-18	253	FTFSSHAMS	319	SAISGSA	385	CAHDTKD
				GSTYYA		FWSGYCI
						FDPW

1-11	254	FTFSSYDMS	320	SAISGSG	386	CARGPLD
				GTTYYA		FW

1-25	255	FTFTSYAMY	321	SAISGSA	387	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-36	256	FTFSDYAMN	322	SIISGSG	388	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-15	257	ITFSSHAMS	323	SGISGSG	389	CAKHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						W

1-51	258	FTFSSYAMS	324	SVISGSG	390	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-52	259	FTFSNYAMS	325	SAISGSA	391	CARVRQG
				GSTYYA		LRRTWYY
						FDYW

1-53	260	FTFSSYTMS	326	SVISGSG	392	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-54	261	FTFSSYAMY	327	SAISGSA	393	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-55	262	FTFSSYAMA	328	SAISGSG	394	CASSSSW
				SSTYYA		QFDYW

1-56	263	FTFSSYAMY	329	SAISGSA	395	CARDTND
				GSTYYA		FWSGYSI
						FDPW

1-57	264	FTFSSYAMT	330	SAISGSG	396	CTRPPYG
				GSTFYA		DYGDYW

1-58	265	FTFSSYAMG	331	SAISTSG	397	CAKGLWF
				GSTYYA		GGGGFDP
						W

1-59	266	FTFSSYAMN	332	SVISGSG	398	CAREGYR
				GSTYYA		DYLWYFD
						LW

1-6	267	FTFSSYAMY	333	SAISSSG	399	CTRPPYG
				GSTYYA		DYGDYW

1-61	268	FTFSSYAVS	334	SDISGSG	400	CVKGTIP
				GSTYYA		IFGVIRS
						AFDYW

1-62	269	FRFSSYAMS	335	SAISGSG	401	CAKDFHG
				GTTYYA		IAAAGID
						YW

1-63	270	FMFSSYAMS	336	SAISGSG	402	CAKDGAS
				GSTYYT		GWPNWHF
						DLW

1-64	271	FAFSSYAMS	337	SAISGSG	403	CAHSRDS
				GDTYYA		SSWYVDY
						W

1-37	272	FTFTSYAMN	338	TAISGSG	404	CTRPPYG
				GSTFYA		DYGDYW

1-38	273	ITFSSYAMS	339	SGISGSG	405	CAKHGSG
				GSTYYA		TIFGVVI
						AKYYFDY
						W

1-39	274	FTFSSYAMY	340	TAISGSG	406	CTRPPYG
				GSTFYA		YYGDYW

1-41	275	FTFSSYDMS	341	SVISGSG	407	CAKGPLV
				GSTYYA		GWYFDLW

1-43	276	FTFSSQAMS	342	TAISGSG	408	CAKDTIF
				GGTYYA		GEFYPW

1-44	277	FTFSSQAMS	343	TAISGSG	409	CAKDRKF
				GGTYYA		GEFDPW

1-45	278	FTFSSYAMS	344	SIISGSA	410	CARDGYK
				GSTYYA		YCLW

1-46	279	FTFTSYAMS	345	SAISGSG	411	CANDTSD
				GSTYYA		FCFGYWI
						FDPW

1-50	280	FTFSSYDMS	346	SAISGSG	412	CARGPLD
				GTTYYA		FW

1-65	281	FTFSSHAMS	347	SAISGSA	413	CARDTKD
				GSTYYA		FWSGYCI
						FDPW

1-66	282	FTFTSYAMS	348	SAISGSG	414	CANDTND
				GSTYYA		FWFGYWI
						FDPW

TABLE 22

SARS-CoV-2 S1 Variable Light Chain CDRs

	SEQ		SEQ		SEQ
	NO		NO		NO
Name	ID	CDRL1	ID	CDRL2	ID	CDRL3

1-21	415	TGTSSDVGSNNLVS	474	EGNKRPS	533	CCSYAGSVVF

1-22	416	TGTSTDVGSYNLVS	475	EGSQRPS	534	CCSYAGSSTVF

1-30	417	TGTSRDVGSYNLVS	476	EGTKRPS	535	CCSYAGSRTPVVF

1-35	418	TGTSSDVGSYSLVS	477	EGTKRPS	536	CCSYAGSYSYVVF

1-17	419	TGTSSDIGSYNLVS	478	EGTKRPS	537	CCSYAGSRTYVF

1-27	420	TGTSSYVGHYNLVS	479	EGSRRPS	538	CCSYAGSYTHYVF

1-12	421	TGTSSDVGHYNLVS	480	EGTKRPS	539	CCSYAGSSSFVVF

1-2	422	TGTSSGVGSYNLVS	481	EGIKRPS	540	CCSYAGSSSFVVF

1-3	423	TGISSDVGSYNLVS	482	EGTKRPS	541	CCSYAGSSSFVVF

1-23	424	TGTSNDVGSYNLVS	483	EGNKRPS	542	CCSYAGSYTVF

1-7	425	TGTSSDFGSYNLVS	484	EGNKRPS	543	CCSYAGSSTFVVF

1-31	426	TGTSSDVGKYNLVS	485	EGSQRPS	544	CCSYAGSRTPVVF

1-4	427	TGTSSDVGTYNLVS	486	EGSQRPS	545	CCSYAGSSSFVVF

1-8	428	TGTSNDVGSYNLVS	487	EGSKRPS	546	CCSYAGSRYVVF

1-9	429	TGTSSDVGDYNLVS	488	EGSNRPS	547	CCSYAGSSSFVVF

1-32	430	TGTSSDVGGYNLVS	489	EGNKRPS	548	CCSYAGSST
						FPVVF

1-33	431	TGTSSDVGSYNLLS	490	EASKRPS	549	CCSYAGSRTPVVF

1-24	432	TGTSSDVGYYNLVS	491	EGNKRPS	550	CCSYAGGSVVF

1-5	433	TGTSSGVGSYNLVS	492	EASKRPS	551	CCSYAGSYTFAVF

1-28	434	TGTSSGVGSYNLVS	493	EGSQRPS	552	CCSYAGSSTHYVF

1-10	435	TGTSSNVGSYNLVS	494	EGTKRPS	553	CCSYAGSSSFVVF

1-26	436	TGTSSDVGGYNLVS	495	EGTKRPS	554	CCSFVRSSAHVVF

1-42	437	TGTSSDVGRYNLVS	496	EGGKRPS	555	CCSYASSSTLVF

1-20	438	TGTSSDVGHYNLVS	497	EGTKRPS	556	CCSYAGSSSFVVF

1-47	439	TGTSSGVGSYNLVS	498	EGIKRPS	557	CCSYAGSSSFVVF

1-29	440	TGTSSDIGSYNLVS	499	EGTKRPS	558	CCSYAGSRTYVF

1-1	441	TGTSSDIGSYNLVS	500	EGTNRPS	559	CCSYAGSRTYVF

1-19	442	TGTSSDVGHYNLVS	501	EGTKRPS	560	CCSYAGSSSFVVF

1-16	443	TGTSSDVGSYSLVS	502	EGDKRPS	561	CCSYAGSYSYVVF

1-34	444	TGTSSYVGHYNLVS	503	EGSRRPS	562	CCSYAGSYTHYVF

1-48	445	TGTSSDIGSYNLVS	504	EGTKRPS	563	CCSYAGSRTYVF

1-49	446	TGTSSDIGSYNLVS	505	EGTKRPS	564	CCSYAGSRTYVF

1-25	447	TGTSSDIGSYNLVS	506	EGTKRPS	565	CCSYAGSRTYVF

1-36	448	SGTSSDVGSYNLVS	507	EASKRPS	566	CCSYAGSSTVF

1-51	449	TGTSSDVGSYDLVS	508	EGNKRPS	567	CCSYAGSSVVF

1-52	450	TGTSSDVGSSNLVS	509	EGSKRPS	568	CCSYAGSLYVF

1-53	451	TGTSTDVGSYNLVS	510	EGTKRPS	569	CCSYAGSYTSVVF

1-54	452	TGTSSDIGSYNLVS	511	EGTKRPS	570	CCYHSRTRTHVF

1-55	453	TGTSSDLGSYNIVS	512	EGSRRPS	571	CCSYAGSYTHYVF

1-56	454	TGTSSDIGSYNLVS	513	EGTKRPS	572	CCYHSRTRTHVS

1-57	455	TGTSSDVGKYNLVS	514	EGVKRPS	573	CCSYAGSRTPVVF

1-58	456	TGTRSDVGSYNLVS	515	EVSKRPS	574	CCSYAGDSFPYVF

1-59	457	TGTSSDVGSFNLVS	516	EVSKRPS	575	CCSYAGSSVVF

1-6	458	TGTSSDVGGYNLVS	517	EASKRPS	576	CCSYAGSYIPVVF

1-61	459	TGTSSDVGSYSLVS	518	EGGKRPS	577	CCSYAGSYSYVVF

1-62	460	TGTSSDVGSHNLVS	519	EGGKRPS	578	CCSYSGRYTYVF

1-63	461	TGTSSDVGSYYLVS	520	EGDKRPS	579	CCSHAGRYPYVF

1-64	462	TGTSSGVGSYNLVS	521	AGSKRPS	580	CCSYLGSGTF
						DVLF

1-37	463	TGTSSDIGSYNLVS	522	EGTKRPS	581	CCSYAGSRTYVF

1-38	464	TGTSSDIGSYNLVS	523	EGTKRPS	582	CCSYAGSRTYVF

1-39	465	TGTSSDIGSYNLVS	524	EGTKRPS	583	CCSYAGSRTYVF

1-41	466	TGTSSDIGSYNLVS	525	EGTKRPS	584	CCSYAGSRTYVF

1-43	467	TGTSSDIGSYNLVS	526	EGTKRPS	585	CCSYAGSRTYVF

1-44	468	TGTSSDIGSYNLVS	527	EGTKRPS	586	CCSYAGSRTYVF

1-45	469	TGTSSDIGSYNLVS	528	EGTKRPS	587	CCSYAGSRTYVF

1-46	470	TGTSSDIGSYNLVS	529	EGTKRPS	588	CCSYAGSRTYVF

1-50	471	TGTSSDIGSYNLVS	530	EGTKRPS	589	CCSYAGSRTYVF

1-65	472	TGTSSDIGSYNLVS	531	EGTKRPS	590	CCSYAGSRTYVF

1-66	473	TGTSSDIGSYNLVS	532	EGTKRPS	591	CCSYAGSRTYVF

TABLE 23

SARS-CoV-2 S1 Variant Sequences
Variable Heavy Chain

Name	SEQ ID	Amino Acid Sequence

1-21	592	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYTMSWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-22	593	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-30	594	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-35	595	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSNYAMSWVRQAPGKGLEWVSD
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCVKGT
		IPIFGVIRSAFDYWGQGTLVTVSS

1-17	596	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-27	597	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-12	598	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-2	599	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-3	600	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-23	601	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAISWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-7	602	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-31	603	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-4	604	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-8	605	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-9	606	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-32	607	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-33	608	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMIWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-24	609	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-40	610	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-5	611	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-28	612	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYGMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-10	613	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-26	614	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAISWVRQAPGKGLEWVSA
		ISGSGYSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARGA
		PDSSGYYFQGEVYFDYWGQGTLVTV
		SS

1-42	615	EVQLLESGGGLVQPGGSLRLSCAAS
		GVTFSSYAMSWVRQAPGKGLEWVSA
		ITGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-13	616	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMSWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		KDFWSGYCIFDPWGQGTLVTVSS

1-14	617	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMSWVRQAPGKGLEWVSA
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCANDT
		NDFWFGYWIFDPWGQGTLVTVSS

1-6	618	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVTA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDT
		IFGEFYPWGQGTLVTVSS

1-20	619	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCANHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-47	620	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-29	621	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-1	622	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		KDFWSGYSIFDPWGQGTLVTVSS

1-19	623	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYCGQGTLVTV
		SS

1-16	624	EVQLLESGGGLVQPGGSLRLSCAAS
		GLTFSSYAMSWVRQAPGKGLEWVSD
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCVKGT
		IPIFGVIRSAFDYWGQGTLVTVSS

1-34	625	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-48	626	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAHDT
		KDFWSGYCIFDPWGQGTLVTVSS

1-49	627	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWGQGTLVTVSS

1-18	628	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMSWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAHDT
		KDFWSGYCIFDPWGQGTLVTVSS

1-11	629	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSA
		ISGSGGTTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARGP
		LDFWGQGTLVTVSS

1-25	630	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-36	631	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSDYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-15	632	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSHAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-51	633	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-52	634	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSNYAMSWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARVR
		QGLRRTWYYFDYWGQGTLVTVSS

1-53	635	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYTMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-54	636	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-55	637	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMAWVRQAPGKGLEWVSA
		ISGSGSSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-56	638	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-57	639	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-58	640	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMGWVRQAPGKGLEWVSA
		ISTSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGL
		WFGGGGFDPWGQGTLVTVSS

1-59	641	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-6	642	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISSSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-61	643	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAVSWVRQAPGKGLEWVSD
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCVKGT
		IPIFGVIRSAFDYWGQGTLVTVSS

1-62	644	EVQLLESGGGLVQPGGSLRLSCAAS
		GFRFSSYAMSWVRQAPGKGLEWVSA
		ISGSGGTTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDF
		HGIAAAGIDYWGQGTLVTVSS

1-63	645	EVQLLESGGGLVQPGGSLRLSCAAS
		GFMFSSYAMSWVRQAPGKGLEWVSA
		ISGSGGSTYYTDSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDG
		ASGWPNWHFDLWGQGTLVTVSS

1-64	646	EVQLLESGGGLVQPGGSLRLSCAAS
		GFAFSSYAMSWVRQAPGKGLEWVSA
		ISGSGGDTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAHSR
		DSSSWYVDYWGQGTLVTVSS

1-37	647	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMNWVRQAPGKGLEWVTA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-38	648	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-39	649	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVTA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGYYGDYWGQGTLVTVSS

1-41	650	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-43	651	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVTA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDT
		IFGEFYPWGQGTLVTVSS

1-44	652	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVTA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		KFGEFDPWGQGTLVTVSS

1-45	653	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMSWVRQAPGKGLEWVSI
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDG
		YKYCLWGQGTLVTVSS

1-46	654	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMSWVRQAPGKGLEWVSA
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCANDT
		SDFCFGYWIFDPWGQGTLVTVSS

1-50	655	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSA
		ISGSGGTTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARGP
		LDFWGQGTLVTVSS

1-65	656	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMSWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		KDFWSGYCIFDPWGQGTLVTVSS

1-66	657	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMSWVRQAPGKGLEWVSA
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCANDT
		NDFWFGYWIFDPWGQGTLVTVSS

TABLE 24

SARS-CoV-2 S1 Variant Sequences Variable Light Chain

Name
ID
NO	SEQ	Amino Acid Sequence

1-21	658	QSALTQPASVSGSPGQSITISCTGTSSDVGSNNLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSVVFGGGTKLTVL

1-22	659	QSALTQPASVSGSPGQSITISCTGTSTDVGSYNLVSWYQQHPGKAPKLMIYEGSQR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVFGGGTKLTVL

1-30	660	QSALTQPASVSGSPGQSITISCTGTSRDVGSYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTPVVFGGGTKLTVL

1-35	661	QSALTQPASVSGSPGQSITISCTGTSSDVGSYSLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYSYVVFGGGTKLTVL

1-17	662	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-27	663	QSALTQPASVSGSPGQSITISCTGTSSYVGHYNLVSWYQQHPGKAPKLMIYEGSRR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-12	664	QSALTQPASVSGSPGQSITISCTGTSSDVGHYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-2	665	QSALTQPASVSGSPGQSITISCTGTSSGVGSYNLVSWYQQHPGKAPKLMIYEGIKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-3	666	QSALTQPASVSGSPGQSITISCTGISSDVGSYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-23	667	QSALTQPASVSGSPGQSITISCTGTSNDVGSYNLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTVFGGGTKLTVL

1-7	668	QSALTQPASVSGSPGQSITISCTGTSSDFGSYNLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFVVFGGGTKLTVL

1-31	669	QSALTQPASVSGSPGQSITISCTGTSSDVGKYNLVSWYQQHPGKAPKLMIYEGSQR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTPVVFGGGTKLTVL

1-4	670	QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKAPKLMIYEGSQR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-8	671	QSALTQPASVSGSPGQSITISCTGTSNDVGSYNLVSWYQQHPGKAPKLMIYEGSKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRYVVFGGGTKLTVL

1-9	672	QSALTQPASVSGSPGQSITISCTGTSSDVGDYNLVSWYQQHPGKAPKLMIYEGSNR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-32	673	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFPVVFGGGTKLTVL

1-33	674	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLLSWYQQHPGKAPKLMIYEASKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTPVVFGGGTKLTVL

1-24	675	QSALTQPASVSGSPGQSITISCTGTSSDVGYYNLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGGSVVFGGGTKLTVL

1-5	676	QSALTQPASVSGSPGQSITISCTGTSSGVGSYNLVSWYQQHPGKAPKLMIYEASKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTFAVFGGGTKLTVL

1-28	677	QSALTQPASVSGSPGQSITISCTGTSSGVGSYNLVSWYQQHPGKAPKLMIYEGSQR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTHYVFGGGTKLTVL

1-10	678	QSALTQPASVSGSPGQSITISCTGTSSNVGSYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-26	679	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSFVRSSAHVVFGGGTKLTVL

1-42	680	QSALTQPASVSGSPGQSITISCTGTSSDVGRYNLVSWYQQHPGKAPKLMIYEGGKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYASSSTLVFGGGTKLTVL

1-20	681	QSALTQPASVSGSPGQSITISCTGTSSDVGHYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-47	682	QSALTQPASVSGSPGQSITISCTGTSSGVGSYNLVSWYQQHPGKAPKLMIYEGIKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-29	683	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-1	684	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTNRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-19	685	QSALTQPASVSGSPGQSITISCTGTSSDVGHYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSSFVVFGGGTKLTVL

1-16	686	QSALTQPASVSGSPGQSITISCTGTSSDVGSYSLVSWYQQHPGKAPKLMIYEGDKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYSYVVFGGGTKLTVL

1-34	687	QSALTQPASVSGSPGQSITISCTGTSSYVGHYNLVSWYQQHPGKAPKLMIYEGSRR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-48	688	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-49	689	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-25	690	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-36	691	QSALTQPASVSGSPGQSITISCSGTSSDVGSYNLVSWYQQHPGKAPKLMIYEASKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVFGGGTKLTVL

1-51	692	QSALTQPASVSGSPGQSITISCTGTSSDVGSYDLVSWYQQHPGKAPKLMIYEGNKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSVVFGGGTKLTVL

1-52	693	QSALTQPASVSGSPGQSITISCTGTSSDVGSSNLVSWYQQHPGKAPKLMIYEGSKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSLYVFGGGTKLTVL

1-53	694	QSALTQPASVSGSPGQSITISCTGTSTDVGSYNLVSWYQQHPGKAPKLMIYEGTKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTSVVFGGGTKLTVL

1-54	695	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCYHSRTRTHVFGGGTKLTVL

1-55	696	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-56	697	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-57	698	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-58	699	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-59	700	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-6	701	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-61	702	QSALTQPASVSGSPGQSITISCTGTSSDLGSYNIVSWYQQHPGKAPKLMIYEGSRRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTHYVFGGGTKLTVL

1-62	703	QSALTQPASVSGSPGQSITISCTGTSSDVGSHNLVSWYQQHPGKAPKLMIYEGGKR
		PSGVSNRFSgSKSGNTaslTISGLQAEDEADYYCCSYSGRYTYVFGGGtKLTVL

1-63	704	QSALTQPASVSGSPGQSITISCTGTSSDVGSYYLVSWYQQHPGKAPKLMIYEGDKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSHAGRYPYVFGGGTKLTVL

1-64	705	QSALTQPASVSGSPGQSITISCTGTSSGVGSYNLVSWYQQHPGKAPKLMIYAGSKR
		PSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYLGSGTFDVLFGGGTKLTVL

1-37	706	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-38	707	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-39	708	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-41	709	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-43	710	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-44	711	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-45	712	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-46	713	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-50	714	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-65	715	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

1-66	716	QSALTQPASVSGSPGQSITISCTGTSSDIGSYNLVSWYQQHPGKAPKLMIYEGTKRP
		SGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSRTYVFGGGTKLTVL

TABLE 25

Reformatted SARS-CoV-2 S1 Variant Sequences

	SEQ
	ID	Amino Acid
Name	NO	Sequence

1-H1	717	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYTMSWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-H2	718	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-H3	719	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-H4	720	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSNYAMSWVRQAPGKGLEWVSD
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCVKGT
		IPIFGVIRSAFDYWGQGTLVTVSS

1-H5	721	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-H6	722	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-H8	723	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-H9	724	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-H10	725	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-H11	726	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAISWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-H12	727	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-H13	728	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-H14	729	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-H16	730	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-H17	731	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-H18	732	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-H19	733	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMIWVRQAPGKGLEWVSA
		ISGSGGSTFYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-H20	734	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-H23	735	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-H25	736	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYGMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-H26	737	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYDMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKGP
		LVGWYFDLWGQGTLVTVSS

1-H27	738	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAISWVRQAPGKGLEWVSA
		ISGSGYSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARGA
		PDSSGYYFQGEVYFDYWGQGTLVTV
		SS

1-H28	739	EVQLLESGGGLVQPGGSLRLSCAAS
		GVTFSSYAMSWVRQAPGKGLEWVSA
		ITGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-H31	740	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFHPWGQGTLVTVSS

1-H36	741	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCANHG
		SGTIFGVVIAKYYFDYWGQGTLVTV
		SS

1-H37	742	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSQAMSWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKDR
		RFGEFDPWGQGTLVTVSS

1-H38	743	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-H39	744	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		KDFWSGYSIFDPWGQGTLVTVSS

1-H40	745	EVQLLESGGGLVQPGGSLRLSCAAS
		GITFSSYAMSWVRQAPGKGLEWVSG
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAKHG
		SGTIFGVVIAKYYFDYCGQGTLVTV
		SS

1-H41	746	EVQLLESGGGLVQPGGSLRLSCAAS
		GLTFSSYAMSWVRQAPGKGLEWVSD
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCVKGT
		IPIFGVIRSAFDYWGQGTLVTVSS

1-H42	747	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMTWVRQAPGKGLEWVSA
		ISGSGGGTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCASSS
		SWQFDYWGQGTLVTVSS

1-H43	748	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSHAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAHDT
		KDFWSGYCIFDPWGQGTLVTVSS

1-H44	749	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWGQGTLVTVSS

1-H47	750	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMYWVRQAPGKGLEWVSA
		ISSSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCTRPP
		YGDYGDYWGQGTLVTVSS

1-H48	751	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFTSYAMYWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARDT
		NDFWSGYSIFDPWGQGTLVTVSS

1-H49	752	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSDYAMNWVRQAPGKGLEWVSI
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-L1	753	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSNNLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSVVFG
		GGTKLTVL

1-L2	754	QSALTQPASVSGSPGQSITISCTGT
		STDVGSYNLVSWYQQHPGKAPKLMI
		YEGSQRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSTVF
		GGGTKLTVL

1-L3	755	QSALTQPASVSGSPGQSITISCTGT
		SRDVGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTPV
		VFGGGTKLTVL

1-L4	756	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSYSLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYSYV
		VFGGGTKLTVL

1-L5	757	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L6	758	QSALTQPASVSGSPGQSITISCTGT
		SSYVGHYNLVSWYQQHPGKAPKLMI
		YEGSRRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYTHY
		VFGGGTKLTVL

1-L8	759	QSALTQPASVSGSPGQSITISCTGT
		SSDVGHYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L9	760	QSALTQPASVSGSPGQSITISCTGT
		SSGVGSYNLVSWYQQHPGKAPKLMI
		YEGIKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L10	761	QSALTQPASVSGSPGQSITISCTGI
		SSDVGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L11	762	QSALTQPASVSGSPGQSITISCTGT
		SNDVGSYNLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYTVF
		GGGTKLTVL

1-L12	763	QSALTQPASVSGSPGQSITISCTGT
		SSDFGSYNLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSTFV
		VFGGGTKLTVL

1-L13	764	QSALTQPASVSGSPGQSITISCTGT
		SSDVGKYNLVSWYQQHPGKAPKLMI
		YEGSQRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTPV
		VFGGGTKLTVL

1-L14	765	QSALTQPASVSGSPGQSITISCTGT
		SSDVGTYNLVSWYQQHPGKAPKLMI
		YEGSQRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L16	766	QSALTQPASVSGSPGQSITISCTGT
		SNDVGSYNLVSWYQQHPGKAPKLMI
		YEGSKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRYVV
		FGGGTKLTVL

1-L17	767	QSALTQPASVSGSPGQSITISCTGT
		SSDVGDYNLVSWYQQHPGKAPKLMI
		YEGSNRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L18	768	QSALTQPASVSGSPGQSITISCTGT
		SSDVGGYNLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSTFP
		VVFGGGTKLTVL

1-L19	769	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSYNLLSWYQQHPGKAPKLMI
		YEASKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTPV
		VFGGGTKLTVL

1-L20	770	QSALTQPASVSGSPGQSITISCTGT
		SSDVGYYNLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGGSVVF
		GGGTKLTVL

1-L23	771	QSALTQPASVSGSPGQSITISCTGT
		SSGVGSYNLVSWYQQHPGKAPKLMI
		YEASKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYTFA
		VFGGGTKLTVL

1-L25	772	QSALTQPASVSGSPGQSITISCTGT
		SSGVGSYNLVSWYQQHPGKAPKLMI
		YEGSQRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSTHY
		VFGGGTKLTVL

1-L26	773	QSALTQPASVSGSPGQSITISCTGT
		SSNVGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L27	774	QSALTQPASVSGSPGQSITISCTGT
		SSDVGGYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSFVRSSAHV
		VFGGGTKLTVL

1-L28	775	QSALTQPASVSGSPGQSITISCTGT
		SSDVGRYNLVSWYQQHPGKAPKLMI
		YEGGKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYASSSTLV
		FGGGTKLTVL

1-L31	776	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L36	777	QSALTQPASVSGSPGQSITISCTGT
		SSDVGHYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L37	778	QSALTQPASVSGSPGQSITISCTGT
		SSGVGSYNLVSWYQQHPGKAPKLMI
		YEGIKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L38	779	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L39	780	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTNRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L40	781	QSALTQPASVSGSPGQSITISCTGT
		SSDVGHYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSSFV
		VFGGGTKLTVL

1-L41	782	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSYSLVSWYQQHPGKAPKLMI
		YEGDKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYSYV
		VFGGGTKLTVL

1-L42	783	QSALTQPASVSGSPGQSITISCTGT
		SSYVGHYNLVSWYQQHPGKAPKLMI
		YEGSRRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYTHY
		VFGGGTKLTVL

1-L43	784	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L44	785	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L47	786	QSALTQPASVSGSPGQSITISCTGT
		SSDVGGYNLVSWYQQHPGKAPKLMI
		YEASKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSYIPV
		VFGGGTKLTVL

1-L48	787	QSALTQPASVSGSPGQSITISCTGT
		SSDIGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSRTYV
		FGGGTKLTVL

1-L49	788	QSALTQPASVSGSPGQSITISCSGT
		SSDVGSYNLVSWYQQHPGKAPKLMI
		YEASKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAGSSTVF
		GGGTKLTVL

1-H51	789	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYAMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-H52	790	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSNYAMSWVRQAPGKGLEWVSA
		ISGSAGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCARVR
		QGLRRTWYYFDYWGQGTLVTVSS

1-H53	791	EVQLLESGGGLVQPGGSLRLSCAAS
		GFTFSSYTMSWVRQAPGKGLEWVSV
		ISGSGGSTYYADSVKGRFTISRDNS
		KNTLYLQMNSLRAEDTAVYYCAREG
		YRDYLWYFDLWGQGTLVTVSS

1-L51	792	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSYDLVSWYQQHPGKAPKLMI
		YEGNKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYAG-
		SSVVFGGGTKLTVL

1-L52	793	QSALTQPASVSGSPGQSITISCTGT
		SSDVGSSNLVSWYQQHPGKAPKLMI
		YEGSKRPSGVSNRFSGSKSGNTASL
		TISGLQAEDEADYYCCSYA-
		GSLYVFGGGTKLTVL

1-L53	794	QSALTQPASVSGSPGQSITISCTGT
		STDVGSYNLVSWYQQHPGKAPKLMI
		YEGTKRPSGVSNRFSGSKSGNTASL
		TISGLQAZDEADYYCCSYAGSYTSV
		VFGGGTKLTVL

While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

1. An antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein VH comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein VL comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein (a) an amino acid sequence of CDRH1 is as set forth in any one of SEQ ID NOs: 1-36 or 217-282; (b) an amino acid sequence of CDRH2 is as set forth in any one of SEQ ID NOs: 37-72 or 283-348; (c) an amino acid sequence of CDRH3 is as set forth in any one of SEQ ID NOs: 73-108 or 349-414; (d) an amino acid sequence of CDRL1 is as set forth in any one of SEQ ID NOs: 109-144 or 415-473; (e) an amino acid sequence of CDRL2 is as set forth in any one of SEQ ID NOs: 145-180 or 415-473; and (f) an amino acid sequence of CDRL3 is as set forth in any one of SEQ ID NOs: 181-216 or 533-591.

2. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 30; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 66; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 102; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 138; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 174; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 210.

3. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 35; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 71; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 107; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 143; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 179; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 215.

4. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 12; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 48; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 84; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 120; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 156; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 192.

5. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 31; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 67; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 103; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 139; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 175; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 211.

6. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 240; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 306; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 372; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555.

7. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 244; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 310; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 376; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 437; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 496; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 555.

8. The antibody or antibody fragment of claim 1, wherein (a) an amino acid sequence of CDRH1 is as set forth in SEQ ID NO: 270; (b) an amino acid sequence of CDRH2 is as set forth in SEQ ID NO: 336; (c) an amino acid sequence of CDRH3 is as set forth in SEQ ID NO: 402; (d) an amino acid sequence of CDRL1 is as set forth in SEQ ID NO: 461; (e) an amino acid sequence of CDRL2 is as set forth in SEQ ID NO: 520; and (f) an amino acid sequence of CDRL3 is as set forth in SEQ ID NO: 579.

9. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment binds to a spike glycoprotein.

10. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment binds to a receptor binding domain of the spike glycoprotein.

11. (canceled)

12. (canceled)

13. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises a K_Dof less than 10 nM.

14. The antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment comprises a K_Dof less than 5 nM.

15. An antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 592-657, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 658-716.

16. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 594, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 660.

17. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 595, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 661.

18. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 598, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 664.

19. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 603, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 669.

20. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 615, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 680.

21. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 631, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 691.

22. The antibody or antibody fragment of claim 15, wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 645, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in SEQ ID NO: 704.

23.-47. (canceled)